#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Subcortical local functional hyperconnectivity in cannabis dependence
#Text=Background
#Text=Cannabis abuse has been associated with psychopathology, including negative emotionality and a higher risk of psychosis, particularly with early age of initiation.
1-1	0-11	Subcortical	_	
1-2	12-17	local	_	
1-3	18-28	functional	_	
1-4	29-46	hyperconnectivity	_	
1-5	47-49	in	_	
1-6	50-58	cannabis	_	
1-7	59-69	dependence	_	
1-8	70-80	Background	_	
1-9	81-89	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
1-10	90-95	abuse	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
1-11	96-99	has	_	
1-12	100-104	been	_	
1-13	105-115	associated	_	
1-14	116-120	with	_	
1-15	121-136	psychopathology	_	
1-16	136-137	,	_	
1-17	138-147	including	_	
1-18	148-156	negative	_	
1-19	157-169	emotionality	_	
1-20	170-173	and	_	
1-21	174-175	a	_	
1-22	176-182	higher	_	
1-23	183-187	risk	_	
1-24	188-190	of	_	
1-25	191-200	psychosis	_	
1-26	200-201	,	_	
1-27	202-214	particularly	_	
1-28	215-219	with	_	
1-29	220-225	early	_	
1-30	226-229	age	_	
1-31	230-232	of	_	
1-32	233-243	initiation	_	
1-33	243-244	.	_	

#Text=However, the mechanisms underlying this association are poorly understood.
2-1	245-252	However	_	
2-2	252-253	,	_	
2-3	254-257	the	_	
2-4	258-268	mechanisms	_	
2-5	269-279	underlying	_	
2-6	280-284	this	_	
2-7	285-296	association	_	
2-8	297-300	are	_	
2-9	301-307	poorly	_	
2-10	308-318	understood	_	
2-11	318-319	.	_	

#Text=Because aberrant dopamine (DA) signaling is implicated in cannabis-associated psychopathology, we hypothesized that regular cannabis abuse (CA) would be associated with altered resting functional connectivity in dopamine midbrain-striatal circuits.
3-1	320-327	Because	_	
3-2	328-336	aberrant	_	
3-3	337-345	dopamine	_	
3-4	346-347	(	_	
3-5	347-349	DA	_	
3-6	349-350	)	_	
3-7	351-360	signaling	_	
3-8	361-363	is	_	
3-9	364-374	implicated	_	
3-10	375-377	in	_	
3-11	378-397	cannabis-associated	_	
3-12	398-413	psychopathology	_	
3-13	413-414	,	_	
3-14	415-417	we	_	
3-15	418-430	hypothesized	_	
3-16	431-435	that	_	
3-17	436-443	regular	_	
3-18	444-452	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
3-19	453-458	abuse	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
3-20	459-460	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
3-21	460-462	CA	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
3-22	462-463	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
3-23	464-469	would	_	
3-24	470-472	be	_	
3-25	473-483	associated	_	
3-26	484-488	with	_	
3-27	489-496	altered	_	
3-28	497-504	resting	_	
3-29	505-515	functional	_	
3-30	516-528	connectivity	_	
3-31	529-531	in	_	
3-32	532-540	dopamine	_	
3-33	541-558	midbrain-striatal	_	
3-34	559-567	circuits	_	
3-35	567-568	.	_	

#Text=Methods
#Text=We examined resting brain activity of subcortical regions in 441 young adults from the Human Connectome Project, including 30 CA meeting DSM criteria for dependence, and 30 controls matched on age, sex, education, BMI, anxiety, depression, and alcohol/tobacco usage.
4-1	569-576	Methods	_	
4-2	577-579	We	_	
4-3	580-588	examined	_	
4-4	589-596	resting	_	
4-5	597-602	brain	_	
4-6	603-611	activity	_	
4-7	612-614	of	_	
4-8	615-626	subcortical	_	
4-9	627-634	regions	_	
4-10	635-637	in	_	
4-11	638-641	441	_	
4-12	642-647	young	_	
4-13	648-654	adults	_	
4-14	655-659	from	_	
4-15	660-663	the	_	
4-16	664-669	Human	_	
4-17	670-680	Connectome	_	
4-18	681-688	Project	_	
4-19	688-689	,	_	
4-20	690-699	including	_	
4-21	700-702	30	_	
4-22	703-705	CA	_	
4-23	706-713	meeting	_	
4-24	714-717	DSM	_	
4-25	718-726	criteria	_	
4-26	727-730	for	_	
4-27	731-741	dependence	_	
4-28	741-742	,	_	
4-29	743-746	and	_	
4-30	747-749	30	_	
4-31	750-758	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-32	759-766	matched	_	
4-33	767-769	on	_	
4-34	770-773	age	_	
4-35	773-774	,	_	
4-36	775-778	sex	_	
4-37	778-779	,	_	
4-38	780-789	education	_	
4-39	789-790	,	_	
4-40	791-794	BMI	_	
4-41	794-795	,	_	
4-42	796-803	anxiety	_	
4-43	803-804	,	_	
4-44	805-815	depression	_	
4-45	815-816	,	_	
4-46	817-820	and	_	
4-47	821-828	alcohol	_	
4-48	828-829	/	_	
4-49	829-836	tobacco	_	
4-50	837-842	usage	_	
4-51	842-843	.	_	

#Text=Results
#Text=Across all subjects, local functional connectivity density (lFCD) hubs in subcortical regions were most prominent in ventral striatum, hippocampus, amygdala, dorsal midbrain, and the posterior-ventral brainstem.
5-1	844-851	Results	_	
5-2	852-858	Across	_	
5-3	859-862	all	_	
5-4	863-871	subjects	_	
5-5	871-872	,	_	
5-6	873-878	local	_	
5-7	879-889	functional	_	
5-8	890-902	connectivity	_	
5-9	903-910	density	_	
5-10	911-912	(	_	
5-11	912-916	lFCD	_	
5-12	916-917	)	_	
5-13	918-922	hubs	_	
5-14	923-925	in	_	
5-15	926-937	subcortical	_	
5-16	938-945	regions	_	
5-17	946-950	were	_	
5-18	951-955	most	_	
5-19	956-965	prominent	_	
5-20	966-968	in	_	
5-21	969-976	ventral	_	
5-22	977-985	striatum	_	
5-23	985-986	,	_	
5-24	987-998	hippocampus	_	
5-25	998-999	,	_	
5-26	1000-1008	amygdala	_	
5-27	1008-1009	,	_	
5-28	1010-1016	dorsal	_	
5-29	1017-1025	midbrain	_	
5-30	1025-1026	,	_	
5-31	1027-1030	and	_	
5-32	1031-1034	the	_	
5-33	1035-1052	posterior-ventral	_	
5-34	1053-1062	brainstem	_	
5-35	1062-1063	.	_	

#Text=As hypothesized, CA showed markedly increased lFCD relative to controls in ventral striatum (where nucleus accumbens is located) and midbrain (where substantia nigra/ventral tegmental nuclei are located) but also in brainstem and lateral thalamus.
6-1	1064-1066	As	_	
6-2	1067-1079	hypothesized	_	
6-3	1079-1080	,	_	
6-4	1081-1083	CA	_	
6-5	1084-1090	showed	_	
6-6	1091-1099	markedly	_	
6-7	1100-1109	increased	_	
6-8	1110-1114	lFCD	_	
6-9	1115-1123	relative	_	
6-10	1124-1126	to	_	
6-11	1127-1135	controls	_	
6-12	1136-1138	in	_	
6-13	1139-1146	ventral	_	
6-14	1147-1155	striatum	_	
6-15	1156-1157	(	_	
6-16	1157-1162	where	_	
6-17	1163-1170	nucleus	_	
6-18	1171-1180	accumbens	_	
6-19	1181-1183	is	_	
6-20	1184-1191	located	_	
6-21	1191-1192	)	_	
6-22	1193-1196	and	_	
6-23	1197-1205	midbrain	_	
6-24	1206-1207	(	_	
6-25	1207-1212	where	_	
6-26	1213-1223	substantia	_	
6-27	1224-1229	nigra	_	
6-28	1229-1230	/	_	
6-29	1230-1237	ventral	_	
6-30	1238-1247	tegmental	_	
6-31	1248-1254	nuclei	_	
6-32	1255-1258	are	_	
6-33	1259-1266	located	_	
6-34	1266-1267	)	_	
6-35	1268-1271	but	_	
6-36	1272-1276	also	_	
6-37	1277-1279	in	_	
6-38	1280-1289	brainstem	_	
6-39	1290-1293	and	_	
6-40	1294-1301	lateral	_	
6-41	1302-1310	thalamus	_	
6-42	1310-1311	.	_	

#Text=These effects were observed in the absence of significant differences in subcortical volumes, and were most pronounced in the individuals who began cannabis use earliest in life and who reported high levels of negative emotionality.
7-1	1312-1317	These	_	
7-2	1318-1325	effects	_	
7-3	1326-1330	were	_	
7-4	1331-1339	observed	_	
7-5	1340-1342	in	_	
7-6	1343-1346	the	_	
7-7	1347-1354	absence	_	
7-8	1355-1357	of	_	
7-9	1358-1369	significant	_	
7-10	1370-1381	differences	_	
7-11	1382-1384	in	_	
7-12	1385-1396	subcortical	_	
7-13	1397-1404	volumes	_	
7-14	1404-1405	,	_	
7-15	1406-1409	and	_	
7-16	1410-1414	were	_	
7-17	1415-1419	most	_	
7-18	1420-1430	pronounced	_	
7-19	1431-1433	in	_	
7-20	1434-1437	the	_	
7-21	1438-1449	individuals	_	
7-22	1450-1453	who	_	
7-23	1454-1459	began	_	
7-24	1460-1468	cannabis	_	
7-25	1469-1472	use	_	
7-26	1473-1481	earliest	_	
7-27	1482-1484	in	_	
7-28	1485-1489	life	_	
7-29	1490-1493	and	_	
7-30	1494-1497	who	_	
7-31	1498-1506	reported	_	
7-32	1507-1511	high	_	
7-33	1512-1518	levels	_	
7-34	1519-1521	of	_	
7-35	1522-1530	negative	_	
7-36	1531-1543	emotionality	_	
7-37	1543-1544	.	_	

#Text=Conclusions
#Text=Together, these findings suggest that chronic cannabis abuse is associated with changes in resting brain function, particularly in dopaminergic nuclei implicated in psychosis but that are also critical for habit formation and reward processing.
8-1	1545-1556	Conclusions	_	
8-2	1557-1565	Together	_	
8-3	1565-1566	,	_	
8-4	1567-1572	these	_	
8-5	1573-1581	findings	_	
8-6	1582-1589	suggest	_	
8-7	1590-1594	that	_	
8-8	1595-1602	chronic	_	
8-9	1603-1611	cannabis	_	
8-10	1612-1617	abuse	_	
8-11	1618-1620	is	_	
8-12	1621-1631	associated	_	
8-13	1632-1636	with	_	
8-14	1637-1644	changes	_	
8-15	1645-1647	in	_	
8-16	1648-1655	resting	_	
8-17	1656-1661	brain	_	
8-18	1662-1670	function	_	
8-19	1670-1671	,	_	
8-20	1672-1684	particularly	_	
8-21	1685-1687	in	_	
8-22	1688-1700	dopaminergic	_	
8-23	1701-1707	nuclei	_	
8-24	1708-1718	implicated	_	
8-25	1719-1721	in	_	
8-26	1722-1731	psychosis	_	
8-27	1732-1735	but	_	
8-28	1736-1740	that	_	
8-29	1741-1744	are	_	
8-30	1745-1749	also	_	
8-31	1750-1758	critical	_	
8-32	1759-1762	for	_	
8-33	1763-1768	habit	_	
8-34	1769-1778	formation	_	
8-35	1779-1782	and	_	
8-36	1783-1789	reward	_	
8-37	1790-1800	processing	_	
8-38	1800-1801	.	_	

#Text=These results shed light on neurobiological differences that may be relevant to psychopathology associated with cannabis use.
9-1	1802-1807	These	_	
9-2	1808-1815	results	_	
9-3	1816-1820	shed	_	
9-4	1821-1826	light	_	
9-5	1827-1829	on	_	
9-6	1830-1845	neurobiological	_	
9-7	1846-1857	differences	_	
9-8	1858-1862	that	_	
9-9	1863-1866	may	_	
9-10	1867-1869	be	_	
9-11	1870-1878	relevant	_	
9-12	1879-1881	to	_	
9-13	1882-1897	psychopathology	_	
9-14	1898-1908	associated	_	
9-15	1909-1913	with	_	
9-16	1914-1922	cannabis	_	
9-17	1923-1926	use	_	
9-18	1926-1927	.	_	

#Text=Introduction
#Text=Cannabis is one of the most widely used addictive substances in the United States, with 44% of individuals over the age of 12 reporting cannabis use at least once in their lifetime.
10-1	1928-1940	Introduction	_	
10-2	1941-1949	Cannabis	_	
10-3	1950-1952	is	_	
10-4	1953-1956	one	_	
10-5	1957-1959	of	_	
10-6	1960-1963	the	_	
10-7	1964-1968	most	_	
10-8	1969-1975	widely	_	
10-9	1976-1980	used	_	
10-10	1981-1990	addictive	_	
10-11	1991-2001	substances	_	
10-12	2002-2004	in	_	
10-13	2005-2008	the	_	
10-14	2009-2015	United	_	
10-15	2016-2022	States	_	
10-16	2022-2023	,	_	
10-17	2024-2028	with	_	
10-18	2029-2032	44%	_	
10-19	2033-2035	of	_	
10-20	2036-2047	individuals	_	
10-21	2048-2052	over	_	
10-22	2053-2056	the	_	
10-23	2057-2060	age	_	
10-24	2061-2063	of	_	
10-25	2064-2066	12	_	
10-26	2067-2076	reporting	_	
10-27	2077-2085	cannabis	_	
10-28	2086-2089	use	_	
10-29	2090-2092	at	_	
10-30	2093-2098	least	_	
10-31	2099-2103	once	_	
10-32	2104-2106	in	_	
10-33	2107-2112	their	_	
10-34	2113-2121	lifetime	_	
10-35	2121-2122	.	_	

#Text=Despite current efforts to legalize cannabis, little is known about the long-term effects of cannabis abuse (CA) on brain function and neuropsychiatric outcomes.
11-1	2123-2130	Despite	_	
11-2	2131-2138	current	_	
11-3	2139-2146	efforts	_	
11-4	2147-2149	to	_	
11-5	2150-2158	legalize	_	
11-6	2159-2167	cannabis	_	
11-7	2167-2168	,	_	
11-8	2169-2175	little	_	
11-9	2176-2178	is	_	
11-10	2179-2184	known	_	
11-11	2185-2190	about	_	
11-12	2191-2194	the	_	
11-13	2195-2204	long-term	_	
11-14	2205-2212	effects	_	
11-15	2213-2215	of	_	
11-16	2216-2224	cannabis	_	
11-17	2225-2230	abuse	_	
11-18	2231-2232	(	_	
11-19	2232-2234	CA	_	
11-20	2234-2235	)	_	
11-21	2236-2238	on	_	
11-22	2239-2244	brain	_	
11-23	2245-2253	function	_	
11-24	2254-2257	and	_	
11-25	2258-2274	neuropsychiatric	_	
11-26	2275-2283	outcomes	_	
11-27	2283-2284	.	_	

#Text=Of particular concern has been the association between regular CA and psychiatric symptoms such as amotivation, negative emotionality and a heightened risk for psychosis.
12-1	2285-2287	Of	_	
12-2	2288-2298	particular	_	
12-3	2299-2306	concern	_	
12-4	2307-2310	has	_	
12-5	2311-2315	been	_	
12-6	2316-2319	the	_	
12-7	2320-2331	association	_	
12-8	2332-2339	between	_	
12-9	2340-2347	regular	_	
12-10	2348-2350	CA	_	
12-11	2351-2354	and	_	
12-12	2355-2366	psychiatric	_	
12-13	2367-2375	symptoms	_	
12-14	2376-2380	such	_	
12-15	2381-2383	as	_	
12-16	2384-2395	amotivation	_	
12-17	2395-2396	,	_	
12-18	2397-2405	negative	_	
12-19	2406-2418	emotionality	_	
12-20	2419-2422	and	_	
12-21	2423-2424	a	_	
12-22	2425-2435	heightened	_	
12-23	2436-2440	risk	_	
12-24	2441-2444	for	_	
12-25	2445-2454	psychosis	_	
12-26	2454-2455	.	_	

#Text=Indeed, CA was associated with up to a 6 fold increase in the risk of schizophrenia in early-onset users and with the use of cannabis with high THC.
13-1	2456-2462	Indeed	_	
13-2	2462-2463	,	_	
13-3	2464-2466	CA	_	
13-4	2467-2470	was	_	
13-5	2471-2481	associated	_	
13-6	2482-2486	with	_	
13-7	2487-2489	up	_	
13-8	2490-2492	to	_	
13-9	2493-2494	a	_	
13-10	2495-2496	6	_	
13-11	2497-2501	fold	_	
13-12	2502-2510	increase	_	
13-13	2511-2513	in	_	
13-14	2514-2517	the	_	
13-15	2518-2522	risk	_	
13-16	2523-2525	of	_	
13-17	2526-2539	schizophrenia	_	
13-18	2540-2542	in	_	
13-19	2543-2554	early-onset	_	
13-20	2555-2560	users	_	
13-21	2561-2564	and	_	
13-22	2565-2569	with	_	
13-23	2570-2573	the	_	
13-24	2574-2577	use	_	
13-25	2578-2580	of	_	
13-26	2581-2589	cannabis	_	
13-27	2590-2594	with	_	
13-28	2595-2599	high	_	
13-29	2600-2603	THC	_	
13-30	2603-2604	.	_	

#Text=The increased risk remains after controlling for other substances of abuse and for familial risk of psychosis.
14-1	2605-2608	The	_	
14-2	2609-2618	increased	_	
14-3	2619-2623	risk	_	
14-4	2624-2631	remains	_	
14-5	2632-2637	after	_	
14-6	2638-2649	controlling	_	
14-7	2650-2653	for	_	
14-8	2654-2659	other	_	
14-9	2660-2670	substances	_	
14-10	2671-2673	of	_	
14-11	2674-2679	abuse	_	
14-12	2680-2683	and	_	
14-13	2684-2687	for	_	
14-14	2688-2696	familial	_	
14-15	2697-2701	risk	_	
14-16	2702-2704	of	_	
14-17	2705-2714	psychosis	_	
14-18	2714-2715	.	_	

#Text=Aberrant dopaminergic function in the midbrain-striatal circuitry, a hallmark feature of schizophrenia, may underlie this association.
15-1	2716-2724	Aberrant	_	
15-2	2725-2737	dopaminergic	_	
15-3	2738-2746	function	_	
15-4	2747-2749	in	_	
15-5	2750-2753	the	_	
15-6	2754-2771	midbrain-striatal	_	
15-7	2772-2781	circuitry	_	
15-8	2781-2782	,	_	
15-9	2783-2784	a	_	
15-10	2785-2793	hallmark	_	
15-11	2794-2801	feature	_	
15-12	2802-2804	of	_	
15-13	2805-2818	schizophrenia	_	
15-14	2818-2819	,	_	
15-15	2820-2823	may	_	
15-16	2824-2832	underlie	_	
15-17	2833-2837	this	_	
15-18	2838-2849	association	_	
15-19	2849-2850	.	_	

#Text=Accordingly, CA with genetic variants that confer high midbrain-striatal dopamine (DA), including the DRD2 rs1076560 T allele, the DAT1 3′ 9-repeat allele, and the AKT1 rs2494732 C allele, have an increased risk of psychosis compared with CA that do not have these genetic variants.
16-1	2851-2862	Accordingly	_	
16-2	2862-2863	,	_	
16-3	2864-2866	CA	_	
16-4	2867-2871	with	_	
16-5	2872-2879	genetic	_	
16-6	2880-2888	variants	_	
16-7	2889-2893	that	_	
16-8	2894-2900	confer	_	
16-9	2901-2905	high	_	
16-10	2906-2923	midbrain-striatal	_	
16-11	2924-2932	dopamine	_	
16-12	2933-2934	(	_	
16-13	2934-2936	DA	_	
16-14	2936-2937	)	_	
16-15	2937-2938	,	_	
16-16	2939-2948	including	_	
16-17	2949-2952	the	_	
16-18	2953-2957	DRD2	_	
16-19	2958-2967	rs1076560	_	
16-20	2968-2969	T	_	
16-21	2970-2976	allele	_	
16-22	2976-2977	,	_	
16-23	2978-2981	the	_	
16-24	2982-2986	DAT1	_	
16-25	2987-2988	3	_	
16-26	2988-2989	′	_	
16-27	2990-2991	9	_	
16-28	2991-2992	-	_	
16-29	2992-2998	repeat	_	
16-30	2999-3005	allele	_	
16-31	3005-3006	,	_	
16-32	3007-3010	and	_	
16-33	3011-3014	the	_	
16-34	3015-3019	AKT1	_	
16-35	3020-3029	rs2494732	_	
16-36	3030-3031	C	_	
16-37	3032-3038	allele	_	
16-38	3038-3039	,	_	
16-39	3040-3044	have	_	
16-40	3045-3047	an	_	
16-41	3048-3057	increased	_	
16-42	3058-3062	risk	_	
16-43	3063-3065	of	_	
16-44	3066-3075	psychosis	_	
16-45	3076-3084	compared	_	
16-46	3085-3089	with	_	
16-47	3090-3092	CA	_	
16-48	3093-3097	that	_	
16-49	3098-3100	do	_	
16-50	3101-3104	not	_	
16-51	3105-3109	have	_	
16-52	3110-3115	these	_	
16-53	3116-3123	genetic	_	
16-54	3124-3132	variants	_	
16-55	3132-3133	.	_	

#Text=However, the effects of chronic CA on the functional organization of subcortical regions modulated by DA, and their relevance for psychiatric symptoms, is poorly understood.
17-1	3134-3141	However	_	
17-2	3141-3142	,	_	
17-3	3143-3146	the	_	
17-4	3147-3154	effects	_	
17-5	3155-3157	of	_	
17-6	3158-3165	chronic	_	
17-7	3166-3168	CA	_	
17-8	3169-3171	on	_	
17-9	3172-3175	the	_	
17-10	3176-3186	functional	_	
17-11	3187-3199	organization	_	
17-12	3200-3202	of	_	
17-13	3203-3214	subcortical	_	
17-14	3215-3222	regions	_	
17-15	3223-3232	modulated	_	
17-16	3233-3235	by	_	
17-17	3236-3238	DA	_	
17-18	3238-3239	,	_	
17-19	3240-3243	and	_	
17-20	3244-3249	their	_	
17-21	3250-3259	relevance	_	
17-22	3260-3263	for	_	
17-23	3264-3275	psychiatric	_	
17-24	3276-3284	symptoms	_	
17-25	3284-3285	,	_	
17-26	3286-3288	is	_	
17-27	3289-3295	poorly	_	
17-28	3296-3306	understood	_	
17-29	3306-3307	.	_	

#Text=Resting-state functional magnetic resonance imaging (rsfMRI) offers a non-invasive method for probing the functional connectedness of neural circuits.
18-1	3308-3321	Resting-state	_	
18-2	3322-3332	functional	_	
18-3	3333-3341	magnetic	_	
18-4	3342-3351	resonance	_	
18-5	3352-3359	imaging	_	
18-6	3360-3361	(	_	
18-7	3361-3367	rsfMRI	_	
18-8	3367-3368	)	_	
18-9	3369-3375	offers	_	
18-10	3376-3377	a	_	
18-11	3378-3390	non-invasive	_	
18-12	3391-3397	method	_	
18-13	3398-3401	for	_	
18-14	3402-3409	probing	_	
18-15	3410-3413	the	_	
18-16	3414-3424	functional	_	
18-17	3425-3438	connectedness	_	
18-18	3439-3441	of	_	
18-19	3442-3448	neural	_	
18-20	3449-3457	circuits	_	
18-21	3457-3458	.	_	

#Text=By measuring correlations among spontaneous low-frequency blood-oxygen-level dependent (BOLD) signals, studies have revealed the involvement of functional changes in subcortical circuits in psychiatric diseases including schizophrenia.
19-1	3459-3461	By	_	
19-2	3462-3471	measuring	_	
19-3	3472-3484	correlations	_	
19-4	3485-3490	among	_	
19-5	3491-3502	spontaneous	_	
19-6	3503-3516	low-frequency	_	
19-7	3517-3535	blood-oxygen-level	_	
19-8	3536-3545	dependent	_	
19-9	3546-3547	(	_	
19-10	3547-3551	BOLD	_	
19-11	3551-3552	)	_	
19-12	3553-3560	signals	_	
19-13	3560-3561	,	_	
19-14	3562-3569	studies	_	
19-15	3570-3574	have	_	
19-16	3575-3583	revealed	_	
19-17	3584-3587	the	_	
19-18	3588-3599	involvement	_	
19-19	3600-3602	of	_	
19-20	3603-3613	functional	_	
19-21	3614-3621	changes	_	
19-22	3622-3624	in	_	
19-23	3625-3636	subcortical	_	
19-24	3637-3645	circuits	_	
19-25	3646-3648	in	_	
19-26	3649-3660	psychiatric	_	
19-27	3661-3669	diseases	_	
19-28	3670-3679	including	_	
19-29	3680-3693	schizophrenia	_	
19-30	3693-3694	.	_	

#Text=For instance, functional connectivity between reward processing regions, such as nucleus accumbens (NAc) and orbitofrontal cortex (OFC), appears to be related to disrupted DA function, and as such, has clinical relevance: higher intrinsic connectivity correlated with amotivation syndrome and with the duration that schizophrenia had been left untreated.
20-1	3695-3698	For	_	
20-2	3699-3707	instance	_	
20-3	3707-3708	,	_	
20-4	3709-3719	functional	_	
20-5	3720-3732	connectivity	_	
20-6	3733-3740	between	_	
20-7	3741-3747	reward	_	
20-8	3748-3758	processing	_	
20-9	3759-3766	regions	_	
20-10	3766-3767	,	_	
20-11	3768-3772	such	_	
20-12	3773-3775	as	_	
20-13	3776-3783	nucleus	_	
20-14	3784-3793	accumbens	_	
20-15	3794-3795	(	_	
20-16	3795-3798	NAc	_	
20-17	3798-3799	)	_	
20-18	3800-3803	and	_	
20-19	3804-3817	orbitofrontal	_	
20-20	3818-3824	cortex	_	
20-21	3825-3826	(	_	
20-22	3826-3829	OFC	_	
20-23	3829-3830	)	_	
20-24	3830-3831	,	_	
20-25	3832-3839	appears	_	
20-26	3840-3842	to	_	
20-27	3843-3845	be	_	
20-28	3846-3853	related	_	
20-29	3854-3856	to	_	
20-30	3857-3866	disrupted	_	
20-31	3867-3869	DA	_	
20-32	3870-3878	function	_	
20-33	3878-3879	,	_	
20-34	3880-3883	and	_	
20-35	3884-3886	as	_	
20-36	3887-3891	such	_	
20-37	3891-3892	,	_	
20-38	3893-3896	has	_	
20-39	3897-3905	clinical	_	
20-40	3906-3915	relevance	_	
20-41	3915-3916	:	_	
20-42	3917-3923	higher	_	
20-43	3924-3933	intrinsic	_	
20-44	3934-3946	connectivity	_	
20-45	3947-3957	correlated	_	
20-46	3958-3962	with	_	
20-47	3963-3974	amotivation	_	
20-48	3975-3983	syndrome	_	
20-49	3984-3987	and	_	
20-50	3988-3992	with	_	
20-51	3993-3996	the	_	
20-52	3997-4005	duration	_	
20-53	4006-4010	that	_	
20-54	4011-4024	schizophrenia	_	
20-55	4025-4028	had	_	
20-56	4029-4033	been	_	
20-57	4034-4038	left	_	
20-58	4039-4048	untreated	_	
20-59	4048-4049	.	_	

#Text=Intriguingly, a similar pattern of NAc-OFC hyperconnectivity was reported in CA.
21-1	4050-4062	Intriguingly	_	
21-2	4062-4063	,	_	
21-3	4064-4065	a	_	
21-4	4066-4073	similar	_	
21-5	4074-4081	pattern	_	
21-6	4082-4084	of	_	
21-7	4085-4092	NAc-OFC	_	
21-8	4093-4110	hyperconnectivity	_	
21-9	4111-4114	was	_	
21-10	4115-4123	reported	_	
21-11	4124-4126	in	_	
21-12	4127-4129	CA	_	
21-13	4129-4130	.	_	

#Text=However, the relevance of these effects for psychopathology in CA is unknown.
22-1	4131-4138	However	_	
22-2	4138-4139	,	_	
22-3	4140-4143	the	_	
22-4	4144-4153	relevance	_	
22-5	4154-4156	of	_	
22-6	4157-4162	these	_	
22-7	4163-4170	effects	_	
22-8	4171-4174	for	_	
22-9	4175-4190	psychopathology	_	
22-10	4191-4193	in	_	
22-11	4194-4196	CA	_	
22-12	4197-4199	is	_	
22-13	4200-4207	unknown	_	
22-14	4207-4208	.	_	

#Text=Further, prior investigations in CA have relied mainly on seed-based connectivity analyses.
23-1	4209-4216	Further	_	
23-2	4216-4217	,	_	
23-3	4218-4223	prior	_	
23-4	4224-4238	investigations	_	
23-5	4239-4241	in	_	
23-6	4242-4244	CA	_	
23-7	4245-4249	have	_	
23-8	4250-4256	relied	_	
23-9	4257-4263	mainly	_	
23-10	4264-4266	on	_	
23-11	4267-4277	seed-based	_	
23-12	4278-4290	connectivity	_	
23-13	4291-4299	analyses	_	
23-14	4299-4300	.	_	

#Text=In contrast, local functional connectivity density (lFCD; the size of a local cluster of correlated voxels) is a data-driven method for identifying functional hubs in the brain. lFCD accounts for up to 70% of resting brain metabolism, and therefore is an index of local brain activity that has superior spatiotemporal resolution to PET imaging.
24-1	4301-4303	In	_	
24-2	4304-4312	contrast	_	
24-3	4312-4313	,	_	
24-4	4314-4319	local	_	
24-5	4320-4330	functional	_	
24-6	4331-4343	connectivity	_	
24-7	4344-4351	density	_	
24-8	4352-4353	(	_	
24-9	4353-4357	lFCD	_	
24-10	4357-4358	;	_	
24-11	4359-4362	the	_	
24-12	4363-4367	size	_	
24-13	4368-4370	of	_	
24-14	4371-4372	a	_	
24-15	4373-4378	local	_	
24-16	4379-4386	cluster	_	
24-17	4387-4389	of	_	
24-18	4390-4400	correlated	_	
24-19	4401-4407	voxels	_	
24-20	4407-4408	)	_	
24-21	4409-4411	is	_	
24-22	4412-4413	a	_	
24-23	4414-4425	data-driven	_	
24-24	4426-4432	method	_	
24-25	4433-4436	for	_	
24-26	4437-4448	identifying	_	
24-27	4449-4459	functional	_	
24-28	4460-4464	hubs	_	
24-29	4465-4467	in	_	
24-30	4468-4471	the	_	
24-31	4472-4477	brain	_	
24-32	4477-4478	.	_	
24-33	4479-4483	lFCD	_	
24-34	4484-4492	accounts	_	
24-35	4493-4496	for	_	
24-36	4497-4499	up	_	
24-37	4500-4502	to	_	
24-38	4503-4506	70%	_	
24-39	4507-4509	of	_	
24-40	4510-4517	resting	_	
24-41	4518-4523	brain	_	
24-42	4524-4534	metabolism	_	
24-43	4534-4535	,	_	
24-44	4536-4539	and	_	
24-45	4540-4549	therefore	_	
24-46	4550-4552	is	_	
24-47	4553-4555	an	_	
24-48	4556-4561	index	_	
24-49	4562-4564	of	_	
24-50	4565-4570	local	_	
24-51	4571-4576	brain	_	
24-52	4577-4585	activity	_	
24-53	4586-4590	that	_	
24-54	4591-4594	has	_	
24-55	4595-4603	superior	_	
24-56	4604-4618	spatiotemporal	_	
24-57	4619-4629	resolution	_	
24-58	4630-4632	to	_	
24-59	4633-4636	PET	_	
24-60	4637-4644	imaging	_	
24-61	4644-4645	.	_	

#Text=We recently used this method to identify functional connectivity changes that were associated with cognitive and mood-related behaviors in heavy drinkers.
25-1	4646-4648	We	_	
25-2	4649-4657	recently	_	
25-3	4658-4662	used	_	
25-4	4663-4667	this	_	
25-5	4668-4674	method	_	
25-6	4675-4677	to	_	
25-7	4678-4686	identify	_	
25-8	4687-4697	functional	_	
25-9	4698-4710	connectivity	_	
25-10	4711-4718	changes	_	
25-11	4719-4723	that	_	
25-12	4724-4728	were	_	
25-13	4729-4739	associated	_	
25-14	4740-4744	with	_	
25-15	4745-4754	cognitive	_	
25-16	4755-4758	and	_	
25-17	4759-4771	mood-related	_	
25-18	4772-4781	behaviors	_	
25-19	4782-4784	in	_	
25-20	4785-4790	heavy	_	
25-21	4791-4799	drinkers	_	
25-22	4799-4800	.	_	

#Text=To our knowledge, no studies have examined the effects of CA on subcortical functional hub organization, and its relevance to negative emotionality, which is elevated in CA and schizophrenia.
26-1	4801-4803	To	_	
26-2	4804-4807	our	_	
26-3	4808-4817	knowledge	_	
26-4	4817-4818	,	_	
26-5	4819-4821	no	_	
26-6	4822-4829	studies	_	
26-7	4830-4834	have	_	
26-8	4835-4843	examined	_	
26-9	4844-4847	the	_	
26-10	4848-4855	effects	_	
26-11	4856-4858	of	_	
26-12	4859-4861	CA	_	
26-13	4862-4864	on	_	
26-14	4865-4876	subcortical	_	
26-15	4877-4887	functional	_	
26-16	4888-4891	hub	_	
26-17	4892-4904	organization	_	
26-18	4904-4905	,	_	
26-19	4906-4909	and	_	
26-20	4910-4913	its	_	
26-21	4914-4923	relevance	_	
26-22	4924-4926	to	_	
26-23	4927-4935	negative	_	
26-24	4936-4948	emotionality	_	
26-25	4948-4949	,	_	
26-26	4950-4955	which	_	
26-27	4956-4958	is	_	
26-28	4959-4967	elevated	_	
26-29	4968-4970	in	_	
26-30	4971-4973	CA	_	
26-31	4974-4977	and	_	
26-32	4978-4991	schizophrenia	_	
26-33	4991-4992	.	_	

#Text=Intriguingly, recent studies using a very similar approach found subcortical hyperconnectivity in a cohort of 95 individuals with Schizophrenia.
27-1	4993-5005	Intriguingly	_	
27-2	5005-5006	,	_	
27-3	5007-5013	recent	_	
27-4	5014-5021	studies	_	
27-5	5022-5027	using	_	
27-6	5028-5029	a	_	
27-7	5030-5034	very	_	
27-8	5035-5042	similar	_	
27-9	5043-5051	approach	_	
27-10	5052-5057	found	_	
27-11	5058-5069	subcortical	_	
27-12	5070-5087	hyperconnectivity	_	
27-13	5088-5090	in	_	
27-14	5091-5092	a	_	
27-15	5093-5099	cohort	_	
27-16	5100-5102	of	_	
27-17	5103-5105	95	_	
27-18	5106-5117	individuals	_	
27-19	5118-5122	with	_	
27-20	5123-5136	Schizophrenia	_	
27-21	5136-5137	.	_	

#Text=We hypothesized similar effects may be observed in CA.
28-1	5138-5140	We	_	
28-2	5141-5153	hypothesized	_	
28-3	5154-5161	similar	_	
28-4	5162-5169	effects	_	
28-5	5170-5173	may	_	
28-6	5174-5176	be	_	
28-7	5177-5185	observed	_	
28-8	5186-5188	in	_	
28-9	5189-5191	CA	_	
28-10	5191-5192	.	_	

#Text=To test this hypothesis, we took advantage of the large dataset produced by the Human Connectome Project.
29-1	5193-5195	To	_	
29-2	5196-5200	test	_	
29-3	5201-5205	this	_	
29-4	5206-5216	hypothesis	_	
29-5	5216-5217	,	_	
29-6	5218-5220	we	_	
29-7	5221-5225	took	_	
29-8	5226-5235	advantage	_	
29-9	5236-5238	of	_	
29-10	5239-5242	the	_	
29-11	5243-5248	large	_	
29-12	5249-5256	dataset	_	
29-13	5257-5265	produced	_	
29-14	5266-5268	by	_	
29-15	5269-5272	the	_	
29-16	5273-5278	Human	_	
29-17	5279-5289	Connectome	_	
29-18	5290-5297	Project	_	
29-19	5297-5298	.	_	

#Text=While the HCP does not have targeted measures that specifically assess psychosis, they do offer measures of negative emotionality, a symptom shared between CA and Schizophrenia that we have previously found to be associated with subcortical dopaminergic function in CA.
30-1	5299-5304	While	_	
30-2	5305-5308	the	_	
30-3	5309-5312	HCP	_	
30-4	5313-5317	does	_	
30-5	5318-5321	not	_	
30-6	5322-5326	have	_	
30-7	5327-5335	targeted	_	
30-8	5336-5344	measures	_	
30-9	5345-5349	that	_	
30-10	5350-5362	specifically	_	
30-11	5363-5369	assess	_	
30-12	5370-5379	psychosis	_	
30-13	5379-5380	,	_	
30-14	5381-5385	they	_	
30-15	5386-5388	do	_	
30-16	5389-5394	offer	_	
30-17	5395-5403	measures	_	
30-18	5404-5406	of	_	
30-19	5407-5415	negative	_	
30-20	5416-5428	emotionality	_	
30-21	5428-5429	,	_	
30-22	5430-5431	a	_	
30-23	5432-5439	symptom	_	
30-24	5440-5446	shared	_	
30-25	5447-5454	between	_	
30-26	5455-5457	CA	_	
30-27	5458-5461	and	_	
30-28	5462-5475	Schizophrenia	_	
30-29	5476-5480	that	_	
30-30	5481-5483	we	_	
30-31	5484-5488	have	_	
30-32	5489-5499	previously	_	
30-33	5500-5505	found	_	
30-34	5506-5508	to	_	
30-35	5509-5511	be	_	
30-36	5512-5522	associated	_	
30-37	5523-5527	with	_	
30-38	5528-5539	subcortical	_	
30-39	5540-5552	dopaminergic	_	
30-40	5553-5561	function	_	
30-41	5562-5564	in	_	
30-42	5565-5567	CA	_	
30-43	5567-5568	.	_	

#Text=Thus, while the present study does not directly study individuals with schizophrenia, negative emotionality is relevant in light of the emerging view that psychiatric disorders represent clusters of symptoms and traits that are elevated over a spectrum of normal functioning, and that elevated negative emotionality predicts development of psychosis.
31-1	5569-5573	Thus	_	
31-2	5573-5574	,	_	
31-3	5575-5580	while	_	
31-4	5581-5584	the	_	
31-5	5585-5592	present	_	
31-6	5593-5598	study	_	
31-7	5599-5603	does	_	
31-8	5604-5607	not	_	
31-9	5608-5616	directly	_	
31-10	5617-5622	study	_	
31-11	5623-5634	individuals	_	
31-12	5635-5639	with	_	
31-13	5640-5653	schizophrenia	_	
31-14	5653-5654	,	_	
31-15	5655-5663	negative	_	
31-16	5664-5676	emotionality	_	
31-17	5677-5679	is	_	
31-18	5680-5688	relevant	_	
31-19	5689-5691	in	_	
31-20	5692-5697	light	_	
31-21	5698-5700	of	_	
31-22	5701-5704	the	_	
31-23	5705-5713	emerging	_	
31-24	5714-5718	view	_	
31-25	5719-5723	that	_	
31-26	5724-5735	psychiatric	_	
31-27	5736-5745	disorders	_	
31-28	5746-5755	represent	_	
31-29	5756-5764	clusters	_	
31-30	5765-5767	of	_	
31-31	5768-5776	symptoms	_	
31-32	5777-5780	and	_	
31-33	5781-5787	traits	_	
31-34	5788-5792	that	_	
31-35	5793-5796	are	_	
31-36	5797-5805	elevated	_	
31-37	5806-5810	over	_	
31-38	5811-5812	a	_	
31-39	5813-5821	spectrum	_	
31-40	5822-5824	of	_	
31-41	5825-5831	normal	_	
31-42	5832-5843	functioning	_	
31-43	5843-5844	,	_	
31-44	5845-5848	and	_	
31-45	5849-5853	that	_	
31-46	5854-5862	elevated	_	
31-47	5863-5871	negative	_	
31-48	5872-5884	emotionality	_	
31-49	5885-5893	predicts	_	
31-50	5894-5905	development	_	
31-51	5906-5908	of	_	
31-52	5909-5918	psychosis	_	
31-53	5918-5919	.	_	

#Text=We were particularly interested in one aspect of negative emotionality: symptoms of alienation (beliefs that others wish them harm, and that they are deceived by friends), after our recent investigation demonstrated that this may be particularly affected in CA and associated with aberrant brain function.
32-1	5920-5922	We	_	
32-2	5923-5927	were	_	
32-3	5928-5940	particularly	_	
32-4	5941-5951	interested	_	
32-5	5952-5954	in	_	
32-6	5955-5958	one	_	
32-7	5959-5965	aspect	_	
32-8	5966-5968	of	_	
32-9	5969-5977	negative	_	
32-10	5978-5990	emotionality	_	
32-11	5990-5991	:	_	
32-12	5992-6000	symptoms	_	
32-13	6001-6003	of	_	
32-14	6004-6014	alienation	_	
32-15	6015-6016	(	_	
32-16	6016-6023	beliefs	_	
32-17	6024-6028	that	_	
32-18	6029-6035	others	_	
32-19	6036-6040	wish	_	
32-20	6041-6045	them	_	
32-21	6046-6050	harm	_	
32-22	6050-6051	,	_	
32-23	6052-6055	and	_	
32-24	6056-6060	that	_	
32-25	6061-6065	they	_	
32-26	6066-6069	are	_	
32-27	6070-6078	deceived	_	
32-28	6079-6081	by	_	
32-29	6082-6089	friends	_	
32-30	6089-6090	)	_	
32-31	6090-6091	,	_	
32-32	6092-6097	after	_	
32-33	6098-6101	our	_	
32-34	6102-6108	recent	_	
32-35	6109-6122	investigation	_	
32-36	6123-6135	demonstrated	_	
32-37	6136-6140	that	_	
32-38	6141-6145	this	_	
32-39	6146-6149	may	_	
32-40	6150-6152	be	_	
32-41	6153-6165	particularly	_	
32-42	6166-6174	affected	_	
32-43	6175-6177	in	_	
32-44	6178-6180	CA	_	
32-45	6181-6184	and	_	
32-46	6185-6195	associated	_	
32-47	6196-6200	with	_	
32-48	6201-6209	aberrant	_	
32-49	6210-6215	brain	_	
32-50	6216-6224	function	_	
32-51	6224-6225	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=We analyzed data from the S500 release (https://www.humanconnectome.org/documentation/S500/index.html) of the WU-Minn HCP Consortium.
33-1	6226-6235	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-2	6236-6239	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-3	6240-6247	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-4	6248-6260	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-5	6261-6263	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-6	6264-6272	analyzed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-7	6273-6277	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-8	6278-6282	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-9	6283-6286	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-10	6287-6291	S500	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-11	6292-6299	release	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-12	6300-6301	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-13	6301-6306	https	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-14	6306-6307	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-15	6307-6308	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-16	6308-6309	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-17	6309-6332	www.humanconnectome.org	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-18	6332-6333	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-19	6333-6346	documentation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-20	6346-6347	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-21	6347-6351	S500	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-22	6351-6352	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-23	6352-6362	index.html	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-24	6362-6363	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-25	6364-6366	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-26	6367-6370	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-27	6371-6378	WU-Minn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-28	6379-6382	HCP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-29	6383-6393	Consortium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
33-30	6393-6394	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=We only included participants who had a) complete structural and rsfMRI imaging data that passed a quality assurance check, and b) complete measures of cognitive function and emotionality (total n=441 participants).
34-1	6395-6397	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-2	6398-6402	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-3	6403-6411	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-4	6412-6424	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-5	6425-6428	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-6	6429-6432	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-7	6433-6434	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-8	6434-6435	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-9	6436-6444	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-10	6445-6455	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
34-11	6456-6459	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-12	6460-6466	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
34-13	6467-6474	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-14	6475-6479	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-15	6480-6484	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-16	6485-6491	passed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-17	6492-6493	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-18	6494-6501	quality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-19	6502-6511	assurance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-20	6512-6517	check	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-21	6517-6518	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-22	6519-6522	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-23	6523-6524	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-24	6524-6525	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-25	6526-6534	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-26	6535-6543	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-27	6544-6546	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-28	6547-6556	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-29	6557-6565	function	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-30	6566-6569	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-31	6570-6582	emotionality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-32	6583-6584	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-33	6584-6589	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-34	6590-6591	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-35	6591-6592	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-36	6592-6595	441	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-37	6596-6608	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-38	6608-6609	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-39	6609-6610	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The HCP initiative studied young adults aged 22–35 from a wide range of backgrounds and behavioral profiles representative of the population at large.
35-1	6611-6614	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-2	6615-6618	HCP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-3	6619-6629	initiative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-4	6630-6637	studied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-5	6638-6643	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-6	6644-6650	adults	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-7	6651-6655	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-8	6656-6658	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-9	6658-6659	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-10	6659-6661	35	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-11	6662-6666	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-12	6667-6668	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-13	6669-6673	wide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-14	6674-6679	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-15	6680-6682	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-16	6683-6694	backgrounds	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-17	6695-6698	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-18	6699-6709	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-19	6710-6718	profiles	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-20	6719-6733	representative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-21	6734-6736	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-22	6737-6740	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-23	6741-6751	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-24	6752-6754	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-25	6755-6760	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
35-26	6760-6761	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Thus, while all participants are considered generally healthy, participants with sub-clinical psychiatric symptomatology and recreational drug use are included.
36-1	6762-6766	Thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-2	6766-6767	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-3	6768-6773	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-4	6774-6777	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-5	6778-6790	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-6	6791-6794	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-7	6795-6805	considered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-8	6806-6815	generally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-9	6816-6823	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-10	6823-6824	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-11	6825-6837	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-12	6838-6842	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-13	6843-6855	sub-clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-14	6856-6867	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-15	6868-6882	symptomatology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-16	6883-6886	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-17	6887-6899	recreational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-18	6900-6904	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-19	6905-6908	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-20	6909-6912	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-21	6913-6921	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-22	6921-6922	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Of the 441 participants, 36 met the DSM-IV criteria for cannabis dependence (see Supplementary Material for a description).
37-1	6923-6925	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-2	6926-6929	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-3	6930-6933	441	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-4	6934-6946	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-5	6946-6947	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-6	6948-6950	36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-7	6951-6954	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-8	6955-6958	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-9	6959-6965	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-10	6966-6974	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-11	6975-6978	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-12	6979-6987	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-13	6988-6998	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-14	6999-7000	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-15	7000-7003	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-16	7004-7017	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-17	7018-7026	Material	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-18	7027-7030	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-19	7031-7032	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-20	7033-7044	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-21	7044-7045	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-22	7045-7046	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Three participants were excluded for comorbid alcohol dependence and one was excluded for anxiety and depression ratings > 3 SD from the group mean.
38-1	7047-7052	Three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-2	7053-7065	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-3	7066-7070	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-4	7071-7079	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-5	7080-7083	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-6	7084-7092	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-7	7093-7100	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-8	7101-7111	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-9	7112-7115	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-10	7116-7119	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-11	7120-7123	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-12	7124-7132	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-13	7133-7136	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-14	7137-7144	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-15	7145-7148	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-16	7149-7159	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-17	7160-7167	ratings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-18	7168-7169	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-19	7170-7171	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-20	7172-7174	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-21	7175-7179	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-22	7180-7183	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-23	7184-7189	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-24	7190-7194	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-25	7194-7195	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Recent studies have indicated that it is critical in studies of cannabis abuse to select a well-matched control group, particularly on measures of alcohol and tobacco usage, e.g.,.
39-1	7196-7202	Recent	_	
39-2	7203-7210	studies	_	
39-3	7211-7215	have	_	
39-4	7216-7225	indicated	_	
39-5	7226-7230	that	_	
39-6	7231-7233	it	_	
39-7	7234-7236	is	_	
39-8	7237-7245	critical	_	
39-9	7246-7248	in	_	
39-10	7249-7256	studies	_	
39-11	7257-7259	of	_	
39-12	7260-7268	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[11]	
39-13	7269-7274	abuse	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[11]	
39-14	7275-7277	to	_	
39-15	7278-7284	select	_	
39-16	7285-7286	a	_	
39-17	7287-7299	well-matched	_	
39-18	7300-7307	control	_	
39-19	7308-7313	group	_	
39-20	7313-7314	,	_	
39-21	7315-7327	particularly	_	
39-22	7328-7330	on	_	
39-23	7331-7339	measures	_	
39-24	7340-7342	of	_	
39-25	7343-7350	alcohol	_	
39-26	7351-7354	and	_	
39-27	7355-7362	tobacco	_	
39-28	7363-7368	usage	_	
39-29	7368-7369	,	_	
39-30	7370-7373	e.g	_	
39-31	7373-7374	.	_	
39-32	7374-7375	,	_	
39-33	7375-7376	.	_	

#Text=Therefore, we matched groups on age, sex, education, BMI, anxiety, depression, and alcohol and tobacco usage (we calculated composite tobacco/alcohol usage the same way as a recent study of HCP data; see Supplementary Material and).
40-1	7377-7386	Therefore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-2	7386-7387	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-3	7388-7390	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-4	7391-7398	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-5	7399-7405	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-6	7406-7408	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-7	7409-7412	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-8	7412-7413	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-9	7414-7417	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-10	7417-7418	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-11	7419-7428	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-12	7428-7429	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-13	7430-7433	BMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-14	7433-7434	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-15	7435-7442	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-16	7442-7443	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-17	7444-7454	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-18	7454-7455	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-19	7456-7459	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-20	7460-7467	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-21	7468-7471	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-22	7472-7479	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-23	7480-7485	usage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-24	7486-7487	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-25	7487-7489	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-26	7490-7500	calculated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-27	7501-7510	composite	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-28	7511-7518	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-29	7518-7519	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-30	7519-7526	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-31	7527-7532	usage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-32	7533-7536	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-33	7537-7541	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-34	7542-7545	way	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-35	7546-7548	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-36	7549-7550	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-37	7551-7557	recent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-38	7558-7563	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-39	7564-7566	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-40	7567-7570	HCP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-41	7571-7575	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-42	7575-7576	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-43	7577-7580	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-44	7581-7594	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-45	7595-7603	Material	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-46	7604-7607	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-47	7607-7608	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
40-48	7608-7609	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Two subjects from each group were excluded to ensure groups were matched on tobacco usage (Supplementary Material), therefore the final sample included 30 CA and 30 controls; demographics and statistical tests are presented in Table 1.
41-1	7610-7613	Two	_	
41-2	7614-7622	subjects	_	
41-3	7623-7627	from	_	
41-4	7628-7632	each	_	
41-5	7633-7638	group	_	
41-6	7639-7643	were	_	
41-7	7644-7652	excluded	_	
41-8	7653-7655	to	_	
41-9	7656-7662	ensure	_	
41-10	7663-7669	groups	_	
41-11	7670-7674	were	_	
41-12	7675-7682	matched	_	
41-13	7683-7685	on	_	
41-14	7686-7693	tobacco	_	
41-15	7694-7699	usage	_	
41-16	7700-7701	(	_	
41-17	7701-7714	Supplementary	_	
41-18	7715-7723	Material	_	
41-19	7723-7724	)	_	
41-20	7724-7725	,	_	
41-21	7726-7735	therefore	_	
41-22	7736-7739	the	_	
41-23	7740-7745	final	_	
41-24	7746-7752	sample	_	
41-25	7753-7761	included	_	
41-26	7762-7764	30	_	
41-27	7765-7767	CA	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	
41-28	7768-7771	and	_	
41-29	7772-7774	30	_	
41-30	7775-7783	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
41-31	7783-7784	;	_	
41-32	7785-7797	demographics	_	
41-33	7798-7801	and	_	
41-34	7802-7813	statistical	_	
41-35	7814-7819	tests	_	
41-36	7820-7823	are	_	
41-37	7824-7833	presented	_	
41-38	7834-7836	in	_	
41-39	7837-7842	Table	_	
41-40	7843-7844	1	_	
41-41	7844-7845	.	_	

#Text=Behavioral Measures of Interest
#Text=We examined data related to cognitive function and negative emotionality, given the interest in potential chronic effects of cannabis in these domains.
42-1	7846-7856	Behavioral	_	
42-2	7857-7865	Measures	_	
42-3	7866-7868	of	_	
42-4	7869-7877	Interest	_	
42-5	7878-7880	We	_	
42-6	7881-7889	examined	_	
42-7	7890-7894	data	_	
42-8	7895-7902	related	_	
42-9	7903-7905	to	_	
42-10	7906-7915	cognitive	_	
42-11	7916-7924	function	_	
42-12	7925-7928	and	_	
42-13	7929-7937	negative	_	
42-14	7938-7950	emotionality	_	
42-15	7950-7951	,	_	
42-16	7952-7957	given	_	
42-17	7958-7961	the	_	
42-18	7962-7970	interest	_	
42-19	7971-7973	in	_	
42-20	7974-7983	potential	_	
42-21	7984-7991	chronic	_	
42-22	7992-7999	effects	_	
42-23	8000-8002	of	_	
42-24	8003-8011	cannabis	_	
42-25	8012-8014	in	_	
42-26	8015-8020	these	_	
42-27	8021-8028	domains	_	
42-28	8028-8029	.	_	

#Text=Participants completed various NIH toolbox measures as part of the HCP.
43-1	8030-8042	Participants	_	
43-2	8043-8052	completed	_	
43-3	8053-8060	various	_	
43-4	8061-8064	NIH	_	
43-5	8065-8072	toolbox	_	
43-6	8073-8081	measures	_	
43-7	8082-8084	as	_	
43-8	8085-8089	part	_	
43-9	8090-8092	of	_	
43-10	8093-8096	the	_	
43-11	8097-8100	HCP	_	
43-12	8100-8101	.	_	

#Text=We were particularly interested in relating the current work to our previous findings that CA are vulnerable to feelings of alienation, i.e. the belief that others wish them harm, and that they are betrayed or deceived by friends.
44-1	8102-8104	We	_	
44-2	8105-8109	were	_	
44-3	8110-8122	particularly	_	
44-4	8123-8133	interested	_	
44-5	8134-8136	in	_	
44-6	8137-8145	relating	_	
44-7	8146-8149	the	_	
44-8	8150-8157	current	_	
44-9	8158-8162	work	_	
44-10	8163-8165	to	_	
44-11	8166-8169	our	_	
44-12	8170-8178	previous	_	
44-13	8179-8187	findings	_	
44-14	8188-8192	that	_	
44-15	8193-8195	CA	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	
44-16	8196-8199	are	_	
44-17	8200-8210	vulnerable	_	
44-18	8211-8213	to	_	
44-19	8214-8222	feelings	_	
44-20	8223-8225	of	_	
44-21	8226-8236	alienation	_	
44-22	8236-8237	,	_	
44-23	8238-8241	i.e	_	
44-24	8241-8242	.	_	
44-25	8243-8246	the	_	
44-26	8247-8253	belief	_	
44-27	8254-8258	that	_	
44-28	8259-8265	others	_	
44-29	8266-8270	wish	_	
44-30	8271-8275	them	_	
44-31	8276-8280	harm	_	
44-32	8280-8281	,	_	
44-33	8282-8285	and	_	
44-34	8286-8290	that	_	
44-35	8291-8295	they	_	
44-36	8296-8299	are	_	
44-37	8300-8308	betrayed	_	
44-38	8309-8311	or	_	
44-39	8312-8320	deceived	_	
44-40	8321-8323	by	_	
44-41	8324-8331	friends	_	
44-42	8331-8332	.	_	

#Text=However, our previous work used the Multidimensional Personality Questionnaire (MPQ) and this was not administered as part of the HCP protocol.
45-1	8333-8340	However	_	
45-2	8340-8341	,	_	
45-3	8342-8345	our	_	
45-4	8346-8354	previous	_	
45-5	8355-8359	work	_	
45-6	8360-8364	used	_	
45-7	8365-8368	the	_	
45-8	8369-8385	Multidimensional	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-9	8386-8397	Personality	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-10	8398-8411	Questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-11	8412-8413	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-12	8413-8416	MPQ	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-13	8416-8417	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[13]	
45-14	8418-8421	and	_	
45-15	8422-8426	this	_	
45-16	8427-8430	was	_	
45-17	8431-8434	not	_	
45-18	8435-8447	administered	_	
45-19	8448-8450	as	_	
45-20	8451-8455	part	_	
45-21	8456-8458	of	_	
45-22	8459-8462	the	_	
45-23	8463-8466	HCP	_	
45-24	8467-8475	protocol	_	
45-25	8475-8476	.	_	

#Text=Therefore, we attempted to find analogous measures for the three main domains of the MPQ: stress reactivity, aggression, and alienation.
46-1	8477-8486	Therefore	_	
46-2	8486-8487	,	_	
46-3	8488-8490	we	_	
46-4	8491-8500	attempted	_	
46-5	8501-8503	to	_	
46-6	8504-8508	find	_	
46-7	8509-8518	analogous	_	
46-8	8519-8527	measures	_	
46-9	8528-8531	for	_	
46-10	8532-8535	the	_	
46-11	8536-8541	three	_	
46-12	8542-8546	main	_	
46-13	8547-8554	domains	_	
46-14	8555-8557	of	_	
46-15	8558-8561	the	_	
46-16	8562-8565	MPQ	_	
46-17	8565-8566	:	_	
46-18	8567-8573	stress	_	
46-19	8574-8584	reactivity	_	
46-20	8584-8585	,	_	
46-21	8586-8596	aggression	_	
46-22	8596-8597	,	_	
46-23	8598-8601	and	_	
46-24	8602-8612	alienation	_	
46-25	8612-8613	.	_	

#Text=For stress reactivity, we used the “perceived stress” measure; for aggression, we averaged together the Z-scores of “Anger Hostility” and “Anger Aggression” (i.e., one’s own behavior in the anger and aggressive domains); and for alienation we averaged together the Z-scores of “Perceived Hostility” and “Perceived Rejection” (i.e., how one perceives others behaving towards them).
47-1	8614-8617	For	_	
47-2	8618-8624	stress	_	
47-3	8625-8635	reactivity	_	
47-4	8635-8636	,	_	
47-5	8637-8639	we	_	
47-6	8640-8644	used	_	
47-7	8645-8648	the	_	
47-8	8649-8650	“	_	
47-9	8650-8659	perceived	_	
47-10	8660-8666	stress	_	
47-11	8666-8667	”	_	
47-12	8668-8675	measure	_	
47-13	8675-8676	;	_	
47-14	8677-8680	for	_	
47-15	8681-8691	aggression	_	
47-16	8691-8692	,	_	
47-17	8693-8695	we	_	
47-18	8696-8704	averaged	_	
47-19	8705-8713	together	_	
47-20	8714-8717	the	_	
47-21	8718-8726	Z-scores	_	
47-22	8727-8729	of	_	
47-23	8730-8731	“	_	
47-24	8731-8736	Anger	_	
47-25	8737-8746	Hostility	_	
47-26	8746-8747	”	_	
47-27	8748-8751	and	_	
47-28	8752-8753	“	_	
47-29	8753-8758	Anger	_	
47-30	8759-8769	Aggression	_	
47-31	8769-8770	”	_	
47-32	8771-8772	(	_	
47-33	8772-8775	i.e	_	
47-34	8775-8776	.	_	
47-35	8776-8777	,	_	
47-36	8778-8781	one	_	
47-37	8781-8782	’	_	
47-38	8782-8783	s	_	
47-39	8784-8787	own	_	
47-40	8788-8796	behavior	_	
47-41	8797-8799	in	_	
47-42	8800-8803	the	_	
47-43	8804-8809	anger	_	
47-44	8810-8813	and	_	
47-45	8814-8824	aggressive	_	
47-46	8825-8832	domains	_	
47-47	8832-8833	)	_	
47-48	8833-8834	;	_	
47-49	8835-8838	and	_	
47-50	8839-8842	for	_	
47-51	8843-8853	alienation	_	
47-52	8854-8856	we	_	
47-53	8857-8865	averaged	_	
47-54	8866-8874	together	_	
47-55	8875-8878	the	_	
47-56	8879-8887	Z-scores	_	
47-57	8888-8890	of	_	
47-58	8891-8892	“	_	
47-59	8892-8901	Perceived	_	
47-60	8902-8911	Hostility	_	
47-61	8911-8912	”	_	
47-62	8913-8916	and	_	
47-63	8917-8918	“	_	
47-64	8918-8927	Perceived	_	
47-65	8928-8937	Rejection	_	
47-66	8937-8938	”	_	
47-67	8939-8940	(	_	
47-68	8940-8943	i.e	_	
47-69	8943-8944	.	_	
47-70	8944-8945	,	_	
47-71	8946-8949	how	_	
47-72	8950-8953	one	_	
47-73	8954-8963	perceives	_	
47-74	8964-8970	others	_	
47-75	8971-8979	behaving	_	
47-76	8980-8987	towards	_	
47-77	8988-8992	them	_	
47-78	8992-8993	)	_	
47-79	8993-8994	.	_	

#Text=We then averaged together these stress, aggression, and alienation measures together for a composite negative emotionality score.
48-1	8995-8997	We	_	
48-2	8998-9002	then	_	
48-3	9003-9011	averaged	_	
48-4	9012-9020	together	_	
48-5	9021-9026	these	_	
48-6	9027-9033	stress	_	
48-7	9033-9034	,	_	
48-8	9035-9045	aggression	_	
48-9	9045-9046	,	_	
48-10	9047-9050	and	_	
48-11	9051-9061	alienation	_	
48-12	9062-9070	measures	_	
48-13	9071-9079	together	_	
48-14	9080-9083	for	_	
48-15	9084-9085	a	_	
48-16	9086-9095	composite	_	
48-17	9096-9104	negative	_	
48-18	9105-9117	emotionality	_	
48-19	9118-9123	score	_	
48-20	9123-9124	.	_	

#Text=All three domains were included to examine if the effects were specific to alienation.
49-1	9125-9128	All	_	
49-2	9129-9134	three	_	
49-3	9135-9142	domains	_	
49-4	9143-9147	were	_	
49-5	9148-9156	included	_	
49-6	9157-9159	to	_	
49-7	9160-9167	examine	_	
49-8	9168-9170	if	_	
49-9	9171-9174	the	_	
49-10	9175-9182	effects	_	
49-11	9183-9187	were	_	
49-12	9188-9196	specific	_	
49-13	9197-9199	to	_	
49-14	9200-9210	alienation	_	
49-15	9210-9211	.	_	

#Text=More comprehensive descriptions of cognitive and emotional measures are available in Supplementary Material and https://wiki.humanconnectome.org/display/PublicData/HCP+Data+Dictionary+Public+500+Subject+Release.
50-1	9212-9216	More	_	
50-2	9217-9230	comprehensive	_	
50-3	9231-9243	descriptions	_	
50-4	9244-9246	of	_	
50-5	9247-9256	cognitive	_	
50-6	9257-9260	and	_	
50-7	9261-9270	emotional	_	
50-8	9271-9279	measures	_	
50-9	9280-9283	are	_	
50-10	9284-9293	available	_	
50-11	9294-9296	in	_	
50-12	9297-9310	Supplementary	_	
50-13	9311-9319	Material	_	
50-14	9320-9323	and	_	
50-15	9324-9329	https	_	
50-16	9329-9330	:	_	
50-17	9330-9331	/	_	
50-18	9331-9332	/	_	
50-19	9332-9356	wiki.humanconnectome.org	_	
50-20	9356-9357	/	_	
50-21	9357-9364	display	_	
50-22	9364-9365	/	_	
50-23	9365-9375	PublicData	_	
50-24	9375-9376	/	_	
50-25	9376-9379	HCP	_	
50-26	9379-9380	+	_	
50-27	9380-9384	Data	_	
50-28	9384-9385	+	_	
50-29	9385-9395	Dictionary	_	
50-30	9395-9396	+	_	
50-31	9396-9402	Public	_	
50-32	9402-9403	+	_	
50-33	9403-9406	500	_	
50-34	9406-9407	+	_	
50-35	9407-9414	Subject	_	
50-36	9414-9415	+	_	
50-37	9415-9422	Release	_	
50-38	9422-9423	.	_	

#Text=MRI image acquisition and preprocessing
#Text=All brain images were collected on a Siemens 3T “connectome Skyra” scanner with a 32-channel coil at Washington University in St.
51-1	9424-9427	MRI	_	
51-2	9428-9433	image	_	
51-3	9434-9445	acquisition	_	
51-4	9446-9449	and	_	
51-5	9450-9463	preprocessing	_	
51-6	9464-9467	All	_	
51-7	9468-9473	brain	_	
51-8	9474-9480	images	_	
51-9	9481-9485	were	_	
51-10	9486-9495	collected	_	
51-11	9496-9498	on	_	
51-12	9499-9500	a	_	
51-13	9501-9508	Siemens	_	
51-14	9509-9511	3T	_	
51-15	9512-9513	“	_	
51-16	9513-9523	connectome	_	
51-17	9524-9529	Skyra	_	
51-18	9529-9530	”	_	
51-19	9531-9538	scanner	_	
51-20	9539-9543	with	_	
51-21	9544-9545	a	_	
51-22	9546-9548	32	_	
51-23	9548-9549	-	_	
51-24	9549-9556	channel	_	
51-25	9557-9561	coil	_	
51-26	9562-9564	at	_	
51-27	9565-9575	Washington	_	
51-28	9576-9586	University	_	
51-29	9587-9589	in	_	
51-30	9590-9592	St	_	
51-31	9592-9593	.	_	

#Text=Louis.
52-1	9594-9599	Louis	_	
52-2	9599-9600	.	_	

#Text=T1- and T2-weighted anatomical scans were acquired (FOV=224 mm, matrix=320, 256 slices, 0.7 mm isotropic voxels). rsfMRI scans were acquired with an EPI sequence (Multiband factor = 8, TR = 720 ms, TE = 33.1 ms, flip angle = 52°, FOV = 208 mm, 104 × 90 matrix, 72 slices of 2 mm isotropic voxels, no gap).
53-1	9601-9603	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[14]	
53-2	9603-9604	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[14]	
53-3	9605-9608	and	_	
53-4	9609-9611	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[15]	
53-5	9611-9612	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[15]	
53-6	9612-9620	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[15]	
53-7	9621-9631	anatomical	_	
53-8	9632-9637	scans	_	
53-9	9638-9642	were	_	
53-10	9643-9651	acquired	_	
53-11	9652-9653	(	_	
53-12	9653-9656	FOV	_	
53-13	9656-9657	=	_	
53-14	9657-9660	224	_	
53-15	9661-9663	mm	_	
53-16	9663-9664	,	_	
53-17	9665-9671	matrix	_	
53-18	9671-9672	=	_	
53-19	9672-9675	320	_	
53-20	9675-9676	,	_	
53-21	9677-9680	256	_	
53-22	9681-9687	slices	_	
53-23	9687-9688	,	_	
53-24	9689-9692	0.7	_	
53-25	9693-9695	mm	_	
53-26	9696-9705	isotropic	_	
53-27	9706-9712	voxels	_	
53-28	9712-9713	)	_	
53-29	9713-9714	.	_	
53-30	9715-9721	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
53-31	9722-9727	scans	_	
53-32	9728-9732	were	_	
53-33	9733-9741	acquired	_	
53-34	9742-9746	with	_	
53-35	9747-9749	an	_	
53-36	9750-9753	EPI	_	
53-37	9754-9762	sequence	_	
53-38	9763-9764	(	_	
53-39	9764-9773	Multiband	_	
53-40	9774-9780	factor	_	
53-41	9781-9782	=	_	
53-42	9783-9784	8	_	
53-43	9784-9785	,	_	
53-44	9786-9788	TR	_	
53-45	9789-9790	=	_	
53-46	9791-9794	720	_	
53-47	9795-9797	ms	_	
53-48	9797-9798	,	_	
53-49	9799-9801	TE	_	
53-50	9802-9803	=	_	
53-51	9804-9808	33.1	_	
53-52	9809-9811	ms	_	
53-53	9811-9812	,	_	
53-54	9813-9817	flip	_	
53-55	9818-9823	angle	_	
53-56	9824-9825	=	_	
53-57	9826-9828	52	_	
53-58	9828-9829	°	_	
53-59	9829-9830	,	_	
53-60	9831-9834	FOV	_	
53-61	9835-9836	=	_	
53-62	9837-9840	208	_	
53-63	9841-9843	mm	_	
53-64	9843-9844	,	_	
53-65	9845-9848	104	_	
53-66	9849-9850	×	_	
53-67	9851-9853	90	_	
53-68	9854-9860	matrix	_	
53-69	9860-9861	,	_	
53-70	9862-9864	72	_	
53-71	9865-9871	slices	_	
53-72	9872-9874	of	_	
53-73	9875-9876	2	_	
53-74	9877-9879	mm	_	
53-75	9880-9889	isotropic	_	
53-76	9890-9896	voxels	_	
53-77	9896-9897	,	_	
53-78	9898-9900	no	_	
53-79	9901-9904	gap	_	
53-80	9904-9905	)	_	
53-81	9905-9906	.	_	

#Text=Two sessions were completed with two rsfMRI scans (one LR and one RL phase encoding) in each session.
54-1	9907-9910	Two	_	
54-2	9911-9919	sessions	_	
54-3	9920-9924	were	_	
54-4	9925-9934	completed	_	
54-5	9935-9939	with	_	
54-6	9940-9943	two	_	
54-7	9944-9950	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
54-8	9951-9956	scans	_	
54-9	9957-9958	(	_	
54-10	9958-9961	one	_	
54-11	9962-9964	LR	_	
54-12	9965-9968	and	_	
54-13	9969-9972	one	_	
54-14	9973-9975	RL	_	
54-15	9976-9981	phase	_	
54-16	9982-9990	encoding	_	
54-17	9990-9991	)	_	
54-18	9992-9994	in	_	
54-19	9995-9999	each	_	
54-20	10000-10007	session	_	
54-21	10007-10008	.	_	

#Text=Each scan was 14:33 min, for a total of 54:15 min.
55-1	10009-10013	Each	_	
55-2	10014-10018	scan	_	
55-3	10019-10022	was	_	
55-4	10023-10025	14	_	
55-5	10025-10026	:	_	
55-6	10026-10028	33	_	
55-7	10029-10032	min	_	
55-8	10032-10033	,	_	
55-9	10034-10037	for	_	
55-10	10038-10039	a	_	
55-11	10040-10045	total	_	
55-12	10046-10048	of	_	
55-13	10049-10051	54	_	
55-14	10051-10052	:	_	
55-15	10052-10054	15	_	
55-16	10055-10058	min	_	
55-17	10058-10059	.	_	

#Text=For rsfMRI, participants were instructed to lie with eyes open, to relax and look at a white cross on a dark background, think of nothing and to not fall asleep.
56-1	10060-10063	For	_	
56-2	10064-10070	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
56-3	10070-10071	,	_	
56-4	10072-10084	participants	_	
56-5	10085-10089	were	_	
56-6	10090-10100	instructed	_	
56-7	10101-10103	to	_	
56-8	10104-10107	lie	_	
56-9	10108-10112	with	_	
56-10	10113-10117	eyes	_	
56-11	10118-10122	open	_	
56-12	10122-10123	,	_	
56-13	10124-10126	to	_	
56-14	10127-10132	relax	_	
56-15	10133-10136	and	_	
56-16	10137-10141	look	_	
56-17	10142-10144	at	_	
56-18	10145-10146	a	_	
56-19	10147-10152	white	_	
56-20	10153-10158	cross	_	
56-21	10159-10161	on	_	
56-22	10162-10163	a	_	
56-23	10164-10168	dark	_	
56-24	10169-10179	background	_	
56-25	10179-10180	,	_	
56-26	10181-10186	think	_	
56-27	10187-10189	of	_	
56-28	10190-10197	nothing	_	
56-29	10198-10201	and	_	
56-30	10202-10204	to	_	
56-31	10205-10208	not	_	
56-32	10209-10213	fall	_	
56-33	10214-10220	asleep	_	
56-34	10220-10221	.	_	

#Text=For further details on image acquisition, see https://www.humanconnectome.org/documentation/S500/HCP_S500+MEG2_Release_Appendix_I.pdf.
57-1	10222-10225	For	_	
57-2	10226-10233	further	_	
57-3	10234-10241	details	_	
57-4	10242-10244	on	_	
57-5	10245-10250	image	_	
57-6	10251-10262	acquisition	_	
57-7	10262-10263	,	_	
57-8	10264-10267	see	_	
57-9	10268-10273	https	_	
57-10	10273-10274	:	_	
57-11	10274-10275	/	_	
57-12	10275-10276	/	_	
57-13	10276-10299	www.humanconnectome.org	_	
57-14	10299-10300	/	_	
57-15	10300-10313	documentation	_	
57-16	10313-10314	/	_	
57-17	10314-10318	S500	_	
57-18	10318-10319	/	_	
57-19	10319-10327	HCP_S500	_	
57-20	10327-10328	+	_	
57-21	10328-10332	MEG2	_	
57-22	10332-10333	_	_	
57-23	10333-10355	Release_Appendix_I.pdf	_	
57-24	10355-10356	.	_	

#Text=For analysis of rsfMRI data, we used the “minimal preprocessing” datasets (hp2000_clean.nii files), where preprocessing included: a) gradient distortion correction, b) rigid body realignment, c) field map processing, d) nonlinear normalization to MNI space, e) high-pass filtering with independent component analysis (ICA)-based denoising, and f) brain masking.
58-1	10357-10360	For	_	
58-2	10361-10369	analysis	_	
58-3	10370-10372	of	_	
58-4	10373-10379	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
58-5	10380-10384	data	_	
58-6	10384-10385	,	_	
58-7	10386-10388	we	_	
58-8	10389-10393	used	_	
58-9	10394-10397	the	_	
58-10	10398-10399	“	_	
58-11	10399-10406	minimal	_	
58-12	10407-10420	preprocessing	_	
58-13	10420-10421	”	_	
58-14	10422-10430	datasets	_	
58-15	10431-10432	(	_	
58-16	10432-10438	hp2000	_	
58-17	10438-10439	_	_	
58-18	10439-10448	clean.nii	_	
58-19	10449-10454	files	_	
58-20	10454-10455	)	_	
58-21	10455-10456	,	_	
58-22	10457-10462	where	_	
58-23	10463-10476	preprocessing	_	
58-24	10477-10485	included	_	
58-25	10485-10486	:	_	
58-26	10487-10488	a	_	
58-27	10488-10489	)	_	
58-28	10490-10498	gradient	_	
58-29	10499-10509	distortion	_	
58-30	10510-10520	correction	_	
58-31	10520-10521	,	_	
58-32	10522-10523	b	_	
58-33	10523-10524	)	_	
58-34	10525-10530	rigid	_	
58-35	10531-10535	body	_	
58-36	10536-10547	realignment	_	
58-37	10547-10548	,	_	
58-38	10549-10550	c	_	
58-39	10550-10551	)	_	
58-40	10552-10557	field	_	
58-41	10558-10561	map	_	
58-42	10562-10572	processing	_	
58-43	10572-10573	,	_	
58-44	10574-10575	d	_	
58-45	10575-10576	)	_	
58-46	10577-10586	nonlinear	_	
58-47	10587-10600	normalization	_	
58-48	10601-10603	to	_	
58-49	10604-10607	MNI	_	
58-50	10608-10613	space	_	
58-51	10613-10614	,	_	
58-52	10615-10616	e	_	
58-53	10616-10617	)	_	
58-54	10618-10627	high-pass	_	
58-55	10628-10637	filtering	_	
58-56	10638-10642	with	_	
58-57	10643-10654	independent	_	
58-58	10655-10664	component	_	
58-59	10665-10673	analysis	_	
58-60	10674-10675	(	_	
58-61	10675-10678	ICA	_	
58-62	10678-10679	)	_	
58-63	10679-10680	-	_	
58-64	10680-10685	based	_	
58-65	10686-10695	denoising	_	
58-66	10695-10696	,	_	
58-67	10697-10700	and	_	
58-68	10701-10702	f	_	
58-69	10702-10703	)	_	
58-70	10704-10709	brain	_	
58-71	10710-10717	masking	_	
58-72	10717-10718	.	_	

#Text=In our own subsequent preprocessing, we removed timepoints that were severely affected by motion using a ‘scrubbing’ approach (Supplementary Material).
59-1	10719-10721	In	_	
59-2	10722-10725	our	_	
59-3	10726-10729	own	_	
59-4	10730-10740	subsequent	_	
59-5	10741-10754	preprocessing	_	
59-6	10754-10755	,	_	
59-7	10756-10758	we	_	
59-8	10759-10766	removed	_	
59-9	10767-10777	timepoints	_	
59-10	10778-10782	that	_	
59-11	10783-10787	were	_	
59-12	10788-10796	severely	_	
59-13	10797-10805	affected	_	
59-14	10806-10808	by	_	
59-15	10809-10815	motion	_	
59-16	10816-10821	using	_	
59-17	10822-10823	a	_	
59-18	10824-10825	‘	_	
59-19	10825-10834	scrubbing	_	
59-20	10834-10835	’	_	
59-21	10836-10844	approach	_	
59-22	10845-10846	(	_	
59-23	10846-10859	Supplementary	_	
59-24	10860-10868	Material	_	
59-25	10868-10869	)	_	
59-26	10869-10870	.	_	

#Text=Remaining motion effects on fMRI time series were regressed out using the six translation and rotation regressors.
60-1	10871-10880	Remaining	_	
60-2	10881-10887	motion	_	
60-3	10888-10895	effects	_	
60-4	10896-10898	on	_	
60-5	10899-10903	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
60-6	10904-10908	time	_	
60-7	10909-10915	series	_	
60-8	10916-10920	were	_	
60-9	10921-10930	regressed	_	
60-10	10931-10934	out	_	
60-11	10935-10940	using	_	
60-12	10941-10944	the	_	
60-13	10945-10948	six	_	
60-14	10949-10960	translation	_	
60-15	10961-10964	and	_	
60-16	10965-10973	rotation	_	
60-17	10974-10984	regressors	_	
60-18	10984-10985	.	_	

#Text=Finally, band-pass temporal filtering (0.01–0.10 Hz) was applied. lFCD was computed separately on each of the four runs of processed, unsmoothed data, masked by each participant’s FreeSurfer subcortical parcellation (wmparc.2.nii.gz), which included bilateral thalamus, caudate, putamen, pallidum, amygdala, nucleus accumbens, hippocampus, midbrain and brainstem (see Local FCD section below).
61-1	10986-10993	Finally	_	
61-2	10993-10994	,	_	
61-3	10995-11004	band-pass	_	
61-4	11005-11013	temporal	_	
61-5	11014-11023	filtering	_	
61-6	11024-11025	(	_	
61-7	11025-11029	0.01	_	
61-8	11029-11030	–	_	
61-9	11030-11034	0.10	_	
61-10	11035-11037	Hz	_	
61-11	11037-11038	)	_	
61-12	11039-11042	was	_	
61-13	11043-11050	applied	_	
61-14	11050-11051	.	_	
61-15	11052-11056	lFCD	_	
61-16	11057-11060	was	_	
61-17	11061-11069	computed	_	
61-18	11070-11080	separately	_	
61-19	11081-11083	on	_	
61-20	11084-11088	each	_	
61-21	11089-11091	of	_	
61-22	11092-11095	the	_	
61-23	11096-11100	four	_	
61-24	11101-11105	runs	_	
61-25	11106-11108	of	_	
61-26	11109-11118	processed	_	
61-27	11118-11119	,	_	
61-28	11120-11130	unsmoothed	_	
61-29	11131-11135	data	_	
61-30	11135-11136	,	_	
61-31	11137-11143	masked	_	
61-32	11144-11146	by	_	
61-33	11147-11151	each	_	
61-34	11152-11163	participant	_	
61-35	11163-11164	’	_	
61-36	11164-11165	s	_	
61-37	11166-11176	FreeSurfer	_	
61-38	11177-11188	subcortical	_	
61-39	11189-11201	parcellation	_	
61-40	11202-11203	(	_	
61-41	11203-11209	wmparc	_	
61-42	11209-11211	.2	_	
61-43	11211-11212	.	_	
61-44	11212-11218	nii.gz	_	
61-45	11218-11219	)	_	
61-46	11219-11220	,	_	
61-47	11221-11226	which	_	
61-48	11227-11235	included	_	
61-49	11236-11245	bilateral	_	
61-50	11246-11254	thalamus	_	
61-51	11254-11255	,	_	
61-52	11256-11263	caudate	_	
61-53	11263-11264	,	_	
61-54	11265-11272	putamen	_	
61-55	11272-11273	,	_	
61-56	11274-11282	pallidum	_	
61-57	11282-11283	,	_	
61-58	11284-11292	amygdala	_	
61-59	11292-11293	,	_	
61-60	11294-11301	nucleus	_	
61-61	11302-11311	accumbens	_	
61-62	11311-11312	,	_	
61-63	11313-11324	hippocampus	_	
61-64	11324-11325	,	_	
61-65	11326-11334	midbrain	_	
61-66	11335-11338	and	_	
61-67	11339-11348	brainstem	_	
61-68	11349-11350	(	_	
61-69	11350-11353	see	_	
61-70	11354-11359	Local	_	
61-71	11360-11363	FCD	_	
61-72	11364-11371	section	_	
61-73	11372-11377	below	_	
61-74	11377-11378	)	_	
61-75	11378-11379	.	_	

#Text=Finally, the four resulting lFCD maps (LR/RL; REST1/REST2) were averaged together and averaged images were smoothed at 2mm FWHM.
62-1	11380-11387	Finally	_	
62-2	11387-11388	,	_	
62-3	11389-11392	the	_	
62-4	11393-11397	four	_	
62-5	11398-11407	resulting	_	
62-6	11408-11412	lFCD	_	
62-7	11413-11417	maps	_	
62-8	11418-11419	(	_	
62-9	11419-11421	LR	_	
62-10	11421-11422	/	_	
62-11	11422-11424	RL	_	
62-12	11424-11425	;	_	
62-13	11426-11431	REST1	_	
62-14	11431-11432	/	_	
62-15	11432-11437	REST2	_	
62-16	11437-11438	)	_	
62-17	11439-11443	were	_	
62-18	11444-11452	averaged	_	
62-19	11453-11461	together	_	
62-20	11462-11465	and	_	
62-21	11466-11474	averaged	_	
62-22	11475-11481	images	_	
62-23	11482-11486	were	_	
62-24	11487-11495	smoothed	_	
62-25	11496-11498	at	_	
62-26	11499-11502	2mm	_	
62-27	11503-11507	FWHM	_	
62-28	11507-11508	.	_	

#Text=Local FCD (lFCD) analysis
#Text=The Pearson correlation was used to assess the strength of functional connectivity, Cij, between voxels i and j.
63-1	11509-11514	Local	_	
63-2	11515-11518	FCD	_	
63-3	11519-11520	(	_	
63-4	11520-11524	lFCD	_	
63-5	11524-11525	)	_	
63-6	11526-11534	analysis	_	
63-7	11535-11538	The	_	
63-8	11539-11546	Pearson	_	
63-9	11547-11558	correlation	_	
63-10	11559-11562	was	_	
63-11	11563-11567	used	_	
63-12	11568-11570	to	_	
63-13	11571-11577	assess	_	
63-14	11578-11581	the	_	
63-15	11582-11590	strength	_	
63-16	11591-11593	of	_	
63-17	11594-11604	functional	_	
63-18	11605-11617	connectivity	_	
63-19	11617-11618	,	_	
63-20	11619-11622	Cij	_	
63-21	11622-11623	,	_	
63-22	11624-11631	between	_	
63-23	11632-11638	voxels	_	
63-24	11639-11640	i	_	
63-25	11641-11644	and	_	
63-26	11645-11646	j	_	
63-27	11646-11647	.	_	

#Text=A positive correlation threshold of r = 0.2 (sufficient to Bonferroni correct for the number of correlations performed in the subcortical mask, p < 1 × 10−4) was used to compute the binary connectivity coefficients, aij = 1 (if Cij > 0.2) or aij = 0 (if Cij ≤ 0.2).
64-1	11648-11649	A	_	
64-2	11650-11658	positive	_	
64-3	11659-11670	correlation	_	
64-4	11671-11680	threshold	_	
64-5	11681-11683	of	_	
64-6	11684-11685	r	_	
64-7	11686-11687	=	_	
64-8	11688-11691	0.2	_	
64-9	11692-11693	(	_	
64-10	11693-11703	sufficient	_	
64-11	11704-11706	to	_	
64-12	11707-11717	Bonferroni	_	
64-13	11718-11725	correct	_	
64-14	11726-11729	for	_	
64-15	11730-11733	the	_	
64-16	11734-11740	number	_	
64-17	11741-11743	of	_	
64-18	11744-11756	correlations	_	
64-19	11757-11766	performed	_	
64-20	11767-11769	in	_	
64-21	11770-11773	the	_	
64-22	11774-11785	subcortical	_	
64-23	11786-11790	mask	_	
64-24	11790-11791	,	_	
64-25	11792-11793	p	_	
64-26	11794-11795	<	_	
64-27	11796-11797	1	_	
64-28	11798-11799	×	_	
64-29	11800-11802	10	_	
64-30	11802-11803	−	_	
64-31	11803-11804	4	_	
64-32	11804-11805	)	_	
64-33	11806-11809	was	_	
64-34	11810-11814	used	_	
64-35	11815-11817	to	_	
64-36	11818-11825	compute	_	
64-37	11826-11829	the	_	
64-38	11830-11836	binary	_	
64-39	11837-11849	connectivity	_	
64-40	11850-11862	coefficients	_	
64-41	11862-11863	,	_	
64-42	11864-11867	aij	_	
64-43	11868-11869	=	_	
64-44	11870-11871	1	_	
64-45	11872-11873	(	_	
64-46	11873-11875	if	_	
64-47	11876-11879	Cij	_	
64-48	11880-11881	>	_	
64-49	11882-11885	0.2	_	
64-50	11885-11886	)	_	
64-51	11887-11889	or	_	
64-52	11890-11893	aij	_	
64-53	11894-11895	=	_	
64-54	11896-11897	0	_	
64-55	11898-11899	(	_	
64-56	11899-11901	if	_	
64-57	11902-11905	Cij	_	
64-58	11906-11907	≤	_	
64-59	11908-11911	0.2	_	
64-60	11911-11912	)	_	
64-61	11912-11913	.	_	

#Text=This threshold was lower than previous investigations to have sensitivity to detect effects in subcortical regions that have noisier signals than the neocortex, and hence have weaker observed resting-state correlations.
65-1	11914-11918	This	_	
65-2	11919-11928	threshold	_	
65-3	11929-11932	was	_	
65-4	11933-11938	lower	_	
65-5	11939-11943	than	_	
65-6	11944-11952	previous	_	
65-7	11953-11967	investigations	_	
65-8	11968-11970	to	_	
65-9	11971-11975	have	_	
65-10	11976-11987	sensitivity	_	
65-11	11988-11990	to	_	
65-12	11991-11997	detect	_	
65-13	11998-12005	effects	_	
65-14	12006-12008	in	_	
65-15	12009-12020	subcortical	_	
65-16	12021-12028	regions	_	
65-17	12029-12033	that	_	
65-18	12034-12038	have	_	
65-19	12039-12046	noisier	_	
65-20	12047-12054	signals	_	
65-21	12055-12059	than	_	
65-22	12060-12063	the	_	
65-23	12064-12073	neocortex	_	
65-24	12073-12074	,	_	
65-25	12075-12078	and	_	
65-26	12079-12084	hence	_	
65-27	12085-12089	have	_	
65-28	12090-12096	weaker	_	
65-29	12097-12105	observed	_	
65-30	12106-12119	resting-state	_	
65-31	12120-12132	correlations	_	
65-32	12132-12133	.	_	

#Text=The local FCD (or ‘local degree’) for voxel i was computed as the size of a continuous cluster of voxels with aij = 1, that are connected by surface.
66-1	12134-12137	The	_	
66-2	12138-12143	local	_	
66-3	12144-12147	FCD	_	
66-4	12148-12149	(	_	
66-5	12149-12151	or	_	
66-6	12152-12153	‘	_	
66-7	12153-12158	local	_	
66-8	12159-12165	degree	_	
66-9	12165-12166	’	_	
66-10	12166-12167	)	_	
66-11	12168-12171	for	_	
66-12	12172-12177	voxel	_	
66-13	12178-12179	i	_	
66-14	12180-12183	was	_	
66-15	12184-12192	computed	_	
66-16	12193-12195	as	_	
66-17	12196-12199	the	_	
66-18	12200-12204	size	_	
66-19	12205-12207	of	_	
66-20	12208-12209	a	_	
66-21	12210-12220	continuous	_	
66-22	12221-12228	cluster	_	
66-23	12229-12231	of	_	
66-24	12232-12238	voxels	_	
66-25	12239-12243	with	_	
66-26	12244-12247	aij	_	
66-27	12248-12249	=	_	
66-28	12250-12251	1	_	
66-29	12251-12252	,	_	
66-30	12253-12257	that	_	
66-31	12258-12261	are	_	
66-32	12262-12271	connected	_	
66-33	12272-12274	by	_	
66-34	12275-12282	surface	_	
66-35	12282-12283	.	_	

#Text=A ‘growing’ algorithm was used for time-efficient estimation of lFCD.
67-1	12284-12285	A	_	
67-2	12286-12287	‘	_	
67-3	12287-12294	growing	_	
67-4	12294-12295	’	_	
67-5	12296-12305	algorithm	_	
67-6	12306-12309	was	_	
67-7	12310-12314	used	_	
67-8	12315-12318	for	_	
67-9	12319-12333	time-efficient	_	
67-10	12334-12344	estimation	_	
67-11	12345-12347	of	_	
67-12	12348-12352	lFCD	_	
67-13	12352-12353	.	_	

#Text=Seed-based functional connectivity analysis
#Text=To examine functional connectivity differences with other regions of the brain, we computed seed-based connectivity using the same methods as our previous work (; Supplementary Material).
68-1	12354-12364	Seed-based	_	
68-2	12365-12375	functional	_	
68-3	12376-12388	connectivity	_	
68-4	12389-12397	analysis	_	
68-5	12398-12400	To	_	
68-6	12401-12408	examine	_	
68-7	12409-12419	functional	_	
68-8	12420-12432	connectivity	_	
68-9	12433-12444	differences	_	
68-10	12445-12449	with	_	
68-11	12450-12455	other	_	
68-12	12456-12463	regions	_	
68-13	12464-12466	of	_	
68-14	12467-12470	the	_	
68-15	12471-12476	brain	_	
68-16	12476-12477	,	_	
68-17	12478-12480	we	_	
68-18	12481-12489	computed	_	
68-19	12490-12500	seed-based	_	
68-20	12501-12513	connectivity	_	
68-21	12514-12519	using	_	
68-22	12520-12523	the	_	
68-23	12524-12528	same	_	
68-24	12529-12536	methods	_	
68-25	12537-12539	as	_	
68-26	12540-12543	our	_	
68-27	12544-12552	previous	_	
68-28	12553-12557	work	_	
68-29	12558-12559	(	_	
68-30	12559-12560	;	_	
68-31	12561-12574	Supplementary	_	
68-32	12575-12583	Material	_	
68-33	12583-12584	)	_	
68-34	12584-12585	.	_	

#Text=Statistical analysis
#Text=Second-level statistical analyses were conducted in SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/) for imaging data and in Graphpad Prism 7.02 (San Diego, CA) for behavioral data.
69-1	12586-12597	Statistical	_	
69-2	12598-12606	analysis	_	
69-3	12607-12619	Second-level	_	
69-4	12620-12631	statistical	_	
69-5	12632-12640	analyses	_	
69-6	12641-12645	were	_	
69-7	12646-12655	conducted	_	
69-8	12656-12658	in	_	
69-9	12659-12664	SPM12	_	
69-10	12665-12666	(	_	
69-11	12666-12670	http	_	
69-12	12670-12671	:	_	
69-13	12671-12672	/	_	
69-14	12672-12673	/	_	
69-15	12673-12694	www.fil.ion.ucl.ac.uk	_	
69-16	12694-12695	/	_	
69-17	12695-12698	spm	_	
69-18	12698-12699	/	_	
69-19	12699-12707	software	_	
69-20	12707-12708	/	_	
69-21	12708-12709	)	_	
69-22	12710-12713	for	_	
69-23	12714-12721	imaging	_	
69-24	12722-12726	data	_	
69-25	12727-12730	and	_	
69-26	12731-12733	in	_	
69-27	12734-12742	Graphpad	_	
69-28	12743-12748	Prism	_	
69-29	12749-12753	7.02	_	
69-30	12754-12755	(	_	
69-31	12755-12758	San	_	
69-32	12759-12764	Diego	_	
69-33	12764-12765	,	_	
69-34	12766-12768	CA	_	
69-35	12768-12769	)	_	
69-36	12770-12773	for	_	
69-37	12774-12784	behavioral	_	
69-38	12785-12789	data	_	
69-39	12789-12790	.	_	

#Text=First, to examine lFCD across the larger population, we conducted a one-sample T-test of lFCD across all 441 participants.
70-1	12791-12796	First	_	
70-2	12796-12797	,	_	
70-3	12798-12800	to	_	
70-4	12801-12808	examine	_	
70-5	12809-12813	lFCD	_	
70-6	12814-12820	across	_	
70-7	12821-12824	the	_	
70-8	12825-12831	larger	_	
70-9	12832-12842	population	_	
70-10	12842-12843	,	_	
70-11	12844-12846	we	_	
70-12	12847-12856	conducted	_	
70-13	12857-12858	a	_	
70-14	12859-12869	one-sample	_	
70-15	12870-12876	T-test	_	
70-16	12877-12879	of	_	
70-17	12880-12884	lFCD	_	
70-18	12885-12891	across	_	
70-19	12892-12895	all	_	
70-20	12896-12899	441	_	
70-21	12900-12912	participants	_	
70-22	12912-12913	.	_	

#Text=Next, to compare CA with the matched control group, we conducted a two-sample T-test of lFCD between groups.
71-1	12914-12918	Next	_	
71-2	12918-12919	,	_	
71-3	12920-12922	to	_	
71-4	12923-12930	compare	_	
71-5	12931-12933	CA	_	
71-6	12934-12938	with	_	
71-7	12939-12942	the	_	
71-8	12943-12950	matched	_	
71-9	12951-12958	control	_	
71-10	12959-12964	group	_	
71-11	12964-12965	,	_	
71-12	12966-12968	we	_	
71-13	12969-12978	conducted	_	
71-14	12979-12980	a	_	
71-15	12981-12991	two-sample	_	
71-16	12992-12998	T-test	_	
71-17	12999-13001	of	_	
71-18	13002-13006	lFCD	_	
71-19	13007-13014	between	_	
71-20	13015-13021	groups	_	
71-21	13021-13022	.	_	

#Text=These analyses were thresholded at p < .001, uncorrected, with a cluster-level correction of p < .05 family-wise error (FWE) corrected, and a minimum cluster size of k = 100 voxels.
72-1	13023-13028	These	_	
72-2	13029-13037	analyses	_	
72-3	13038-13042	were	_	
72-4	13043-13054	thresholded	_	
72-5	13055-13057	at	_	
72-6	13058-13059	p	_	
72-7	13060-13061	<	_	
72-8	13062-13066	.001	_	
72-9	13066-13067	,	_	
72-10	13068-13079	uncorrected	_	
72-11	13079-13080	,	_	
72-12	13081-13085	with	_	
72-13	13086-13087	a	_	
72-14	13088-13101	cluster-level	_	
72-15	13102-13112	correction	_	
72-16	13113-13115	of	_	
72-17	13116-13117	p	_	
72-18	13118-13119	<	_	
72-19	13120-13123	.05	_	
72-20	13124-13135	family-wise	_	
72-21	13136-13141	error	_	
72-22	13142-13143	(	_	
72-23	13143-13146	FWE	_	
72-24	13146-13147	)	_	
72-25	13148-13157	corrected	_	
72-26	13157-13158	,	_	
72-27	13159-13162	and	_	
72-28	13163-13164	a	_	
72-29	13165-13172	minimum	_	
72-30	13173-13180	cluster	_	
72-31	13181-13185	size	_	
72-32	13186-13188	of	_	
72-33	13189-13190	k	_	
72-34	13191-13192	=	_	
72-35	13193-13196	100	_	
72-36	13197-13203	voxels	_	
72-37	13203-13204	.	_	

#Text=To control cluster-level type I error rates, we calculated cluster corrections with the Statistical nonparametric mapping toolbox (SnPM13: http://warwick.ac.uk/snpm; 5000 permutations).
73-1	13205-13207	To	_	
73-2	13208-13215	control	_	
73-3	13216-13229	cluster-level	_	
73-4	13230-13234	type	_	
73-5	13235-13236	I	_	
73-6	13237-13242	error	_	
73-7	13243-13248	rates	_	
73-8	13248-13249	,	_	
73-9	13250-13252	we	_	
73-10	13253-13263	calculated	_	
73-11	13264-13271	cluster	_	
73-12	13272-13283	corrections	_	
73-13	13284-13288	with	_	
73-14	13289-13292	the	_	
73-15	13293-13304	Statistical	_	
73-16	13305-13318	nonparametric	_	
73-17	13319-13326	mapping	_	
73-18	13327-13334	toolbox	_	
73-19	13335-13336	(	_	
73-20	13336-13342	SnPM13	_	
73-21	13342-13343	:	_	
73-22	13344-13348	http	_	
73-23	13348-13349	:	_	
73-24	13349-13350	/	_	
73-25	13350-13351	/	_	
73-26	13351-13364	warwick.ac.uk	_	
73-27	13364-13365	/	_	
73-28	13365-13369	snpm	_	
73-29	13369-13370	;	_	
73-30	13371-13375	5000	_	
73-31	13376-13388	permutations	_	
73-32	13388-13389	)	_	
73-33	13389-13390	.	_	

#Text=Because lFCD has a power law distribution, we also conducted analyses with log-transformed lFCD values; this did not alter the findings, and so we report these data in Supplementary material.
74-1	13391-13398	Because	_	
74-2	13399-13403	lFCD	_	
74-3	13404-13407	has	_	
74-4	13408-13409	a	_	
74-5	13410-13415	power	_	
74-6	13416-13419	law	_	
74-7	13420-13432	distribution	_	
74-8	13432-13433	,	_	
74-9	13434-13436	we	_	
74-10	13437-13441	also	_	
74-11	13442-13451	conducted	_	
74-12	13452-13460	analyses	_	
74-13	13461-13465	with	_	
74-14	13466-13481	log-transformed	_	
74-15	13482-13486	lFCD	_	
74-16	13487-13493	values	_	
74-17	13493-13494	;	_	
74-18	13495-13499	this	_	
74-19	13500-13503	did	_	
74-20	13504-13507	not	_	
74-21	13508-13513	alter	_	
74-22	13514-13517	the	_	
74-23	13518-13526	findings	_	
74-24	13526-13527	,	_	
74-25	13528-13531	and	_	
74-26	13532-13534	so	_	
74-27	13535-13537	we	_	
74-28	13538-13544	report	_	
74-29	13545-13550	these	_	
74-30	13551-13555	data	_	
74-31	13556-13558	in	_	
74-32	13559-13572	Supplementary	_	
74-33	13573-13581	material	_	
74-34	13581-13582	.	_	

#Text=We also conducted two-sample T-tests on the volume of subcortical nuclei (from FreeSurfer output), as well as measures of cognition and negative emotionality.
75-1	13583-13585	We	_	
75-2	13586-13590	also	_	
75-3	13591-13600	conducted	_	
75-4	13601-13611	two-sample	_	
75-5	13612-13619	T-tests	_	
75-6	13620-13622	on	_	
75-7	13623-13626	the	_	
75-8	13627-13633	volume	_	
75-9	13634-13636	of	_	
75-10	13637-13648	subcortical	_	
75-11	13649-13655	nuclei	_	
75-12	13656-13657	(	_	
75-13	13657-13661	from	_	
75-14	13662-13672	FreeSurfer	_	
75-15	13673-13679	output	_	
75-16	13679-13680	)	_	
75-17	13680-13681	,	_	
75-18	13682-13684	as	_	
75-19	13685-13689	well	_	
75-20	13690-13692	as	_	
75-21	13693-13701	measures	_	
75-22	13702-13704	of	_	
75-23	13705-13714	cognition	_	
75-24	13715-13718	and	_	
75-25	13719-13727	negative	_	
75-26	13728-13740	emotionality	_	
75-27	13740-13741	.	_	

#Text=To examine if subcortical lFCD had relevance for aberrant cognition and/or negative emotionality in CA, we conducted correlation analysis between lFCD in regions showing significant group differences and in behavioral measures showing significant group differences.
76-1	13742-13744	To	_	
76-2	13745-13752	examine	_	
76-3	13753-13755	if	_	
76-4	13756-13767	subcortical	_	
76-5	13768-13772	lFCD	_	
76-6	13773-13776	had	_	
76-7	13777-13786	relevance	_	
76-8	13787-13790	for	_	
76-9	13791-13799	aberrant	_	
76-10	13800-13809	cognition	_	
76-11	13810-13813	and	_	
76-12	13813-13814	/	_	
76-13	13814-13816	or	_	
76-14	13817-13825	negative	_	
76-15	13826-13838	emotionality	_	
76-16	13839-13841	in	_	
76-17	13842-13844	CA	_	
76-18	13844-13845	,	_	
76-19	13846-13848	we	_	
76-20	13849-13858	conducted	_	
76-21	13859-13870	correlation	_	
76-22	13871-13879	analysis	_	
76-23	13880-13887	between	_	
76-24	13888-13892	lFCD	_	
76-25	13893-13895	in	_	
76-26	13896-13903	regions	_	
76-27	13904-13911	showing	_	
76-28	13912-13923	significant	_	
76-29	13924-13929	group	_	
76-30	13930-13941	differences	_	
76-31	13942-13945	and	_	
76-32	13946-13948	in	_	
76-33	13949-13959	behavioral	_	
76-34	13960-13968	measures	_	
76-35	13969-13976	showing	_	
76-36	13977-13988	significant	_	
76-37	13989-13994	group	_	
76-38	13995-14006	differences	_	
76-39	14006-14007	.	_	

#Text=Results
#Text=Demographics and behavioral measures
#Text=Demographics and lifestyle factors with descriptive statistics are presented in Table 1.
77-1	14008-14015	Results	_	
77-2	14016-14028	Demographics	_	
77-3	14029-14032	and	_	
77-4	14033-14043	behavioral	_	
77-5	14044-14052	measures	_	
77-6	14053-14065	Demographics	_	
77-7	14066-14069	and	_	
77-8	14070-14079	lifestyle	_	
77-9	14080-14087	factors	_	
77-10	14088-14092	with	_	
77-11	14093-14104	descriptive	_	
77-12	14105-14115	statistics	_	
77-13	14116-14119	are	_	
77-14	14120-14129	presented	_	
77-15	14130-14132	in	_	
77-16	14133-14138	Table	_	
77-17	14139-14140	1	_	
77-18	14140-14141	.	_	

#Text=The groups did not significantly differ on any of the DSM-oriented scales, including depression, ADHD, panic disorder, agoraphobia, anxiety, and somatic problems (all p’s > .15), except the CA group reported higher levels of antisocial behavior (p = .05) and more childhood conduct problems (p = .008).
78-1	14142-14145	The	_	
78-2	14146-14152	groups	_	
78-3	14153-14156	did	_	
78-4	14157-14160	not	_	
78-5	14161-14174	significantly	_	
78-6	14175-14181	differ	_	
78-7	14182-14184	on	_	
78-8	14185-14188	any	_	
78-9	14189-14191	of	_	
78-10	14192-14195	the	_	
78-11	14196-14208	DSM-oriented	_	
78-12	14209-14215	scales	_	
78-13	14215-14216	,	_	
78-14	14217-14226	including	_	
78-15	14227-14237	depression	_	
78-16	14237-14238	,	_	
78-17	14239-14243	ADHD	_	
78-18	14243-14244	,	_	
78-19	14245-14250	panic	_	
78-20	14251-14259	disorder	_	
78-21	14259-14260	,	_	
78-22	14261-14272	agoraphobia	_	
78-23	14272-14273	,	_	
78-24	14274-14281	anxiety	_	
78-25	14281-14282	,	_	
78-26	14283-14286	and	_	
78-27	14287-14294	somatic	_	
78-28	14295-14303	problems	_	
78-29	14304-14305	(	_	
78-30	14305-14308	all	_	
78-31	14309-14310	p	_	
78-32	14310-14311	’	_	
78-33	14311-14312	s	_	
78-34	14313-14314	>	_	
78-35	14315-14318	.15	_	
78-36	14318-14319	)	_	
78-37	14319-14320	,	_	
78-38	14321-14327	except	_	
78-39	14328-14331	the	_	
78-40	14332-14334	CA	_	
78-41	14335-14340	group	_	
78-42	14341-14349	reported	_	
78-43	14350-14356	higher	_	
78-44	14357-14363	levels	_	
78-45	14364-14366	of	_	
78-46	14367-14377	antisocial	_	
78-47	14378-14386	behavior	_	
78-48	14387-14388	(	_	
78-49	14388-14389	p	_	
78-50	14390-14391	=	_	
78-51	14392-14395	.05	_	
78-52	14395-14396	)	_	
78-53	14397-14400	and	_	
78-54	14401-14405	more	_	
78-55	14406-14415	childhood	_	
78-56	14416-14423	conduct	_	
78-57	14424-14432	problems	_	
78-58	14433-14434	(	_	
78-59	14434-14435	p	_	
78-60	14436-14437	=	_	
78-61	14438-14442	.008	_	
78-62	14442-14443	)	_	
78-63	14443-14444	.	_	

#Text=Cognitive scores and measures of negative emotionality are presented in Table 2.
79-1	14445-14454	Cognitive	_	
79-2	14455-14461	scores	_	
79-3	14462-14465	and	_	
79-4	14466-14474	measures	_	
79-5	14475-14477	of	_	
79-6	14478-14486	negative	_	
79-7	14487-14499	emotionality	_	
79-8	14500-14503	are	_	
79-9	14504-14513	presented	_	
79-10	14514-14516	in	_	
79-11	14517-14522	Table	_	
79-12	14523-14524	2	_	
79-13	14524-14525	.	_	

#Text=Notably, while there were no obvious differences in cognitive performance, the CA group showed significantly higher levels of negative emotionality (t = 2.14, p = .036), particularly alienation (t = 2.34, p = .023), in line with our previous work.
80-1	14526-14533	Notably	_	
80-2	14533-14534	,	_	
80-3	14535-14540	while	_	
80-4	14541-14546	there	_	
80-5	14547-14551	were	_	
80-6	14552-14554	no	_	
80-7	14555-14562	obvious	_	
80-8	14563-14574	differences	_	
80-9	14575-14577	in	_	
80-10	14578-14587	cognitive	_	
80-11	14588-14599	performance	_	
80-12	14599-14600	,	_	
80-13	14601-14604	the	_	
80-14	14605-14607	CA	_	
80-15	14608-14613	group	_	
80-16	14614-14620	showed	_	
80-17	14621-14634	significantly	_	
80-18	14635-14641	higher	_	
80-19	14642-14648	levels	_	
80-20	14649-14651	of	_	
80-21	14652-14660	negative	_	
80-22	14661-14673	emotionality	_	
80-23	14674-14675	(	_	
80-24	14675-14676	t	_	
80-25	14677-14678	=	_	
80-26	14679-14683	2.14	_	
80-27	14683-14684	,	_	
80-28	14685-14686	p	_	
80-29	14687-14688	=	_	
80-30	14689-14693	.036	_	
80-31	14693-14694	)	_	
80-32	14694-14695	,	_	
80-33	14696-14708	particularly	_	
80-34	14709-14719	alienation	_	
80-35	14720-14721	(	_	
80-36	14721-14722	t	_	
80-37	14723-14724	=	_	
80-38	14725-14729	2.34	_	
80-39	14729-14730	,	_	
80-40	14731-14732	p	_	
80-41	14733-14734	=	_	
80-42	14735-14739	.023	_	
80-43	14739-14740	)	_	
80-44	14740-14741	,	_	
80-45	14742-14744	in	_	
80-46	14745-14749	line	_	
80-47	14750-14754	with	_	
80-48	14755-14758	our	_	
80-49	14759-14767	previous	_	
80-50	14768-14772	work	_	
80-51	14772-14773	.	_	

#Text=Subcortical Volume
#Text=Volumetric data and descriptive statistics are reported in Supplementary Table S1.
81-1	14774-14785	Subcortical	_	
81-2	14786-14792	Volume	_	
81-3	14793-14803	Volumetric	_	
81-4	14804-14808	data	_	
81-5	14809-14812	and	_	
81-6	14813-14824	descriptive	_	
81-7	14825-14835	statistics	_	
81-8	14836-14839	are	_	
81-9	14840-14848	reported	_	
81-10	14849-14851	in	_	
81-11	14852-14865	Supplementary	_	
81-12	14866-14871	Table	_	
81-13	14872-14874	S1	_	
81-14	14874-14875	.	_	

#Text=In line with recent work, no subcortical regions showed significantly different volume between CA and controls.
82-1	14876-14878	In	_	
82-2	14879-14883	line	_	
82-3	14884-14888	with	_	
82-4	14889-14895	recent	_	
82-5	14896-14900	work	_	
82-6	14900-14901	,	_	
82-7	14902-14904	no	_	
82-8	14905-14916	subcortical	_	
82-9	14917-14924	regions	_	
82-10	14925-14931	showed	_	
82-11	14932-14945	significantly	_	
82-12	14946-14955	different	_	
82-13	14956-14962	volume	_	
82-14	14963-14970	between	_	
82-15	14971-14973	CA	_	
82-16	14974-14977	and	_	
82-17	14978-14986	controls	_	
82-18	14986-14987	.	_	

#Text=However, CA did show a trend towards smaller volume of the left hippocampus (p = .068), consistent with findings of structural hippocampal abnormalities by prior studies in CA.
#Text=lFCD Analyses
#Text=We first conducted a voxelwise one-sample t-test of lFCD across all 441 participants.
83-1	14988-14995	However	_	
83-2	14995-14996	,	_	
83-3	14997-14999	CA	_	
83-4	15000-15003	did	_	
83-5	15004-15008	show	_	
83-6	15009-15010	a	_	
83-7	15011-15016	trend	_	
83-8	15017-15024	towards	_	
83-9	15025-15032	smaller	_	
83-10	15033-15039	volume	_	
83-11	15040-15042	of	_	
83-12	15043-15046	the	_	
83-13	15047-15051	left	_	
83-14	15052-15063	hippocampus	_	
83-15	15064-15065	(	_	
83-16	15065-15066	p	_	
83-17	15067-15068	=	_	
83-18	15069-15073	.068	_	
83-19	15073-15074	)	_	
83-20	15074-15075	,	_	
83-21	15076-15086	consistent	_	
83-22	15087-15091	with	_	
83-23	15092-15100	findings	_	
83-24	15101-15103	of	_	
83-25	15104-15114	structural	_	
83-26	15115-15126	hippocampal	_	
83-27	15127-15140	abnormalities	_	
83-28	15141-15143	by	_	
83-29	15144-15149	prior	_	
83-30	15150-15157	studies	_	
83-31	15158-15160	in	_	
83-32	15161-15163	CA	_	
83-33	15163-15164	.	_	
83-34	15165-15169	lFCD	_	
83-35	15170-15178	Analyses	_	
83-36	15179-15181	We	_	
83-37	15182-15187	first	_	
83-38	15188-15197	conducted	_	
83-39	15198-15199	a	_	
83-40	15200-15209	voxelwise	_	
83-41	15210-15220	one-sample	_	
83-42	15221-15227	t-test	_	
83-43	15228-15230	of	_	
83-44	15231-15235	lFCD	_	
83-45	15236-15242	across	_	
83-46	15243-15246	all	_	
83-47	15247-15250	441	_	
83-48	15251-15263	participants	_	
83-49	15263-15264	.	_	

#Text=Results showed widespread lFCD; to summarize, peaks were observed in ventral striatum, hippocampus, amygdala, midbrain, and the posterior-ventral brainstem (Figure 1; see Supplementary Figure S2 for maps restricted to CA and control groups).
84-1	15265-15272	Results	_	
84-2	15273-15279	showed	_	
84-3	15280-15290	widespread	_	
84-4	15291-15295	lFCD	_	
84-5	15295-15296	;	_	
84-6	15297-15299	to	_	
84-7	15300-15309	summarize	_	
84-8	15309-15310	,	_	
84-9	15311-15316	peaks	_	
84-10	15317-15321	were	_	
84-11	15322-15330	observed	_	
84-12	15331-15333	in	_	
84-13	15334-15341	ventral	_	
84-14	15342-15350	striatum	_	
84-15	15350-15351	,	_	
84-16	15352-15363	hippocampus	_	
84-17	15363-15364	,	_	
84-18	15365-15373	amygdala	_	
84-19	15373-15374	,	_	
84-20	15375-15383	midbrain	_	
84-21	15383-15384	,	_	
84-22	15385-15388	and	_	
84-23	15389-15392	the	_	
84-24	15393-15410	posterior-ventral	_	
84-25	15411-15420	brainstem	_	
84-26	15421-15422	(	_	
84-27	15422-15428	Figure	_	
84-28	15429-15430	1	_	
84-29	15430-15431	;	_	
84-30	15432-15435	see	_	
84-31	15436-15449	Supplementary	_	
84-32	15450-15456	Figure	_	
84-33	15457-15459	S2	_	
84-34	15460-15463	for	_	
84-35	15464-15468	maps	_	
84-36	15469-15479	restricted	_	
84-37	15480-15482	to	_	
84-38	15483-15485	CA	_	
84-39	15486-15489	and	_	
84-40	15490-15497	control	_	
84-41	15498-15504	groups	_	
84-42	15504-15505	)	_	
84-43	15505-15506	.	_	

#Text=We then examined group differences in lFCD between CA and matched controls.
85-1	15507-15509	We	_	
85-2	15510-15514	then	_	
85-3	15515-15523	examined	_	
85-4	15524-15529	group	_	
85-5	15530-15541	differences	_	
85-6	15542-15544	in	_	
85-7	15545-15549	lFCD	_	
85-8	15550-15557	between	_	
85-9	15558-15560	CA	_	
85-10	15561-15564	and	_	
85-11	15565-15572	matched	_	
85-12	15573-15581	controls	_	
85-13	15581-15582	.	_	

#Text=In voxelwise two-sample T-tests, CA demonstrated significantly higher lFCD in the ventral striatum, dorsal midbrain (including substantia nigra and ventral tegmental area), brainstem, and lateral thalamus (all p’s < 1×10−5, Figure 2a,b).
86-1	15583-15585	In	_	
86-2	15586-15595	voxelwise	_	
86-3	15596-15606	two-sample	_	
86-4	15607-15614	T-tests	_	
86-5	15614-15615	,	_	
86-6	15616-15618	CA	_	
86-7	15619-15631	demonstrated	_	
86-8	15632-15645	significantly	_	
86-9	15646-15652	higher	_	
86-10	15653-15657	lFCD	_	
86-11	15658-15660	in	_	
86-12	15661-15664	the	_	
86-13	15665-15672	ventral	_	
86-14	15673-15681	striatum	_	
86-15	15681-15682	,	_	
86-16	15683-15689	dorsal	_	
86-17	15690-15698	midbrain	_	
86-18	15699-15700	(	_	
86-19	15700-15709	including	_	
86-20	15710-15720	substantia	_	
86-21	15721-15726	nigra	_	
86-22	15727-15730	and	_	
86-23	15731-15738	ventral	_	
86-24	15739-15748	tegmental	_	
86-25	15749-15753	area	_	
86-26	15753-15754	)	_	
86-27	15754-15755	,	_	
86-28	15756-15765	brainstem	_	
86-29	15765-15766	,	_	
86-30	15767-15770	and	_	
86-31	15771-15778	lateral	_	
86-32	15779-15787	thalamus	_	
86-33	15788-15789	(	_	
86-34	15789-15792	all	_	
86-35	15793-15794	p	_	
86-36	15794-15795	’	_	
86-37	15795-15796	s	_	
86-38	15797-15798	<	_	
86-39	15799-15800	1	_	
86-40	15800-15801	×	_	
86-41	15801-15803	10	_	
86-42	15803-15804	−	_	
86-43	15804-15805	5	_	
86-44	15805-15806	,	_	
86-45	15807-15813	Figure	_	
86-46	15814-15816	2a	_	
86-47	15816-15817	,	_	
86-48	15817-15818	b	_	
86-49	15818-15819	)	_	
86-50	15819-15820	.	_	

#Text=Motion estimates were highly similar between the CA and control groups (mean framewise displacement across all images for CA: 0.171 ± 0.05, and for controls: 0.163 ± 0.05; t = −.557, p = .580); results were nearly identical when including motion or FreeSurfer-estimated subcortical volume as covariates in the model.
87-1	15821-15827	Motion	_	
87-2	15828-15837	estimates	_	
87-3	15838-15842	were	_	
87-4	15843-15849	highly	_	
87-5	15850-15857	similar	_	
87-6	15858-15865	between	_	
87-7	15866-15869	the	_	
87-8	15870-15872	CA	_	
87-9	15873-15876	and	_	
87-10	15877-15884	control	_	
87-11	15885-15891	groups	_	
87-12	15892-15893	(	_	
87-13	15893-15897	mean	_	
87-14	15898-15907	framewise	_	
87-15	15908-15920	displacement	_	
87-16	15921-15927	across	_	
87-17	15928-15931	all	_	
87-18	15932-15938	images	_	
87-19	15939-15942	for	_	
87-20	15943-15945	CA	_	
87-21	15945-15946	:	_	
87-22	15947-15952	0.171	_	
87-23	15953-15954	±	_	
87-24	15955-15959	0.05	_	
87-25	15959-15960	,	_	
87-26	15961-15964	and	_	
87-27	15965-15968	for	_	
87-28	15969-15977	controls	_	
87-29	15977-15978	:	_	
87-30	15979-15984	0.163	_	
87-31	15985-15986	±	_	
87-32	15987-15991	0.05	_	
87-33	15991-15992	;	_	
87-34	15993-15994	t	_	
87-35	15995-15996	=	_	
87-36	15997-15998	−	_	
87-37	15998-16002	.557	_	
87-38	16002-16003	,	_	
87-39	16004-16005	p	_	
87-40	16006-16007	=	_	
87-41	16008-16012	.580	_	
87-42	16012-16013	)	_	
87-43	16013-16014	;	_	
87-44	16015-16022	results	_	
87-45	16023-16027	were	_	
87-46	16028-16034	nearly	_	
87-47	16035-16044	identical	_	
87-48	16045-16049	when	_	
87-49	16050-16059	including	_	
87-50	16060-16066	motion	_	
87-51	16067-16069	or	_	
87-52	16070-16090	FreeSurfer-estimated	_	
87-53	16091-16102	subcortical	_	
87-54	16103-16109	volume	_	
87-55	16110-16112	as	_	
87-56	16113-16123	covariates	_	
87-57	16124-16126	in	_	
87-58	16127-16130	the	_	
87-59	16131-16136	model	_	
87-60	16136-16137	.	_	

#Text=Because the lFCD values across these four ROIs was highly correlated across subjects (mean bivariate correlation: r = 0.78), we averaged together the lFCD values across the four ROIs to increase statistical power; subsequent analyses refer to this averaged value.
88-1	16138-16145	Because	_	
88-2	16146-16149	the	_	
88-3	16150-16154	lFCD	_	
88-4	16155-16161	values	_	
88-5	16162-16168	across	_	
88-6	16169-16174	these	_	
88-7	16175-16179	four	_	
88-8	16180-16184	ROIs	_	
88-9	16185-16188	was	_	
88-10	16189-16195	highly	_	
88-11	16196-16206	correlated	_	
88-12	16207-16213	across	_	
88-13	16214-16222	subjects	_	
88-14	16223-16224	(	_	
88-15	16224-16228	mean	_	
88-16	16229-16238	bivariate	_	
88-17	16239-16250	correlation	_	
88-18	16250-16251	:	_	
88-19	16252-16253	r	_	
88-20	16254-16255	=	_	
88-21	16256-16260	0.78	_	
88-22	16260-16261	)	_	
88-23	16261-16262	,	_	
88-24	16263-16265	we	_	
88-25	16266-16274	averaged	_	
88-26	16275-16283	together	_	
88-27	16284-16287	the	_	
88-28	16288-16292	lFCD	_	
88-29	16293-16299	values	_	
88-30	16300-16306	across	_	
88-31	16307-16310	the	_	
88-32	16311-16315	four	_	
88-33	16316-16320	ROIs	_	
88-34	16321-16323	to	_	
88-35	16324-16332	increase	_	
88-36	16333-16344	statistical	_	
88-37	16345-16350	power	_	
88-38	16350-16351	;	_	
88-39	16352-16362	subsequent	_	
88-40	16363-16371	analyses	_	
88-41	16372-16377	refer	_	
88-42	16378-16380	to	_	
88-43	16381-16385	this	_	
88-44	16386-16394	averaged	_	
88-45	16395-16400	value	_	
88-46	16400-16401	.	_	

#Text=This averaged lFCD value did not significantly correlate with FreeSurfer subcortical volume estimates across subjects (r = −.10, p = .432).
89-1	16402-16406	This	_	
89-2	16407-16415	averaged	_	
89-3	16416-16420	lFCD	_	
89-4	16421-16426	value	_	
89-5	16427-16430	did	_	
89-6	16431-16434	not	_	
89-7	16435-16448	significantly	_	
89-8	16449-16458	correlate	_	
89-9	16459-16463	with	_	
89-10	16464-16474	FreeSurfer	_	
89-11	16475-16486	subcortical	_	
89-12	16487-16493	volume	_	
89-13	16494-16503	estimates	_	
89-14	16504-16510	across	_	
89-15	16511-16519	subjects	_	
89-16	16520-16521	(	_	
89-17	16521-16522	r	_	
89-18	16523-16524	=	_	
89-19	16525-16526	−	_	
89-20	16526-16529	.10	_	
89-21	16529-16530	,	_	
89-22	16531-16532	p	_	
89-23	16533-16534	=	_	
89-24	16535-16539	.432	_	
89-25	16539-16540	)	_	
89-26	16540-16541	.	_	

#Text=In whole-brain functional connectivity analysis using the four clusters from Figure 2A as seed regions, no significant between-group differences emerged at an exploratory threshold of p < .005 uncorrected.
90-1	16542-16544	In	_	
90-2	16545-16556	whole-brain	_	
90-3	16557-16567	functional	_	
90-4	16568-16580	connectivity	_	
90-5	16581-16589	analysis	_	
90-6	16590-16595	using	_	
90-7	16596-16599	the	_	
90-8	16600-16604	four	_	
90-9	16605-16613	clusters	_	
90-10	16614-16618	from	_	
90-11	16619-16625	Figure	_	
90-12	16626-16628	2A	_	
90-13	16629-16631	as	_	
90-14	16632-16636	seed	_	
90-15	16637-16644	regions	_	
90-16	16644-16645	,	_	
90-17	16646-16648	no	_	
90-18	16649-16660	significant	_	
90-19	16661-16674	between-group	_	
90-20	16675-16686	differences	_	
90-21	16687-16694	emerged	_	
90-22	16695-16697	at	_	
90-23	16698-16700	an	_	
90-24	16701-16712	exploratory	_	
90-25	16713-16722	threshold	_	
90-26	16723-16725	of	_	
90-27	16726-16727	p	_	
90-28	16728-16729	<	_	
90-29	16730-16734	.005	_	
90-30	16735-16746	uncorrected	_	
90-31	16746-16747	.	_	

#Text=Early onset of cannabis abuse in life is associated with a higher risk for poor neuropsychiatric outcomes.
91-1	16748-16753	Early	_	
91-2	16754-16759	onset	_	
91-3	16760-16762	of	_	
91-4	16763-16771	cannabis	_	
91-5	16772-16777	abuse	_	
91-6	16778-16780	in	_	
91-7	16781-16785	life	_	
91-8	16786-16788	is	_	
91-9	16789-16799	associated	_	
91-10	16800-16804	with	_	
91-11	16805-16806	a	_	
91-12	16807-16813	higher	_	
91-13	16814-16818	risk	_	
91-14	16819-16822	for	_	
91-15	16823-16827	poor	_	
91-16	16828-16844	neuropsychiatric	_	
91-17	16845-16853	outcomes	_	
91-18	16853-16854	.	_	

#Text=Therefore, we ran a one-way analysis of variance (ANOVA) between subcortical lFCD and self-reported age of first use.
92-1	16855-16864	Therefore	_	
92-2	16864-16865	,	_	
92-3	16866-16868	we	_	
92-4	16869-16872	ran	_	
92-5	16873-16874	a	_	
92-6	16875-16882	one-way	_	
92-7	16883-16891	analysis	_	
92-8	16892-16894	of	_	
92-9	16895-16903	variance	_	
92-10	16904-16905	(	_	
92-11	16905-16910	ANOVA	_	
92-12	16910-16911	)	_	
92-13	16912-16919	between	_	
92-14	16920-16931	subcortical	_	
92-15	16932-16936	lFCD	_	
92-16	16937-16940	and	_	
92-17	16941-16954	self-reported	_	
92-18	16955-16958	age	_	
92-19	16959-16961	of	_	
92-20	16962-16967	first	_	
92-21	16968-16971	use	_	
92-22	16971-16972	.	_	

#Text=Indeed, subcortical lFCD was significantly different across age of first use, F = 4.13, p = .005, such that higher lFCD was associated with earlier age of cannabis use onset (Figure 3a).
93-1	16973-16979	Indeed	_	
93-2	16979-16980	,	_	
93-3	16981-16992	subcortical	_	
93-4	16993-16997	lFCD	_	
93-5	16998-17001	was	_	
93-6	17002-17015	significantly	_	
93-7	17016-17025	different	_	
93-8	17026-17032	across	_	
93-9	17033-17036	age	_	
93-10	17037-17039	of	_	
93-11	17040-17045	first	_	
93-12	17046-17049	use	_	
93-13	17049-17050	,	_	
93-14	17051-17052	F	_	
93-15	17053-17054	=	_	
93-16	17055-17059	4.13	_	
93-17	17059-17060	,	_	
93-18	17061-17062	p	_	
93-19	17063-17064	=	_	
93-20	17065-17069	.005	_	
93-21	17069-17070	,	_	
93-22	17071-17075	such	_	
93-23	17076-17080	that	_	
93-24	17081-17087	higher	_	
93-25	17088-17092	lFCD	_	
93-26	17093-17096	was	_	
93-27	17097-17107	associated	_	
93-28	17108-17112	with	_	
93-29	17113-17120	earlier	_	
93-30	17121-17124	age	_	
93-31	17125-17127	of	_	
93-32	17128-17136	cannabis	_	
93-33	17137-17140	use	_	
93-34	17141-17146	onset	_	
93-35	17147-17148	(	_	
93-36	17148-17154	Figure	_	
93-37	17155-17157	3a	_	
93-38	17157-17158	)	_	
93-39	17158-17159	.	_	

#Text=In a two-way ANOVA including group and sex as factors, there was no significant main effect of sex on lFCD (F = .49, p = .488), nor was there a significant group by sex interaction (F = .09, p = .761).
94-1	17160-17162	In	_	
94-2	17163-17164	a	_	
94-3	17165-17172	two-way	_	
94-4	17173-17178	ANOVA	_	
94-5	17179-17188	including	_	
94-6	17189-17194	group	_	
94-7	17195-17198	and	_	
94-8	17199-17202	sex	_	
94-9	17203-17205	as	_	
94-10	17206-17213	factors	_	
94-11	17213-17214	,	_	
94-12	17215-17220	there	_	
94-13	17221-17224	was	_	
94-14	17225-17227	no	_	
94-15	17228-17239	significant	_	
94-16	17240-17244	main	_	
94-17	17245-17251	effect	_	
94-18	17252-17254	of	_	
94-19	17255-17258	sex	_	
94-20	17259-17261	on	_	
94-21	17262-17266	lFCD	_	
94-22	17267-17268	(	_	
94-23	17268-17269	F	_	
94-24	17270-17271	=	_	
94-25	17272-17275	.49	_	
94-26	17275-17276	,	_	
94-27	17277-17278	p	_	
94-28	17279-17280	=	_	
94-29	17281-17285	.488	_	
94-30	17285-17286	)	_	
94-31	17286-17287	,	_	
94-32	17288-17291	nor	_	
94-33	17292-17295	was	_	
94-34	17296-17301	there	_	
94-35	17302-17303	a	_	
94-36	17304-17315	significant	_	
94-37	17316-17321	group	_	
94-38	17322-17324	by	_	
94-39	17325-17328	sex	_	
94-40	17329-17340	interaction	_	
94-41	17341-17342	(	_	
94-42	17342-17343	F	_	
94-43	17344-17345	=	_	
94-44	17346-17349	.09	_	
94-45	17349-17350	,	_	
94-46	17351-17352	p	_	
94-47	17353-17354	=	_	
94-48	17355-17359	.761	_	
94-49	17359-17360	)	_	
94-50	17360-17361	.	_	

#Text=Finally, because CA reported significantly higher feelings of alienation than controls, in line with our previous work, we ran an across-subject correlation between the alienation scores and subcortical lFCD.
95-1	17362-17369	Finally	_	
95-2	17369-17370	,	_	
95-3	17371-17378	because	_	
95-4	17379-17381	CA	_	
95-5	17382-17390	reported	_	
95-6	17391-17404	significantly	_	
95-7	17405-17411	higher	_	
95-8	17412-17420	feelings	_	
95-9	17421-17423	of	_	
95-10	17424-17434	alienation	_	
95-11	17435-17439	than	_	
95-12	17440-17448	controls	_	
95-13	17448-17449	,	_	
95-14	17450-17452	in	_	
95-15	17453-17457	line	_	
95-16	17458-17462	with	_	
95-17	17463-17466	our	_	
95-18	17467-17475	previous	_	
95-19	17476-17480	work	_	
95-20	17480-17481	,	_	
95-21	17482-17484	we	_	
95-22	17485-17488	ran	_	
95-23	17489-17491	an	_	
95-24	17492-17506	across-subject	_	
95-25	17507-17518	correlation	_	
95-26	17519-17526	between	_	
95-27	17527-17530	the	_	
95-28	17531-17541	alienation	_	
95-29	17542-17548	scores	_	
95-30	17549-17552	and	_	
95-31	17553-17564	subcortical	_	
95-32	17565-17569	lFCD	_	
95-33	17569-17570	.	_	

#Text=CA showed a significant correlation between lFCD and alienation scores (r = .43, p = .019), whereas the control subjects did not (r = −.09, p = .615) (Figure 3b).
96-1	17571-17573	CA	_	
96-2	17574-17580	showed	_	
96-3	17581-17582	a	_	
96-4	17583-17594	significant	_	
96-5	17595-17606	correlation	_	
96-6	17607-17614	between	_	
96-7	17615-17619	lFCD	_	
96-8	17620-17623	and	_	
96-9	17624-17634	alienation	_	
96-10	17635-17641	scores	_	
96-11	17642-17643	(	_	
96-12	17643-17644	r	_	
96-13	17645-17646	=	_	
96-14	17647-17650	.43	_	
96-15	17650-17651	,	_	
96-16	17652-17653	p	_	
96-17	17654-17655	=	_	
96-18	17656-17660	.019	_	
96-19	17660-17661	)	_	
96-20	17661-17662	,	_	
96-21	17663-17670	whereas	_	
96-22	17671-17674	the	_	
96-23	17675-17682	control	_	
96-24	17683-17691	subjects	_	
96-25	17692-17695	did	_	
96-26	17696-17699	not	_	
96-27	17700-17701	(	_	
96-28	17701-17702	r	_	
96-29	17703-17704	=	_	
96-30	17705-17706	−	_	
96-31	17706-17709	.09	_	
96-32	17709-17710	,	_	
96-33	17711-17712	p	_	
96-34	17713-17714	=	_	
96-35	17715-17719	.615	_	
96-36	17719-17720	)	_	
96-37	17721-17722	(	_	
96-38	17722-17728	Figure	_	
96-39	17729-17731	3b	_	
96-40	17731-17732	)	_	
96-41	17732-17733	.	_	

#Text=The correlation among CA may be most strongly driven by lFCD near the midbrain; see Supplementary Figure S3 for a voxelwise regression analysis.
97-1	17734-17737	The	_	
97-2	17738-17749	correlation	_	
97-3	17750-17755	among	_	
97-4	17756-17758	CA	_	
97-5	17759-17762	may	_	
97-6	17763-17765	be	_	
97-7	17766-17770	most	_	
97-8	17771-17779	strongly	_	
97-9	17780-17786	driven	_	
97-10	17787-17789	by	_	
97-11	17790-17794	lFCD	_	
97-12	17795-17799	near	_	
97-13	17800-17803	the	_	
97-14	17804-17812	midbrain	_	
97-15	17812-17813	;	_	
97-16	17814-17817	see	_	
97-17	17818-17831	Supplementary	_	
97-18	17832-17838	Figure	_	
97-19	17839-17841	S3	_	
97-20	17842-17845	for	_	
97-21	17846-17847	a	_	
97-22	17848-17857	voxelwise	_	
97-23	17858-17868	regression	_	
97-24	17869-17877	analysis	_	
97-25	17877-17878	.	_	

#Text=These results remained significant when conducting a partial correlation to control for the FreeSurfer-estimated subcortical volume of each subject (CA: r = .43, p = .04; controls: r = .02, p = .895).
98-1	17879-17884	These	_	
98-2	17885-17892	results	_	
98-3	17893-17901	remained	_	
98-4	17902-17913	significant	_	
98-5	17914-17918	when	_	
98-6	17919-17929	conducting	_	
98-7	17930-17931	a	_	
98-8	17932-17939	partial	_	
98-9	17940-17951	correlation	_	
98-10	17952-17954	to	_	
98-11	17955-17962	control	_	
98-12	17963-17966	for	_	
98-13	17967-17970	the	_	
98-14	17971-17991	FreeSurfer-estimated	_	
98-15	17992-18003	subcortical	_	
98-16	18004-18010	volume	_	
98-17	18011-18013	of	_	
98-18	18014-18018	each	_	
98-19	18019-18026	subject	_	
98-20	18027-18028	(	_	
98-21	18028-18030	CA	_	
98-22	18030-18031	:	_	
98-23	18032-18033	r	_	
98-24	18034-18035	=	_	
98-25	18036-18039	.43	_	
98-26	18039-18040	,	_	
98-27	18041-18042	p	_	
98-28	18043-18044	=	_	
98-29	18045-18048	.04	_	
98-30	18048-18049	;	_	
98-31	18050-18058	controls	_	
98-32	18058-18059	:	_	
98-33	18060-18061	r	_	
98-34	18062-18063	=	_	
98-35	18064-18067	.02	_	
98-36	18067-18068	,	_	
98-37	18069-18070	p	_	
98-38	18071-18072	=	_	
98-39	18073-18077	.895	_	
98-40	18077-18078	)	_	
98-41	18078-18079	.	_	

#Text=The difference in slopes between CA and controls was significant, F = 5.95, p = .018.
99-1	18080-18083	The	_	
99-2	18084-18094	difference	_	
99-3	18095-18097	in	_	
99-4	18098-18104	slopes	_	
99-5	18105-18112	between	_	
99-6	18113-18115	CA	_	
99-7	18116-18119	and	_	
99-8	18120-18128	controls	_	
99-9	18129-18132	was	_	
99-10	18133-18144	significant	_	
99-11	18144-18145	,	_	
99-12	18146-18147	F	_	
99-13	18148-18149	=	_	
99-14	18150-18154	5.95	_	
99-15	18154-18155	,	_	
99-16	18156-18157	p	_	
99-17	18158-18159	=	_	
99-18	18160-18164	.018	_	
99-19	18164-18165	.	_	

#Text=Discussion
#Text=Despite the high prevalence of cannabis use, little is known about potential chronic effects of CA on brain function and behavior.
100-1	18166-18176	Discussion	_	
100-2	18177-18184	Despite	_	
100-3	18185-18188	the	_	
100-4	18189-18193	high	_	
100-5	18194-18204	prevalence	_	
100-6	18205-18207	of	_	
100-7	18208-18216	cannabis	_	
100-8	18217-18220	use	_	
100-9	18220-18221	,	_	
100-10	18222-18228	little	_	
100-11	18229-18231	is	_	
100-12	18232-18237	known	_	
100-13	18238-18243	about	_	
100-14	18244-18253	potential	_	
100-15	18254-18261	chronic	_	
100-16	18262-18269	effects	_	
100-17	18270-18272	of	_	
100-18	18273-18275	CA	_	
100-19	18276-18278	on	_	
100-20	18279-18284	brain	_	
100-21	18285-18293	function	_	
100-22	18294-18297	and	_	
100-23	18298-18306	behavior	_	
100-24	18306-18307	.	_	

#Text=Here, we demonstrate that heavy CA is associated with a marked increase in subcortical lFCD, including the midbrain (where the main DA nuclei are located) and the ventral striatum, relative to a well-matched control group.
101-1	18308-18312	Here	_	
101-2	18312-18313	,	_	
101-3	18314-18316	we	_	
101-4	18317-18328	demonstrate	_	
101-5	18329-18333	that	_	
101-6	18334-18339	heavy	_	
101-7	18340-18342	CA	_	
101-8	18343-18345	is	_	
101-9	18346-18356	associated	_	
101-10	18357-18361	with	_	
101-11	18362-18363	a	_	
101-12	18364-18370	marked	_	
101-13	18371-18379	increase	_	
101-14	18380-18382	in	_	
101-15	18383-18394	subcortical	_	
101-16	18395-18399	lFCD	_	
101-17	18399-18400	,	_	
101-18	18401-18410	including	_	
101-19	18411-18414	the	_	
101-20	18415-18423	midbrain	_	
101-21	18424-18425	(	_	
101-22	18425-18430	where	_	
101-23	18431-18434	the	_	
101-24	18435-18439	main	_	
101-25	18440-18442	DA	_	
101-26	18443-18449	nuclei	_	
101-27	18450-18453	are	_	
101-28	18454-18461	located	_	
101-29	18461-18462	)	_	
101-30	18463-18466	and	_	
101-31	18467-18470	the	_	
101-32	18471-18478	ventral	_	
101-33	18479-18487	striatum	_	
101-34	18487-18488	,	_	
101-35	18489-18497	relative	_	
101-36	18498-18500	to	_	
101-37	18501-18502	a	_	
101-38	18503-18515	well-matched	_	
101-39	18516-18523	control	_	
101-40	18524-18529	group	_	
101-41	18529-18530	.	_	

#Text=These effects are not explained by volumetric differences, and they associate with critical features of CA: hyperconnectivity was most pronounced in early-onset CA, a demographic that is particularly vulnerable to the harmful effects of CA, and in those reporting the highest levels of negative emotionality, particularly alienation.
102-1	18531-18536	These	_	
102-2	18537-18544	effects	_	
102-3	18545-18548	are	_	
102-4	18549-18552	not	_	
102-5	18553-18562	explained	_	
102-6	18563-18565	by	_	
102-7	18566-18576	volumetric	_	
102-8	18577-18588	differences	_	
102-9	18588-18589	,	_	
102-10	18590-18593	and	_	
102-11	18594-18598	they	_	
102-12	18599-18608	associate	_	
102-13	18609-18613	with	_	
102-14	18614-18622	critical	_	
102-15	18623-18631	features	_	
102-16	18632-18634	of	_	
102-17	18635-18637	CA	_	
102-18	18637-18638	:	_	
102-19	18639-18656	hyperconnectivity	_	
102-20	18657-18660	was	_	
102-21	18661-18665	most	_	
102-22	18666-18676	pronounced	_	
102-23	18677-18679	in	_	
102-24	18680-18691	early-onset	_	
102-25	18692-18694	CA	_	
102-26	18694-18695	,	_	
102-27	18696-18697	a	_	
102-28	18698-18709	demographic	_	
102-29	18710-18714	that	_	
102-30	18715-18717	is	_	
102-31	18718-18730	particularly	_	
102-32	18731-18741	vulnerable	_	
102-33	18742-18744	to	_	
102-34	18745-18748	the	_	
102-35	18749-18756	harmful	_	
102-36	18757-18764	effects	_	
102-37	18765-18767	of	_	
102-38	18768-18770	CA	_	
102-39	18770-18771	,	_	
102-40	18772-18775	and	_	
102-41	18776-18778	in	_	
102-42	18779-18784	those	_	
102-43	18785-18794	reporting	_	
102-44	18795-18798	the	_	
102-45	18799-18806	highest	_	
102-46	18807-18813	levels	_	
102-47	18814-18816	of	_	
102-48	18817-18825	negative	_	
102-49	18826-18838	emotionality	_	
102-50	18838-18839	,	_	
102-51	18840-18852	particularly	_	
102-52	18853-18863	alienation	_	
102-53	18863-18864	.	_	

#Text=These findings indicate that the resting functional organization of the subcortical regions is altered in CA, and this may have relevance for some of the adverse effects of early-onset CA, including emotional disturbance and increased risk for psychosis.
103-1	18865-18870	These	_	
103-2	18871-18879	findings	_	
103-3	18880-18888	indicate	_	
103-4	18889-18893	that	_	
103-5	18894-18897	the	_	
103-6	18898-18905	resting	_	
103-7	18906-18916	functional	_	
103-8	18917-18929	organization	_	
103-9	18930-18932	of	_	
103-10	18933-18936	the	_	
103-11	18937-18948	subcortical	_	
103-12	18949-18956	regions	_	
103-13	18957-18959	is	_	
103-14	18960-18967	altered	_	
103-15	18968-18970	in	_	
103-16	18971-18973	CA	_	
103-17	18973-18974	,	_	
103-18	18975-18978	and	_	
103-19	18979-18983	this	_	
103-20	18984-18987	may	_	
103-21	18988-18992	have	_	
103-22	18993-19002	relevance	_	
103-23	19003-19006	for	_	
103-24	19007-19011	some	_	
103-25	19012-19014	of	_	
103-26	19015-19018	the	_	
103-27	19019-19026	adverse	_	
103-28	19027-19034	effects	_	
103-29	19035-19037	of	_	
103-30	19038-19049	early-onset	_	
103-31	19050-19052	CA	_	
103-32	19052-19053	,	_	
103-33	19054-19063	including	_	
103-34	19064-19073	emotional	_	
103-35	19074-19085	disturbance	_	
103-36	19086-19089	and	_	
103-37	19090-19099	increased	_	
103-38	19100-19104	risk	_	
103-39	19105-19108	for	_	
103-40	19109-19118	psychosis	_	
103-41	19118-19119	.	_	

#Text=Increased lFCD in the ventral striatum (VS) and midbrain, including regions where the substantia nigra and ventral tegmental area are located, may be related to hyperdopaminergia in CA.
104-1	19120-19129	Increased	_	
104-2	19130-19134	lFCD	_	
104-3	19135-19137	in	_	
104-4	19138-19141	the	_	
104-5	19142-19149	ventral	_	
104-6	19150-19158	striatum	_	
104-7	19159-19160	(	_	
104-8	19160-19162	VS	_	
104-9	19162-19163	)	_	
104-10	19164-19167	and	_	
104-11	19168-19176	midbrain	_	
104-12	19176-19177	,	_	
104-13	19178-19187	including	_	
104-14	19188-19195	regions	_	
104-15	19196-19201	where	_	
104-16	19202-19205	the	_	
104-17	19206-19216	substantia	_	
104-18	19217-19222	nigra	_	
104-19	19223-19226	and	_	
104-20	19227-19234	ventral	_	
104-21	19235-19244	tegmental	_	
104-22	19245-19249	area	_	
104-23	19250-19253	are	_	
104-24	19254-19261	located	_	
104-25	19261-19262	,	_	
104-26	19263-19266	may	_	
104-27	19267-19269	be	_	
104-28	19270-19277	related	_	
104-29	19278-19280	to	_	
104-30	19281-19298	hyperdopaminergia	_	
104-31	19299-19301	in	_	
104-32	19302-19304	CA	_	
104-33	19304-19305	.	_	

#Text=Indeed, using PET and [11C]raclopride to measure DA-induced changes to methylphenidate we found that CA when compared to controls showed increased DA release in the midbrain, though they showed an attenuated response in striatal regions.
105-1	19306-19312	Indeed	_	
105-2	19312-19313	,	_	
105-3	19314-19319	using	_	
105-4	19320-19323	PET	_	
105-5	19324-19327	and	_	
105-6	19328-19329	[	_	
105-7	19329-19332	11C	_	
105-8	19332-19333	]	_	
105-9	19333-19343	raclopride	_	
105-10	19344-19346	to	_	
105-11	19347-19354	measure	_	
105-12	19355-19365	DA-induced	_	
105-13	19366-19373	changes	_	
105-14	19374-19376	to	_	
105-15	19377-19392	methylphenidate	_	
105-16	19393-19395	we	_	
105-17	19396-19401	found	_	
105-18	19402-19406	that	_	
105-19	19407-19409	CA	_	
105-20	19410-19414	when	_	
105-21	19415-19423	compared	_	
105-22	19424-19426	to	_	
105-23	19427-19435	controls	_	
105-24	19436-19442	showed	_	
105-25	19443-19452	increased	_	
105-26	19453-19455	DA	_	
105-27	19456-19463	release	_	
105-28	19464-19466	in	_	
105-29	19467-19470	the	_	
105-30	19471-19479	midbrain	_	
105-31	19479-19480	,	_	
105-32	19481-19487	though	_	
105-33	19488-19492	they	_	
105-34	19493-19499	showed	_	
105-35	19500-19502	an	_	
105-36	19503-19513	attenuated	_	
105-37	19514-19522	response	_	
105-38	19523-19525	in	_	
105-39	19526-19534	striatal	_	
105-40	19535-19542	regions	_	
105-41	19542-19543	.	_	

#Text=Functional connectivity between VS and VTA is higher in patients with Schizophrenia with symptoms of hyperdopaminergia, such as auditory and visual hallucinations, than in patients who do not experience these symptoms.
106-1	19544-19554	Functional	_	
106-2	19555-19567	connectivity	_	
106-3	19568-19575	between	_	
106-4	19576-19578	VS	_	
106-5	19579-19582	and	_	
106-6	19583-19586	VTA	_	
106-7	19587-19589	is	_	
106-8	19590-19596	higher	_	
106-9	19597-19599	in	_	
106-10	19600-19608	patients	_	
106-11	19609-19613	with	_	
106-12	19614-19627	Schizophrenia	_	
106-13	19628-19632	with	_	
106-14	19633-19641	symptoms	_	
106-15	19642-19644	of	_	
106-16	19645-19662	hyperdopaminergia	_	
106-17	19662-19663	,	_	
106-18	19664-19668	such	_	
106-19	19669-19671	as	_	
106-20	19672-19680	auditory	_	
106-21	19681-19684	and	_	
106-22	19685-19691	visual	_	
106-23	19692-19706	hallucinations	_	
106-24	19706-19707	,	_	
106-25	19708-19712	than	_	
106-26	19713-19715	in	_	
106-27	19716-19724	patients	_	
106-28	19725-19728	who	_	
106-29	19729-19731	do	_	
106-30	19732-19735	not	_	
106-31	19736-19746	experience	_	
106-32	19747-19752	these	_	
106-33	19753-19761	symptoms	_	
106-34	19761-19762	.	_	

#Text=Further, in healthy adults and in rats, drugs that increase (levodopa) and decrease (haloperidol) DA signaling have been demonstrated to increase and decrease functional connectivity of these regions, respectively.
107-1	19763-19770	Further	_	
107-2	19770-19771	,	_	
107-3	19772-19774	in	_	
107-4	19775-19782	healthy	_	
107-5	19783-19789	adults	_	
107-6	19790-19793	and	_	
107-7	19794-19796	in	_	
107-8	19797-19801	rats	_	
107-9	19801-19802	,	_	
107-10	19803-19808	drugs	_	
107-11	19809-19813	that	_	
107-12	19814-19822	increase	_	
107-13	19823-19824	(	_	
107-14	19824-19832	levodopa	_	
107-15	19832-19833	)	_	
107-16	19834-19837	and	_	
107-17	19838-19846	decrease	_	
107-18	19847-19848	(	_	
107-19	19848-19859	haloperidol	_	
107-20	19859-19860	)	_	
107-21	19861-19863	DA	_	
107-22	19864-19873	signaling	_	
107-23	19874-19878	have	_	
107-24	19879-19883	been	_	
107-25	19884-19896	demonstrated	_	
107-26	19897-19899	to	_	
107-27	19900-19908	increase	_	
107-28	19909-19912	and	_	
107-29	19913-19921	decrease	_	
107-30	19922-19932	functional	_	
107-31	19933-19945	connectivity	_	
107-32	19946-19948	of	_	
107-33	19949-19954	these	_	
107-34	19955-19962	regions	_	
107-35	19962-19963	,	_	
107-36	19964-19976	respectively	_	
107-37	19976-19977	.	_	

#Text=However, it is important to note that the findings from these seed-based connectivity studies are likely network-specific, because abnormal DA levels attenuate the connectivity between different resting state networks.
108-1	19978-19985	However	_	
108-2	19985-19986	,	_	
108-3	19987-19989	it	_	
108-4	19990-19992	is	_	
108-5	19993-20002	important	_	
108-6	20003-20005	to	_	
108-7	20006-20010	note	_	
108-8	20011-20015	that	_	
108-9	20016-20019	the	_	
108-10	20020-20028	findings	_	
108-11	20029-20033	from	_	
108-12	20034-20039	these	_	
108-13	20040-20050	seed-based	_	
108-14	20051-20063	connectivity	_	
108-15	20064-20071	studies	_	
108-16	20072-20075	are	_	
108-17	20076-20082	likely	_	
108-18	20083-20099	network-specific	_	
108-19	20099-20100	,	_	
108-20	20101-20108	because	_	
108-21	20109-20117	abnormal	_	
108-22	20118-20120	DA	_	
108-23	20121-20127	levels	_	
108-24	20128-20137	attenuate	_	
108-25	20138-20141	the	_	
108-26	20142-20154	connectivity	_	
108-27	20155-20162	between	_	
108-28	20163-20172	different	_	
108-29	20173-20180	resting	_	
108-30	20181-20186	state	_	
108-31	20187-20195	networks	_	
108-32	20195-20196	.	_	

#Text=This may explain why CA show hypoconnectivity between nodes of the mesolimbic reward network and nodes of the salience network; e.g. between the dopaminergic midbrain and insula and between NAc and dorsal anterior cingulate cortex.
109-1	20197-20201	This	_	
109-2	20202-20205	may	_	
109-3	20206-20213	explain	_	
109-4	20214-20217	why	_	
109-5	20218-20220	CA	_	
109-6	20221-20225	show	_	
109-7	20226-20242	hypoconnectivity	_	
109-8	20243-20250	between	_	
109-9	20251-20256	nodes	_	
109-10	20257-20259	of	_	
109-11	20260-20263	the	_	
109-12	20264-20274	mesolimbic	_	
109-13	20275-20281	reward	_	
109-14	20282-20289	network	_	
109-15	20290-20293	and	_	
109-16	20294-20299	nodes	_	
109-17	20300-20302	of	_	
109-18	20303-20306	the	_	
109-19	20307-20315	salience	_	
109-20	20316-20323	network	_	
109-21	20323-20324	;	_	
109-22	20325-20328	e.g	_	
109-23	20328-20329	.	_	
109-24	20330-20337	between	_	
109-25	20338-20341	the	_	
109-26	20342-20354	dopaminergic	_	
109-27	20355-20363	midbrain	_	
109-28	20364-20367	and	_	
109-29	20368-20374	insula	_	
109-30	20375-20378	and	_	
109-31	20379-20386	between	_	
109-32	20387-20390	NAc	_	
109-33	20391-20394	and	_	
109-34	20395-20401	dorsal	_	
109-35	20402-20410	anterior	_	
109-36	20411-20420	cingulate	_	
109-37	20421-20427	cortex	_	
109-38	20427-20428	.	_	

#Text=Interestingly, our seed-based connectivity analysis from these regions did not yield significant group differences.
110-1	20429-20442	Interestingly	_	
110-2	20442-20443	,	_	
110-3	20444-20447	our	_	
110-4	20448-20458	seed-based	_	
110-5	20459-20471	connectivity	_	
110-6	20472-20480	analysis	_	
110-7	20481-20485	from	_	
110-8	20486-20491	these	_	
110-9	20492-20499	regions	_	
110-10	20500-20503	did	_	
110-11	20504-20507	not	_	
110-12	20508-20513	yield	_	
110-13	20514-20525	significant	_	
110-14	20526-20531	group	_	
110-15	20532-20543	differences	_	
110-16	20543-20544	.	_	

#Text=Thus, while previous studies have observed long-range subcortical-cortical connectivity alterations in CA, the current results appear to be confined to local hub differences in subcortical circuits.
111-1	20545-20549	Thus	_	
111-2	20549-20550	,	_	
111-3	20551-20556	while	_	
111-4	20557-20565	previous	_	
111-5	20566-20573	studies	_	
111-6	20574-20578	have	_	
111-7	20579-20587	observed	_	
111-8	20588-20598	long-range	_	
111-9	20599-20619	subcortical-cortical	_	
111-10	20620-20632	connectivity	_	
111-11	20633-20644	alterations	_	
111-12	20645-20647	in	_	
111-13	20648-20650	CA	_	
111-14	20650-20651	,	_	
111-15	20652-20655	the	_	
111-16	20656-20663	current	_	
111-17	20664-20671	results	_	
111-18	20672-20678	appear	_	
111-19	20679-20681	to	_	
111-20	20682-20684	be	_	
111-21	20685-20693	confined	_	
111-22	20694-20696	to	_	
111-23	20697-20702	local	_	
111-24	20703-20706	hub	_	
111-25	20707-20718	differences	_	
111-26	20719-20721	in	_	
111-27	20722-20733	subcortical	_	
111-28	20734-20742	circuits	_	
111-29	20742-20743	.	_	

#Text=There are at least two possible explanations for this.
112-1	20744-20749	There	_	
112-2	20750-20753	are	_	
112-3	20754-20756	at	_	
112-4	20757-20762	least	_	
112-5	20763-20766	two	_	
112-6	20767-20775	possible	_	
112-7	20776-20788	explanations	_	
112-8	20789-20792	for	_	
112-9	20793-20797	this	_	
112-10	20797-20798	.	_	

#Text=First, this study carefully controlled for factors such as alcohol and tobacco usage, which may have influenced findings from previous studies.
113-1	20799-20804	First	_	
113-2	20804-20805	,	_	
113-3	20806-20810	this	_	
113-4	20811-20816	study	_	
113-5	20817-20826	carefully	_	
113-6	20827-20837	controlled	_	
113-7	20838-20841	for	_	
113-8	20842-20849	factors	_	
113-9	20850-20854	such	_	
113-10	20855-20857	as	_	
113-11	20858-20865	alcohol	_	
113-12	20866-20869	and	_	
113-13	20870-20877	tobacco	_	
113-14	20878-20883	usage	_	
113-15	20883-20884	,	_	
113-16	20885-20890	which	_	
113-17	20891-20894	may	_	
113-18	20895-20899	have	_	
113-19	20900-20910	influenced	_	
113-20	20911-20919	findings	_	
113-21	20920-20924	from	_	
113-22	20925-20933	previous	_	
113-23	20934-20941	studies	_	
113-24	20941-20942	.	_	

#Text=Second, the HCP uses a high-resolution sequence with an aggressive multiband factor, and this contributes to lower subcortical signal-to-noise ratio than is observed with low-resolution sequences. lFCD is more resilient to noise than seed-voxel correlations because lFCD capitalizes on locally shared synchrony and high sampling rate, which makes it possible to reach significant correlations in the absence of significant long-range synchrony.
114-1	20943-20949	Second	_	
114-2	20949-20950	,	_	
114-3	20951-20954	the	_	
114-4	20955-20958	HCP	_	
114-5	20959-20963	uses	_	
114-6	20964-20965	a	_	
114-7	20966-20981	high-resolution	_	
114-8	20982-20990	sequence	_	
114-9	20991-20995	with	_	
114-10	20996-20998	an	_	
114-11	20999-21009	aggressive	_	
114-12	21010-21019	multiband	_	
114-13	21020-21026	factor	_	
114-14	21026-21027	,	_	
114-15	21028-21031	and	_	
114-16	21032-21036	this	_	
114-17	21037-21048	contributes	_	
114-18	21049-21051	to	_	
114-19	21052-21057	lower	_	
114-20	21058-21069	subcortical	_	
114-21	21070-21085	signal-to-noise	_	
114-22	21086-21091	ratio	_	
114-23	21092-21096	than	_	
114-24	21097-21099	is	_	
114-25	21100-21108	observed	_	
114-26	21109-21113	with	_	
114-27	21114-21128	low-resolution	_	
114-28	21129-21138	sequences	_	
114-29	21138-21139	.	_	
114-30	21140-21144	lFCD	_	
114-31	21145-21147	is	_	
114-32	21148-21152	more	_	
114-33	21153-21162	resilient	_	
114-34	21163-21165	to	_	
114-35	21166-21171	noise	_	
114-36	21172-21176	than	_	
114-37	21177-21187	seed-voxel	_	
114-38	21188-21200	correlations	_	
114-39	21201-21208	because	_	
114-40	21209-21213	lFCD	_	
114-41	21214-21225	capitalizes	_	
114-42	21226-21228	on	_	
114-43	21229-21236	locally	_	
114-44	21237-21243	shared	_	
114-45	21244-21253	synchrony	_	
114-46	21254-21257	and	_	
114-47	21258-21262	high	_	
114-48	21263-21271	sampling	_	
114-49	21272-21276	rate	_	
114-50	21276-21277	,	_	
114-51	21278-21283	which	_	
114-52	21284-21289	makes	_	
114-53	21290-21292	it	_	
114-54	21293-21301	possible	_	
114-55	21302-21304	to	_	
114-56	21305-21310	reach	_	
114-57	21311-21322	significant	_	
114-58	21323-21335	correlations	_	
114-59	21336-21338	in	_	
114-60	21339-21342	the	_	
114-61	21343-21350	absence	_	
114-62	21351-21353	of	_	
114-63	21354-21365	significant	_	
114-64	21366-21376	long-range	_	
114-65	21377-21386	synchrony	_	
114-66	21386-21387	.	_	

#Text=Nevertheless, our lFCD results seem to be broadly in line with previous studies using the FCD technique, although evidence is limited.
115-1	21388-21400	Nevertheless	_	
115-2	21400-21401	,	_	
115-3	21402-21405	our	_	
115-4	21406-21410	lFCD	_	
115-5	21411-21418	results	_	
115-6	21419-21423	seem	_	
115-7	21424-21426	to	_	
115-8	21427-21429	be	_	
115-9	21430-21437	broadly	_	
115-10	21438-21440	in	_	
115-11	21441-21445	line	_	
115-12	21446-21450	with	_	
115-13	21451-21459	previous	_	
115-14	21460-21467	studies	_	
115-15	21468-21473	using	_	
115-16	21474-21477	the	_	
115-17	21478-21481	FCD	_	
115-18	21482-21491	technique	_	
115-19	21491-21492	,	_	
115-20	21493-21501	although	_	
115-21	21502-21510	evidence	_	
115-22	21511-21513	is	_	
115-23	21514-21521	limited	_	
115-24	21521-21522	.	_	

#Text=For instance, subcortical global FCD (a measure that is highly correlated with lFCD,) is increased in schizophrenia relative to healthy controls (, but see, where the dopaminergic medication status of the patients was unknown).
116-1	21523-21526	For	_	
116-2	21527-21535	instance	_	
116-3	21535-21536	,	_	
116-4	21537-21548	subcortical	_	
116-5	21549-21555	global	_	
116-6	21556-21559	FCD	_	
116-7	21560-21561	(	_	
116-8	21561-21562	a	_	
116-9	21563-21570	measure	_	
116-10	21571-21575	that	_	
116-11	21576-21578	is	_	
116-12	21579-21585	highly	_	
116-13	21586-21596	correlated	_	
116-14	21597-21601	with	_	
116-15	21602-21606	lFCD	_	
116-16	21606-21607	,	_	
116-17	21607-21608	)	_	
116-18	21609-21611	is	_	
116-19	21612-21621	increased	_	
116-20	21622-21624	in	_	
116-21	21625-21638	schizophrenia	_	
116-22	21639-21647	relative	_	
116-23	21648-21650	to	_	
116-24	21651-21658	healthy	_	
116-25	21659-21667	controls	_	
116-26	21668-21669	(	_	
116-27	21669-21670	,	_	
116-28	21671-21674	but	_	
116-29	21675-21678	see	_	
116-30	21678-21679	,	_	
116-31	21680-21685	where	_	
116-32	21686-21689	the	_	
116-33	21690-21702	dopaminergic	_	
116-34	21703-21713	medication	_	
116-35	21714-21720	status	_	
116-36	21721-21723	of	_	
116-37	21724-21727	the	_	
116-38	21728-21736	patients	_	
116-39	21737-21740	was	_	
116-40	21741-21748	unknown	_	
116-41	21748-21749	)	_	
116-42	21749-21750	.	_	

#Text=On the other hand, increased lFCD in the VS and midbrain may be a general consequence of pathology to these circuits, as this pattern is observed in various conditions with aberrant DA signaling.
117-1	21751-21753	On	_	
117-2	21754-21757	the	_	
117-3	21758-21763	other	_	
117-4	21764-21768	hand	_	
117-5	21768-21769	,	_	
117-6	21770-21779	increased	_	
117-7	21780-21784	lFCD	_	
117-8	21785-21787	in	_	
117-9	21788-21791	the	_	
117-10	21792-21794	VS	_	
117-11	21795-21798	and	_	
117-12	21799-21807	midbrain	_	
117-13	21808-21811	may	_	
117-14	21812-21814	be	_	
117-15	21815-21816	a	_	
117-16	21817-21824	general	_	
117-17	21825-21836	consequence	_	
117-18	21837-21839	of	_	
117-19	21840-21849	pathology	_	
117-20	21850-21852	to	_	
117-21	21853-21858	these	_	
117-22	21859-21867	circuits	_	
117-23	21867-21868	,	_	
117-24	21869-21871	as	_	
117-25	21872-21876	this	_	
117-26	21877-21884	pattern	_	
117-27	21885-21887	is	_	
117-28	21888-21896	observed	_	
117-29	21897-21899	in	_	
117-30	21900-21907	various	_	
117-31	21908-21918	conditions	_	
117-32	21919-21923	with	_	
117-33	21924-21932	aberrant	_	
117-34	21933-21935	DA	_	
117-35	21936-21945	signaling	_	
117-36	21945-21946	.	_	

#Text=Subcortical lFCD is increased in aging, ADHD, and cocaine use disorder, which are all implicated in altered dopaminergic function.
118-1	21947-21958	Subcortical	_	
118-2	21959-21963	lFCD	_	
118-3	21964-21966	is	_	
118-4	21967-21976	increased	_	
118-5	21977-21979	in	_	
118-6	21980-21985	aging	_	
118-7	21985-21986	,	_	
118-8	21987-21991	ADHD	_	
118-9	21991-21992	,	_	
118-10	21993-21996	and	_	
118-11	21997-22004	cocaine	_	
118-12	22005-22008	use	_	
118-13	22009-22017	disorder	_	
118-14	22017-22018	,	_	
118-15	22019-22024	which	_	
118-16	22025-22028	are	_	
118-17	22029-22032	all	_	
118-18	22033-22043	implicated	_	
118-19	22044-22046	in	_	
118-20	22047-22054	altered	_	
118-21	22055-22067	dopaminergic	_	
118-22	22068-22076	function	_	
118-23	22076-22077	.	_	

#Text=These results are also generally in line with the notion that altered connectivity in high-cost hubs is linked to neuropsychiatric disease burden.
119-1	22078-22083	These	_	
119-2	22084-22091	results	_	
119-3	22092-22095	are	_	
119-4	22096-22100	also	_	
119-5	22101-22110	generally	_	
119-6	22111-22113	in	_	
119-7	22114-22118	line	_	
119-8	22119-22123	with	_	
119-9	22124-22127	the	_	
119-10	22128-22134	notion	_	
119-11	22135-22139	that	_	
119-12	22140-22147	altered	_	
119-13	22148-22160	connectivity	_	
119-14	22161-22163	in	_	
119-15	22164-22173	high-cost	_	
119-16	22174-22178	hubs	_	
119-17	22179-22181	is	_	
119-18	22182-22188	linked	_	
119-19	22189-22191	to	_	
119-20	22192-22208	neuropsychiatric	_	
119-21	22209-22216	disease	_	
119-22	22217-22223	burden	_	
119-23	22223-22224	.	_	

#Text=An important next step is to examine how tonic, resting subcortical hyperconnectivity may have consequences for phasic DA-dependent processes that are altered in CA, such as punishment-based learning.
120-1	22225-22227	An	_	
120-2	22228-22237	important	_	
120-3	22238-22242	next	_	
120-4	22243-22247	step	_	
120-5	22248-22250	is	_	
120-6	22251-22253	to	_	
120-7	22254-22261	examine	_	
120-8	22262-22265	how	_	
120-9	22266-22271	tonic	_	
120-10	22271-22272	,	_	
120-11	22273-22280	resting	_	
120-12	22281-22292	subcortical	_	
120-13	22293-22310	hyperconnectivity	_	
120-14	22311-22314	may	_	
120-15	22315-22319	have	_	
120-16	22320-22332	consequences	_	
120-17	22333-22336	for	_	
120-18	22337-22343	phasic	_	
120-19	22344-22356	DA-dependent	_	
120-20	22357-22366	processes	_	
120-21	22367-22371	that	_	
120-22	22372-22375	are	_	
120-23	22376-22383	altered	_	
120-24	22384-22386	in	_	
120-25	22387-22389	CA	_	
120-26	22389-22390	,	_	
120-27	22391-22395	such	_	
120-28	22396-22398	as	_	
120-29	22399-22415	punishment-based	_	
120-30	22416-22424	learning	_	
120-31	22424-22425	.	_	

#Text=CA show altered subcortical activations and impaired learning from non-drug rewards and punishment.
121-1	22426-22428	CA	_	
121-2	22429-22433	show	_	
121-3	22434-22441	altered	_	
121-4	22442-22453	subcortical	_	
121-5	22454-22465	activations	_	
121-6	22466-22469	and	_	
121-7	22470-22478	impaired	_	
121-8	22479-22487	learning	_	
121-9	22488-22492	from	_	
121-10	22493-22501	non-drug	_	
121-11	22502-22509	rewards	_	
121-12	22510-22513	and	_	
121-13	22514-22524	punishment	_	
121-14	22524-22525	.	_	

#Text=If higher resting subcortical lFCD is indeed due to higher tonic DA transmission, then this increased baseline activity would confer weaker ability to generate the “dips” in activity necessary to learn from negative outcomes, in line with extant models of dopaminergic function.
122-1	22526-22528	If	_	
122-2	22529-22535	higher	_	
122-3	22536-22543	resting	_	
122-4	22544-22555	subcortical	_	
122-5	22556-22560	lFCD	_	
122-6	22561-22563	is	_	
122-7	22564-22570	indeed	_	
122-8	22571-22574	due	_	
122-9	22575-22577	to	_	
122-10	22578-22584	higher	_	
122-11	22585-22590	tonic	_	
122-12	22591-22593	DA	_	
122-13	22594-22606	transmission	_	
122-14	22606-22607	,	_	
122-15	22608-22612	then	_	
122-16	22613-22617	this	_	
122-17	22618-22627	increased	_	
122-18	22628-22636	baseline	_	
122-19	22637-22645	activity	_	
122-20	22646-22651	would	_	
122-21	22652-22658	confer	_	
122-22	22659-22665	weaker	_	
122-23	22666-22673	ability	_	
122-24	22674-22676	to	_	
122-25	22677-22685	generate	_	
122-26	22686-22689	the	_	
122-27	22690-22691	“	_	
122-28	22691-22695	dips	_	
122-29	22695-22696	”	_	
122-30	22697-22699	in	_	
122-31	22700-22708	activity	_	
122-32	22709-22718	necessary	_	
122-33	22719-22721	to	_	
122-34	22722-22727	learn	_	
122-35	22728-22732	from	_	
122-36	22733-22741	negative	_	
122-37	22742-22750	outcomes	_	
122-38	22750-22751	,	_	
122-39	22752-22754	in	_	
122-40	22755-22759	line	_	
122-41	22760-22764	with	_	
122-42	22765-22771	extant	_	
122-43	22772-22778	models	_	
122-44	22779-22781	of	_	
122-45	22782-22794	dopaminergic	_	
122-46	22795-22803	function	_	
122-47	22803-22804	.	_	

#Text=Future studies with combined PET-fMRI could examine this possibility.
123-1	22805-22811	Future	_	
123-2	22812-22819	studies	_	
123-3	22820-22824	with	_	
123-4	22825-22833	combined	_	
123-5	22834-22842	PET-fMRI	_	
123-6	22843-22848	could	_	
123-7	22849-22856	examine	_	
123-8	22857-22861	this	_	
123-9	22862-22873	possibility	_	
123-10	22873-22874	.	_	

#Text=We also observed heightened lFCD in CA relative to controls in the pulvinar nucleus of the thalamus and in the brainstem, regions critical for sensory processing and maintenance of autonomic functions, respectively.
124-1	22875-22877	We	_	
124-2	22878-22882	also	_	
124-3	22883-22891	observed	_	
124-4	22892-22902	heightened	_	
124-5	22903-22907	lFCD	_	
124-6	22908-22910	in	_	
124-7	22911-22913	CA	_	
124-8	22914-22922	relative	_	
124-9	22923-22925	to	_	
124-10	22926-22934	controls	_	
124-11	22935-22937	in	_	
124-12	22938-22941	the	_	
124-13	22942-22950	pulvinar	_	
124-14	22951-22958	nucleus	_	
124-15	22959-22961	of	_	
124-16	22962-22965	the	_	
124-17	22966-22974	thalamus	_	
124-18	22975-22978	and	_	
124-19	22979-22981	in	_	
124-20	22982-22985	the	_	
124-21	22986-22995	brainstem	_	
124-22	22995-22996	,	_	
124-23	22997-23004	regions	_	
124-24	23005-23013	critical	_	
124-25	23014-23017	for	_	
124-26	23018-23025	sensory	_	
124-27	23026-23036	processing	_	
124-28	23037-23040	and	_	
124-29	23041-23052	maintenance	_	
124-30	23053-23055	of	_	
124-31	23056-23065	autonomic	_	
124-32	23066-23075	functions	_	
124-33	23075-23076	,	_	
124-34	23077-23089	respectively	_	
124-35	23089-23090	.	_	

#Text=CA is hypothesized to increase thalamic neuronal excitability, disrupt burst firing patterns and impair thalamocortical connectivity, leading to impaired sensory processing.
125-1	23091-23093	CA	_	
125-2	23094-23096	is	_	
125-3	23097-23109	hypothesized	_	
125-4	23110-23112	to	_	
125-5	23113-23121	increase	_	
125-6	23122-23130	thalamic	_	
125-7	23131-23139	neuronal	_	
125-8	23140-23152	excitability	_	
125-9	23152-23153	,	_	
125-10	23154-23161	disrupt	_	
125-11	23162-23167	burst	_	
125-12	23168-23174	firing	_	
125-13	23175-23183	patterns	_	
125-14	23184-23187	and	_	
125-15	23188-23194	impair	_	
125-16	23195-23210	thalamocortical	_	
125-17	23211-23223	connectivity	_	
125-18	23223-23224	,	_	
125-19	23225-23232	leading	_	
125-20	23233-23235	to	_	
125-21	23236-23244	impaired	_	
125-22	23245-23252	sensory	_	
125-23	23253-23263	processing	_	
125-24	23263-23264	.	_	

#Text=In correspondence, we find increased local thalamic connectivity while others found decreased thalamocortical connectivity in CA, and both are exacerbated in early-onset CA.
126-1	23265-23267	In	_	
126-2	23268-23282	correspondence	_	
126-3	23282-23283	,	_	
126-4	23284-23286	we	_	
126-5	23287-23291	find	_	
126-6	23292-23301	increased	_	
126-7	23302-23307	local	_	
126-8	23308-23316	thalamic	_	
126-9	23317-23329	connectivity	_	
126-10	23330-23335	while	_	
126-11	23336-23342	others	_	
126-12	23343-23348	found	_	
126-13	23349-23358	decreased	_	
126-14	23359-23374	thalamocortical	_	
126-15	23375-23387	connectivity	_	
126-16	23388-23390	in	_	
126-17	23391-23393	CA	_	
126-18	23393-23394	,	_	
126-19	23395-23398	and	_	
126-20	23399-23403	both	_	
126-21	23404-23407	are	_	
126-22	23408-23419	exacerbated	_	
126-23	23420-23422	in	_	
126-24	23423-23434	early-onset	_	
126-25	23435-23437	CA	_	
126-26	23437-23438	.	_	

#Text=In addition, CA show hyperactive thalamic responses to cannabis cues, which correlate with subjective craving of cannabis and are thought to contribute to sensorimotor deficits.
127-1	23439-23441	In	_	
127-2	23442-23450	addition	_	
127-3	23450-23451	,	_	
127-4	23452-23454	CA	_	
127-5	23455-23459	show	_	
127-6	23460-23471	hyperactive	_	
127-7	23472-23480	thalamic	_	
127-8	23481-23490	responses	_	
127-9	23491-23493	to	_	
127-10	23494-23502	cannabis	_	
127-11	23503-23507	cues	_	
127-12	23507-23508	,	_	
127-13	23509-23514	which	_	
127-14	23515-23524	correlate	_	
127-15	23525-23529	with	_	
127-16	23530-23540	subjective	_	
127-17	23541-23548	craving	_	
127-18	23549-23551	of	_	
127-19	23552-23560	cannabis	_	
127-20	23561-23564	and	_	
127-21	23565-23568	are	_	
127-22	23569-23576	thought	_	
127-23	23577-23579	to	_	
127-24	23580-23590	contribute	_	
127-25	23591-23593	to	_	
127-26	23594-23606	sensorimotor	_	
127-27	23607-23615	deficits	_	
127-28	23615-23616	.	_	

#Text=There has been comparatively less attention on changes to brainstem function in CA, perhaps because this region has lower concentrations of cannabinoid receptors than the basal ganglia.
128-1	23617-23622	There	_	
128-2	23623-23626	has	_	
128-3	23627-23631	been	_	
128-4	23632-23645	comparatively	_	
128-5	23646-23650	less	_	
128-6	23651-23660	attention	_	
128-7	23661-23663	on	_	
128-8	23664-23671	changes	_	
128-9	23672-23674	to	_	
128-10	23675-23684	brainstem	_	
128-11	23685-23693	function	_	
128-12	23694-23696	in	_	
128-13	23697-23699	CA	_	
128-14	23699-23700	,	_	
128-15	23701-23708	perhaps	_	
128-16	23709-23716	because	_	
128-17	23717-23721	this	_	
128-18	23722-23728	region	_	
128-19	23729-23732	has	_	
128-20	23733-23738	lower	_	
128-21	23739-23753	concentrations	_	
128-22	23754-23756	of	_	
128-23	23757-23768	cannabinoid	_	
128-24	23769-23778	receptors	_	
128-25	23779-23783	than	_	
128-26	23784-23787	the	_	
128-27	23788-23793	basal	_	
128-28	23794-23801	ganglia	_	
128-29	23801-23802	.	_	

#Text=Yet CA impacts functions regulated by the brainstem region identified here, which includes the ventral raphe nuclei extending into the nucleus of the solitary tract.
129-1	23803-23806	Yet	_	
129-2	23807-23809	CA	_	
129-3	23810-23817	impacts	_	
129-4	23818-23827	functions	_	
129-5	23828-23837	regulated	_	
129-6	23838-23840	by	_	
129-7	23841-23844	the	_	
129-8	23845-23854	brainstem	_	
129-9	23855-23861	region	_	
129-10	23862-23872	identified	_	
129-11	23873-23877	here	_	
129-12	23877-23878	,	_	
129-13	23879-23884	which	_	
129-14	23885-23893	includes	_	
129-15	23894-23897	the	_	
129-16	23898-23905	ventral	_	
129-17	23906-23911	raphe	_	
129-18	23912-23918	nuclei	_	
129-19	23919-23928	extending	_	
129-20	23929-23933	into	_	
129-21	23934-23937	the	_	
129-22	23938-23945	nucleus	_	
129-23	23946-23948	of	_	
129-24	23949-23952	the	_	
129-25	23953-23961	solitary	_	
129-26	23962-23967	tract	_	
129-27	23967-23968	.	_	

#Text=For instance, regular CA disrupts rapid eye movement (REM) sleep and increases insomnia and negatively influences mood.
130-1	23969-23972	For	_	
130-2	23973-23981	instance	_	
130-3	23981-23982	,	_	
130-4	23983-23990	regular	_	
130-5	23991-23993	CA	_	
130-6	23994-24002	disrupts	_	
130-7	24003-24008	rapid	_	
130-8	24009-24012	eye	_	
130-9	24013-24021	movement	_	
130-10	24022-24023	(	_	
130-11	24023-24026	REM	_	
130-12	24026-24027	)	_	
130-13	24028-24033	sleep	_	
130-14	24034-24037	and	_	
130-15	24038-24047	increases	_	
130-16	24048-24056	insomnia	_	
130-17	24057-24060	and	_	
130-18	24061-24071	negatively	_	
130-19	24072-24082	influences	_	
130-20	24083-24087	mood	_	
130-21	24087-24088	.	_	

#Text=Interestingly, in individuals with post-traumatic stress disorder, sleep disturbance is associated with heightened brainstem glucose metabolism, a measure that strongly correlates with lFCD.
131-1	24089-24102	Interestingly	_	
131-2	24102-24103	,	_	
131-3	24104-24106	in	_	
131-4	24107-24118	individuals	_	
131-5	24119-24123	with	_	
131-6	24124-24138	post-traumatic	_	
131-7	24139-24145	stress	_	
131-8	24146-24154	disorder	_	
131-9	24154-24155	,	_	
131-10	24156-24161	sleep	_	
131-11	24162-24173	disturbance	_	
131-12	24174-24176	is	_	
131-13	24177-24187	associated	_	
131-14	24188-24192	with	_	
131-15	24193-24203	heightened	_	
131-16	24204-24213	brainstem	_	
131-17	24214-24221	glucose	_	
131-18	24222-24232	metabolism	_	
131-19	24232-24233	,	_	
131-20	24234-24235	a	_	
131-21	24236-24243	measure	_	
131-22	24244-24248	that	_	
131-23	24249-24257	strongly	_	
131-24	24258-24268	correlates	_	
131-25	24269-24273	with	_	
131-26	24274-24278	lFCD	_	
131-27	24278-24279	.	_	

#Text=More work is needed to describe how changes to brain functional organization in CA have relevance for sensory and autonomic functions.
132-1	24280-24284	More	_	
132-2	24285-24289	work	_	
132-3	24290-24292	is	_	
132-4	24293-24299	needed	_	
132-5	24300-24302	to	_	
132-6	24303-24311	describe	_	
132-7	24312-24315	how	_	
132-8	24316-24323	changes	_	
132-9	24324-24326	to	_	
132-10	24327-24332	brain	_	
132-11	24333-24343	functional	_	
132-12	24344-24356	organization	_	
132-13	24357-24359	in	_	
132-14	24360-24362	CA	_	
132-15	24363-24367	have	_	
132-16	24368-24377	relevance	_	
132-17	24378-24381	for	_	
132-18	24382-24389	sensory	_	
132-19	24390-24393	and	_	
132-20	24394-24403	autonomic	_	
132-21	24404-24413	functions	_	
132-22	24413-24414	.	_	

#Text=Finally, subcortical hyperconnectivity was most pronounced in early-onset CA and correlated with feelings of alienation (especially in the midbrain).
133-1	24415-24422	Finally	_	
133-2	24422-24423	,	_	
133-3	24424-24435	subcortical	_	
133-4	24436-24453	hyperconnectivity	_	
133-5	24454-24457	was	_	
133-6	24458-24462	most	_	
133-7	24463-24473	pronounced	_	
133-8	24474-24476	in	_	
133-9	24477-24488	early-onset	_	
133-10	24489-24491	CA	_	
133-11	24492-24495	and	_	
133-12	24496-24506	correlated	_	
133-13	24507-24511	with	_	
133-14	24512-24520	feelings	_	
133-15	24521-24523	of	_	
133-16	24524-24534	alienation	_	
133-17	24535-24536	(	_	
133-18	24536-24546	especially	_	
133-19	24547-24549	in	_	
133-20	24550-24553	the	_	
133-21	24554-24562	midbrain	_	
133-22	24562-24563	)	_	
133-23	24563-24564	.	_	

#Text=CA is thought to be particularly detrimental in adolescence because the brain is in a critical period of increased myelination and extensive synaptic pruning.
134-1	24565-24567	CA	_	
134-2	24568-24570	is	_	
134-3	24571-24578	thought	_	
134-4	24579-24581	to	_	
134-5	24582-24584	be	_	
134-6	24585-24597	particularly	_	
134-7	24598-24609	detrimental	_	
134-8	24610-24612	in	_	
134-9	24613-24624	adolescence	_	
134-10	24625-24632	because	_	
134-11	24633-24636	the	_	
134-12	24637-24642	brain	_	
134-13	24643-24645	is	_	
134-14	24646-24648	in	_	
134-15	24649-24650	a	_	
134-16	24651-24659	critical	_	
134-17	24660-24666	period	_	
134-18	24667-24669	of	_	
134-19	24670-24679	increased	_	
134-20	24680-24691	myelination	_	
134-21	24692-24695	and	_	
134-22	24696-24705	extensive	_	
134-23	24706-24714	synaptic	_	
134-24	24715-24722	pruning	_	
134-25	24722-24723	.	_	

#Text=Subcortical cannabinoid receptor development is ongoing at this time, and exogenous cannabis perturbs the normal development of the mesolimbic system, which is thought to contribute to psychopathology.
135-1	24724-24735	Subcortical	_	
135-2	24736-24747	cannabinoid	_	
135-3	24748-24756	receptor	_	
135-4	24757-24768	development	_	
135-5	24769-24771	is	_	
135-6	24772-24779	ongoing	_	
135-7	24780-24782	at	_	
135-8	24783-24787	this	_	
135-9	24788-24792	time	_	
135-10	24792-24793	,	_	
135-11	24794-24797	and	_	
135-12	24798-24807	exogenous	_	
135-13	24808-24816	cannabis	_	
135-14	24817-24825	perturbs	_	
135-15	24826-24829	the	_	
135-16	24830-24836	normal	_	
135-17	24837-24848	development	_	
135-18	24849-24851	of	_	
135-19	24852-24855	the	_	
135-20	24856-24866	mesolimbic	_	
135-21	24867-24873	system	_	
135-22	24873-24874	,	_	
135-23	24875-24880	which	_	
135-24	24881-24883	is	_	
135-25	24884-24891	thought	_	
135-26	24892-24894	to	_	
135-27	24895-24905	contribute	_	
135-28	24906-24908	to	_	
135-29	24909-24924	psychopathology	_	
135-30	24924-24925	.	_	

#Text=It is well-established that early-onset CA have poor cognitive and emotional outcomes, but the neural basis of this phenomenon is not well understood.
136-1	24926-24928	It	_	
136-2	24929-24931	is	_	
136-3	24932-24948	well-established	_	
136-4	24949-24953	that	_	
136-5	24954-24965	early-onset	_	
136-6	24966-24968	CA	_	
136-7	24969-24973	have	_	
136-8	24974-24978	poor	_	
136-9	24979-24988	cognitive	_	
136-10	24989-24992	and	_	
136-11	24993-25002	emotional	_	
136-12	25003-25011	outcomes	_	
136-13	25011-25012	,	_	
136-14	25013-25016	but	_	
136-15	25017-25020	the	_	
136-16	25021-25027	neural	_	
136-17	25028-25033	basis	_	
136-18	25034-25036	of	_	
136-19	25037-25041	this	_	
136-20	25042-25052	phenomenon	_	
136-21	25053-25055	is	_	
136-22	25056-25059	not	_	
136-23	25060-25064	well	_	
136-24	25065-25075	understood	_	
136-25	25075-25076	.	_	

#Text=Prior rsfMRI studies suggested that increased functional connectivity within cortical networks involved in self-awareness, including the salience and default-mode networks, could lead to aberrant emotional/motivational processing.
137-1	25077-25082	Prior	_	
137-2	25083-25089	rsfMRI	_	
137-3	25090-25097	studies	_	
137-4	25098-25107	suggested	_	
137-5	25108-25112	that	_	
137-6	25113-25122	increased	_	
137-7	25123-25133	functional	_	
137-8	25134-25146	connectivity	_	
137-9	25147-25153	within	_	
137-10	25154-25162	cortical	_	
137-11	25163-25171	networks	_	
137-12	25172-25180	involved	_	
137-13	25181-25183	in	_	
137-14	25184-25198	self-awareness	_	
137-15	25198-25199	,	_	
137-16	25200-25209	including	_	
137-17	25210-25213	the	_	
137-18	25214-25222	salience	_	
137-19	25223-25226	and	_	
137-20	25227-25239	default-mode	_	
137-21	25240-25248	networks	_	
137-22	25248-25249	,	_	
137-23	25250-25255	could	_	
137-24	25256-25260	lead	_	
137-25	25261-25263	to	_	
137-26	25264-25272	aberrant	_	
137-27	25273-25282	emotional	_	
137-28	25282-25283	/	_	
137-29	25283-25295	motivational	_	
137-30	25296-25306	processing	_	
137-31	25306-25307	.	_	

#Text=We also recently showed that glucose metabolism in inferior frontal gyrus negatively correlated with feelings of alienation in CA.
138-1	25308-25310	We	_	
138-2	25311-25315	also	_	
138-3	25316-25324	recently	_	
138-4	25325-25331	showed	_	
138-5	25332-25336	that	_	
138-6	25337-25344	glucose	_	
138-7	25345-25355	metabolism	_	
138-8	25356-25358	in	_	
138-9	25359-25367	inferior	_	
138-10	25368-25375	frontal	_	
138-11	25376-25381	gyrus	_	
138-12	25382-25392	negatively	_	
138-13	25393-25403	correlated	_	
138-14	25404-25408	with	_	
138-15	25409-25417	feelings	_	
138-16	25418-25420	of	_	
138-17	25421-25431	alienation	_	
138-18	25432-25434	in	_	
138-19	25435-25437	CA	_	
138-20	25437-25438	.	_	

#Text=These findings, together with the current data provide convergent evidence supporting the notion that impaired prefrontal regulation of subcortical activity contributes to the negative emotionality seen in addictions.
139-1	25439-25444	These	_	
139-2	25445-25453	findings	_	
139-3	25453-25454	,	_	
139-4	25455-25463	together	_	
139-5	25464-25468	with	_	
139-6	25469-25472	the	_	
139-7	25473-25480	current	_	
139-8	25481-25485	data	_	
139-9	25486-25493	provide	_	
139-10	25494-25504	convergent	_	
139-11	25505-25513	evidence	_	
139-12	25514-25524	supporting	_	
139-13	25525-25528	the	_	
139-14	25529-25535	notion	_	
139-15	25536-25540	that	_	
139-16	25541-25549	impaired	_	
139-17	25550-25560	prefrontal	_	
139-18	25561-25571	regulation	_	
139-19	25572-25574	of	_	
139-20	25575-25586	subcortical	_	
139-21	25587-25595	activity	_	
139-22	25596-25607	contributes	_	
139-23	25608-25610	to	_	
139-24	25611-25614	the	_	
139-25	25615-25623	negative	_	
139-26	25624-25636	emotionality	_	
139-27	25637-25641	seen	_	
139-28	25642-25644	in	_	
139-29	25645-25655	addictions	_	
139-30	25655-25656	.	_	

#Text=The data presented here build on the small body of work in CA using HCP data.
140-1	25657-25660	The	_	
140-2	25661-25665	data	_	
140-3	25666-25675	presented	_	
140-4	25676-25680	here	_	
140-5	25681-25686	build	_	
140-6	25687-25689	on	_	
140-7	25690-25693	the	_	
140-8	25694-25699	small	_	
140-9	25700-25704	body	_	
140-10	25705-25707	of	_	
140-11	25708-25712	work	_	
140-12	25713-25715	in	_	
140-13	25716-25718	CA	_	
140-14	25719-25724	using	_	
140-15	25725-25728	HCP	_	
140-16	25729-25733	data	_	
140-17	25733-25734	.	_	

#Text=An initial investigation using structural MRI data found that effects of cannabis exposure on subcortical volumetry were minimal, but critically, they concluded that cannabis effects may be stronger in DA-rich regions including the VS and in the most frequent CA.
141-1	25735-25737	An	_	
141-2	25738-25745	initial	_	
141-3	25746-25759	investigation	_	
141-4	25760-25765	using	_	
141-5	25766-25776	structural	_	
141-6	25777-25780	MRI	_	
141-7	25781-25785	data	_	
141-8	25786-25791	found	_	
141-9	25792-25796	that	_	
141-10	25797-25804	effects	_	
141-11	25805-25807	of	_	
141-12	25808-25816	cannabis	_	
141-13	25817-25825	exposure	_	
141-14	25826-25828	on	_	
141-15	25829-25840	subcortical	_	
141-16	25841-25850	volumetry	_	
141-17	25851-25855	were	_	
141-18	25856-25863	minimal	_	
141-19	25863-25864	,	_	
141-20	25865-25868	but	_	
141-21	25869-25879	critically	_	
141-22	25879-25880	,	_	
141-23	25881-25885	they	_	
141-24	25886-25895	concluded	_	
141-25	25896-25900	that	_	
141-26	25901-25909	cannabis	_	
141-27	25910-25917	effects	_	
141-28	25918-25921	may	_	
141-29	25922-25924	be	_	
141-30	25925-25933	stronger	_	
141-31	25934-25936	in	_	
141-32	25937-25944	DA-rich	_	
141-33	25945-25952	regions	_	
141-34	25953-25962	including	_	
141-35	25963-25966	the	_	
141-36	25967-25969	VS	_	
141-37	25970-25973	and	_	
141-38	25974-25976	in	_	
141-39	25977-25980	the	_	
141-40	25981-25985	most	_	
141-41	25986-25994	frequent	_	
141-42	25995-25997	CA	_	
141-43	25997-25998	.	_	

#Text=Another diffusion-tensor imaging study examined 466 individuals reporting at least one lifetime experience with cannabis, and found that frequency of cannabis use did not associate with cortical volumes, but did associate with changes to the shape of the amygdala and hippocampus.
142-1	25999-26006	Another	_	
142-2	26007-26023	diffusion-tensor	_	
142-3	26024-26031	imaging	_	
142-4	26032-26037	study	_	
142-5	26038-26046	examined	_	
142-6	26047-26050	466	_	
142-7	26051-26062	individuals	_	
142-8	26063-26072	reporting	_	
142-9	26073-26075	at	_	
142-10	26076-26081	least	_	
142-11	26082-26085	one	_	
142-12	26086-26094	lifetime	_	
142-13	26095-26105	experience	_	
142-14	26106-26110	with	_	
142-15	26111-26119	cannabis	_	
142-16	26119-26120	,	_	
142-17	26121-26124	and	_	
142-18	26125-26130	found	_	
142-19	26131-26135	that	_	
142-20	26136-26145	frequency	_	
142-21	26146-26148	of	_	
142-22	26149-26157	cannabis	_	
142-23	26158-26161	use	_	
142-24	26162-26165	did	_	
142-25	26166-26169	not	_	
142-26	26170-26179	associate	_	
142-27	26180-26184	with	_	
142-28	26185-26193	cortical	_	
142-29	26194-26201	volumes	_	
142-30	26201-26202	,	_	
142-31	26203-26206	but	_	
142-32	26207-26210	did	_	
142-33	26211-26220	associate	_	
142-34	26221-26225	with	_	
142-35	26226-26233	changes	_	
142-36	26234-26236	to	_	
142-37	26237-26240	the	_	
142-38	26241-26246	shape	_	
142-39	26247-26249	of	_	
142-40	26250-26253	the	_	
142-41	26254-26262	amygdala	_	
142-42	26263-26266	and	_	
142-43	26267-26278	hippocampus	_	
142-44	26278-26279	.	_	

#Text=Most notably, they observed that early-onset CA was associated with altered shape of the nucleus accumbens and loss of white matter integrity throughout the cortex.
143-1	26280-26284	Most	_	
143-2	26285-26292	notably	_	
143-3	26292-26293	,	_	
143-4	26294-26298	they	_	
143-5	26299-26307	observed	_	
143-6	26308-26312	that	_	
143-7	26313-26324	early-onset	_	
143-8	26325-26327	CA	_	
143-9	26328-26331	was	_	
143-10	26332-26342	associated	_	
143-11	26343-26347	with	_	
143-12	26348-26355	altered	_	
143-13	26356-26361	shape	_	
143-14	26362-26364	of	_	
143-15	26365-26368	the	_	
143-16	26369-26376	nucleus	_	
143-17	26377-26386	accumbens	_	
143-18	26387-26390	and	_	
143-19	26391-26395	loss	_	
143-20	26396-26398	of	_	
143-21	26399-26404	white	_	
143-22	26405-26411	matter	_	
143-23	26412-26421	integrity	_	
143-24	26422-26432	throughout	_	
143-25	26433-26436	the	_	
143-26	26437-26443	cortex	_	
143-27	26443-26444	.	_	

#Text=To our knowledge, the present study is the first to extend HCP investigations of CA to rsfMRI data.
144-1	26445-26447	To	_	
144-2	26448-26451	our	_	
144-3	26452-26461	knowledge	_	
144-4	26461-26462	,	_	
144-5	26463-26466	the	_	
144-6	26467-26474	present	_	
144-7	26475-26480	study	_	
144-8	26481-26483	is	_	
144-9	26484-26487	the	_	
144-10	26488-26493	first	_	
144-11	26494-26496	to	_	
144-12	26497-26503	extend	_	
144-13	26504-26507	HCP	_	
144-14	26508-26522	investigations	_	
144-15	26523-26525	of	_	
144-16	26526-26528	CA	_	
144-17	26529-26531	to	_	
144-18	26532-26538	rsfMRI	_	
144-19	26539-26543	data	_	
144-20	26543-26544	.	_	

#Text=Because the HCP project is open access, there is a rich opportunity for further examination of the chronic effects of CA using a common dataset.
145-1	26545-26552	Because	_	
145-2	26553-26556	the	_	
145-3	26557-26560	HCP	_	
145-4	26561-26568	project	_	
145-5	26569-26571	is	_	
145-6	26572-26576	open	_	
145-7	26577-26583	access	_	
145-8	26583-26584	,	_	
145-9	26585-26590	there	_	
145-10	26591-26593	is	_	
145-11	26594-26595	a	_	
145-12	26596-26600	rich	_	
145-13	26601-26612	opportunity	_	
145-14	26613-26616	for	_	
145-15	26617-26624	further	_	
145-16	26625-26636	examination	_	
145-17	26637-26639	of	_	
145-18	26640-26643	the	_	
145-19	26644-26651	chronic	_	
145-20	26652-26659	effects	_	
145-21	26660-26662	of	_	
145-22	26663-26665	CA	_	
145-23	26666-26671	using	_	
145-24	26672-26673	a	_	
145-25	26674-26680	common	_	
145-26	26681-26688	dataset	_	
145-27	26688-26689	.	_	

#Text=Limitations
#Text=The HCP does not have in vivo measures of subcortical DA release or receptor function, and so we could not directly assess the hypothesis of hyperdopaminergia and psychosis risk in CA.
146-1	26690-26701	Limitations	_	
146-2	26702-26705	The	_	
146-3	26706-26709	HCP	_	
146-4	26710-26714	does	_	
146-5	26715-26718	not	_	
146-6	26719-26723	have	_	
146-7	26724-26726	in	_	
146-8	26727-26731	vivo	_	
146-9	26732-26740	measures	_	
146-10	26741-26743	of	_	
146-11	26744-26755	subcortical	_	
146-12	26756-26758	DA	_	
146-13	26759-26766	release	_	
146-14	26767-26769	or	_	
146-15	26770-26778	receptor	_	
146-16	26779-26787	function	_	
146-17	26787-26788	,	_	
146-18	26789-26792	and	_	
146-19	26793-26795	so	_	
146-20	26796-26798	we	_	
146-21	26799-26804	could	_	
146-22	26805-26808	not	_	
146-23	26809-26817	directly	_	
146-24	26818-26824	assess	_	
146-25	26825-26828	the	_	
146-26	26829-26839	hypothesis	_	
146-27	26840-26842	of	_	
146-28	26843-26860	hyperdopaminergia	_	
146-29	26861-26864	and	_	
146-30	26865-26874	psychosis	_	
146-31	26875-26879	risk	_	
146-32	26880-26882	in	_	
146-33	26883-26885	CA	_	
146-34	26885-26886	.	_	

#Text=Resting-state lFCD is an indirect measure of neuronal activity and the true neurobiological basis of this measure needs further exploration.
147-1	26887-26900	Resting-state	_	
147-2	26901-26905	lFCD	_	
147-3	26906-26908	is	_	
147-4	26909-26911	an	_	
147-5	26912-26920	indirect	_	
147-6	26921-26928	measure	_	
147-7	26929-26931	of	_	
147-8	26932-26940	neuronal	_	
147-9	26941-26949	activity	_	
147-10	26950-26953	and	_	
147-11	26954-26957	the	_	
147-12	26958-26962	true	_	
147-13	26963-26978	neurobiological	_	
147-14	26979-26984	basis	_	
147-15	26985-26987	of	_	
147-16	26988-26992	this	_	
147-17	26993-27000	measure	_	
147-18	27001-27006	needs	_	
147-19	27007-27014	further	_	
147-20	27015-27026	exploration	_	
147-21	27026-27027	.	_	

#Text=Further, how exactly hyperdopaminergia manifests at the neural level is disputed.
148-1	27028-27035	Further	_	
148-2	27035-27036	,	_	
148-3	27037-27040	how	_	
148-4	27041-27048	exactly	_	
148-5	27049-27066	hyperdopaminergia	_	
148-6	27067-27076	manifests	_	
148-7	27077-27079	at	_	
148-8	27080-27083	the	_	
148-9	27084-27090	neural	_	
148-10	27091-27096	level	_	
148-11	27097-27099	is	_	
148-12	27100-27108	disputed	_	
148-13	27108-27109	.	_	

#Text=While CA with psychosis do not show elevated striatal DA release, stimulant-induced changes in DA correlate with psychosis, suggesting that hyperdopaminergia may be more related to postsynaptic hypersensitivity than to total levels of synaptic DA.
149-1	27110-27115	While	_	
149-2	27116-27118	CA	_	
149-3	27119-27123	with	_	
149-4	27124-27133	psychosis	_	
149-5	27134-27136	do	_	
149-6	27137-27140	not	_	
149-7	27141-27145	show	_	
149-8	27146-27154	elevated	_	
149-9	27155-27163	striatal	_	
149-10	27164-27166	DA	_	
149-11	27167-27174	release	_	
149-12	27174-27175	,	_	
149-13	27176-27193	stimulant-induced	_	
149-14	27194-27201	changes	_	
149-15	27202-27204	in	_	
149-16	27205-27207	DA	_	
149-17	27208-27217	correlate	_	
149-18	27218-27222	with	_	
149-19	27223-27232	psychosis	_	
149-20	27232-27233	,	_	
149-21	27234-27244	suggesting	_	
149-22	27245-27249	that	_	
149-23	27250-27267	hyperdopaminergia	_	
149-24	27268-27271	may	_	
149-25	27272-27274	be	_	
149-26	27275-27279	more	_	
149-27	27280-27287	related	_	
149-28	27288-27290	to	_	
149-29	27291-27303	postsynaptic	_	
149-30	27304-27320	hypersensitivity	_	
149-31	27321-27325	than	_	
149-32	27326-27328	to	_	
149-33	27329-27334	total	_	
149-34	27335-27341	levels	_	
149-35	27342-27344	of	_	
149-36	27345-27353	synaptic	_	
149-37	27354-27356	DA	_	
149-38	27356-27357	.	_	

#Text=Nevertheless, the final release of the HCP will include single-nucleotide polymorphism (SNP) data for all participants; future studies should examine how genetic differences predicting D2/3 function, e.g.
150-1	27358-27370	Nevertheless	_	
150-2	27370-27371	,	_	
150-3	27372-27375	the	_	
150-4	27376-27381	final	_	
150-5	27382-27389	release	_	
150-6	27390-27392	of	_	
150-7	27393-27396	the	_	
150-8	27397-27400	HCP	_	
150-9	27401-27405	will	_	
150-10	27406-27413	include	_	
150-11	27414-27431	single-nucleotide	_	
150-12	27432-27444	polymorphism	_	
150-13	27445-27446	(	_	
150-14	27446-27449	SNP	_	
150-15	27449-27450	)	_	
150-16	27451-27455	data	_	
150-17	27456-27459	for	_	
150-18	27460-27463	all	_	
150-19	27464-27476	participants	_	
150-20	27476-27477	;	_	
150-21	27478-27484	future	_	
150-22	27485-27492	studies	_	
150-23	27493-27499	should	_	
150-24	27500-27507	examine	_	
150-25	27508-27511	how	_	
150-26	27512-27519	genetic	_	
150-27	27520-27531	differences	_	
150-28	27532-27542	predicting	_	
150-29	27543-27545	D2	_	
150-30	27545-27546	/	_	
150-31	27546-27547	3	_	
150-32	27548-27556	function	_	
150-33	27556-27557	,	_	
150-34	27558-27561	e.g	_	
150-35	27561-27562	.	_	

#Text=Taq1A and C957T SNPs, predict risk for CA and subcortical lFCD, which would help shed light on this issue.
151-1	27563-27568	Taq1A	_	
151-2	27569-27572	and	_	
151-3	27573-27578	C957T	_	
151-4	27579-27583	SNPs	_	
151-5	27583-27584	,	_	
151-6	27585-27592	predict	_	
151-7	27593-27597	risk	_	
151-8	27598-27601	for	_	
151-9	27602-27604	CA	_	
151-10	27605-27608	and	_	
151-11	27609-27620	subcortical	_	
151-12	27621-27625	lFCD	_	
151-13	27625-27626	,	_	
151-14	27627-27632	which	_	
151-15	27633-27638	would	_	
151-16	27639-27643	help	_	
151-17	27644-27648	shed	_	
151-18	27649-27654	light	_	
151-19	27655-27657	on	_	
151-20	27658-27662	this	_	
151-21	27663-27668	issue	_	
151-22	27668-27669	.	_	

#Text=Additionally, it remains unknown whether emotional disturbance is directly caused by CA or if individuals use cannabis to self-medicate feelings of negative emotionality.
152-1	27670-27682	Additionally	_	
152-2	27682-27683	,	_	
152-3	27684-27686	it	_	
152-4	27687-27694	remains	_	
152-5	27695-27702	unknown	_	
152-6	27703-27710	whether	_	
152-7	27711-27720	emotional	_	
152-8	27721-27732	disturbance	_	
152-9	27733-27735	is	_	
152-10	27736-27744	directly	_	
152-11	27745-27751	caused	_	
152-12	27752-27754	by	_	
152-13	27755-27757	CA	_	
152-14	27758-27760	or	_	
152-15	27761-27763	if	_	
152-16	27764-27775	individuals	_	
152-17	27776-27779	use	_	
152-18	27780-27788	cannabis	_	
152-19	27789-27791	to	_	
152-20	27792-27805	self-medicate	_	
152-21	27806-27814	feelings	_	
152-22	27815-27817	of	_	
152-23	27818-27826	negative	_	
152-24	27827-27839	emotionality	_	
152-25	27839-27840	.	_	

#Text=Finally, we cannot rule out the possibility that subcortical hyperconnectivity may be associated with cannabis withdrawal and the extent to which it abates with prolonged abstinence, as has been observed with other functional connectivity abnormalities in CA.
153-1	27841-27848	Finally	_	
153-2	27848-27849	,	_	
153-3	27850-27852	we	_	
153-4	27853-27859	cannot	_	
153-5	27860-27864	rule	_	
153-6	27865-27868	out	_	
153-7	27869-27872	the	_	
153-8	27873-27884	possibility	_	
153-9	27885-27889	that	_	
153-10	27890-27901	subcortical	_	
153-11	27902-27919	hyperconnectivity	_	
153-12	27920-27923	may	_	
153-13	27924-27926	be	_	
153-14	27927-27937	associated	_	
153-15	27938-27942	with	_	
153-16	27943-27951	cannabis	_	
153-17	27952-27962	withdrawal	_	
153-18	27963-27966	and	_	
153-19	27967-27970	the	_	
153-20	27971-27977	extent	_	
153-21	27978-27980	to	_	
153-22	27981-27986	which	_	
153-23	27987-27989	it	_	
153-24	27990-27996	abates	_	
153-25	27997-28001	with	_	
153-26	28002-28011	prolonged	_	
153-27	28012-28022	abstinence	_	
153-28	28022-28023	,	_	
153-29	28024-28026	as	_	
153-30	28027-28030	has	_	
153-31	28031-28035	been	_	
153-32	28036-28044	observed	_	
153-33	28045-28049	with	_	
153-34	28050-28055	other	_	
153-35	28056-28066	functional	_	
153-36	28067-28079	connectivity	_	
153-37	28080-28093	abnormalities	_	
153-38	28094-28096	in	_	
153-39	28097-28099	CA	_	
153-40	28099-28100	.	_	

#Text=Conclusion
#Text=Despite increased usage of cannabis worldwide, little is known about the neuropsychiatric effects of CA, especially in early-onset users.
154-1	28101-28111	Conclusion	_	
154-2	28112-28119	Despite	_	
154-3	28120-28129	increased	_	
154-4	28130-28135	usage	_	
154-5	28136-28138	of	_	
154-6	28139-28147	cannabis	_	
154-7	28148-28157	worldwide	_	
154-8	28157-28158	,	_	
154-9	28159-28165	little	_	
154-10	28166-28168	is	_	
154-11	28169-28174	known	_	
154-12	28175-28180	about	_	
154-13	28181-28184	the	_	
154-14	28185-28201	neuropsychiatric	_	
154-15	28202-28209	effects	_	
154-16	28210-28212	of	_	
154-17	28213-28215	CA	_	
154-18	28215-28216	,	_	
154-19	28217-28227	especially	_	
154-20	28228-28230	in	_	
154-21	28231-28242	early-onset	_	
154-22	28243-28248	users	_	
154-23	28248-28249	.	_	

#Text=Here we show that resting connectivity of subcortical functional hubs, particularly within dopaminergic nuclei implicated in psychopathology, is greatly increased in CA.
155-1	28250-28254	Here	_	
155-2	28255-28257	we	_	
155-3	28258-28262	show	_	
155-4	28263-28267	that	_	
155-5	28268-28275	resting	_	
155-6	28276-28288	connectivity	_	
155-7	28289-28291	of	_	
155-8	28292-28303	subcortical	_	
155-9	28304-28314	functional	_	
155-10	28315-28319	hubs	_	
155-11	28319-28320	,	_	
155-12	28321-28333	particularly	_	
155-13	28334-28340	within	_	
155-14	28341-28353	dopaminergic	_	
155-15	28354-28360	nuclei	_	
155-16	28361-28371	implicated	_	
155-17	28372-28374	in	_	
155-18	28375-28390	psychopathology	_	
155-19	28390-28391	,	_	
155-20	28392-28394	is	_	
155-21	28395-28402	greatly	_	
155-22	28403-28412	increased	_	
155-23	28413-28415	in	_	
155-24	28416-28418	CA	_	
155-25	28418-28419	.	_	

#Text=This pattern was exaggerated in individuals who began using in early adolescence and were associated with high levels of negative emotionality.
156-1	28420-28424	This	_	
156-2	28425-28432	pattern	_	
156-3	28433-28436	was	_	
156-4	28437-28448	exaggerated	_	
156-5	28449-28451	in	_	
156-6	28452-28463	individuals	_	
156-7	28464-28467	who	_	
156-8	28468-28473	began	_	
156-9	28474-28479	using	_	
156-10	28480-28482	in	_	
156-11	28483-28488	early	_	
156-12	28489-28500	adolescence	_	
156-13	28501-28504	and	_	
156-14	28505-28509	were	_	
156-15	28510-28520	associated	_	
156-16	28521-28525	with	_	
156-17	28526-28530	high	_	
156-18	28531-28537	levels	_	
156-19	28538-28540	of	_	
156-20	28541-28549	negative	_	
156-21	28550-28562	emotionality	_	
156-22	28562-28563	.	_	

#Text=Thus, subcortical functional connectivity may be a useful marker for tracking the development of psychopathology with prolonged CA.
157-1	28564-28568	Thus	_	
157-2	28568-28569	,	_	
157-3	28570-28581	subcortical	_	
157-4	28582-28592	functional	_	
157-5	28593-28605	connectivity	_	
157-6	28606-28609	may	_	
157-7	28610-28612	be	_	
157-8	28613-28614	a	_	
157-9	28615-28621	useful	_	
157-10	28622-28628	marker	_	
157-11	28629-28632	for	_	
157-12	28633-28641	tracking	_	
157-13	28642-28645	the	_	
157-14	28646-28657	development	_	
157-15	28658-28660	of	_	
157-16	28661-28676	psychopathology	_	
157-17	28677-28681	with	_	
157-18	28682-28691	prolonged	_	
157-19	28692-28694	CA	_	
157-20	28694-28695	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
158-1	28696-28709	Supplementary	_	
158-2	28710-28718	Material	_	
158-3	28719-28723	This	_	
158-4	28724-28726	is	_	
158-5	28727-28728	a	_	
158-6	28729-28732	PDF	_	
158-7	28733-28737	file	_	
158-8	28738-28740	of	_	
158-9	28741-28743	an	_	
158-10	28744-28752	unedited	_	
158-11	28753-28763	manuscript	_	
158-12	28764-28768	that	_	
158-13	28769-28772	has	_	
158-14	28773-28777	been	_	
158-15	28778-28786	accepted	_	
158-16	28787-28790	for	_	
158-17	28791-28802	publication	_	
158-18	28802-28803	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
159-1	28804-28806	As	_	
159-2	28807-28808	a	_	
159-3	28809-28816	service	_	
159-4	28817-28819	to	_	
159-5	28820-28823	our	_	
159-6	28824-28833	customers	_	
159-7	28834-28836	we	_	
159-8	28837-28840	are	_	
159-9	28841-28850	providing	_	
159-10	28851-28855	this	_	
159-11	28856-28861	early	_	
159-12	28862-28869	version	_	
159-13	28870-28872	of	_	
159-14	28873-28876	the	_	
159-15	28877-28887	manuscript	_	
159-16	28887-28888	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
160-1	28889-28892	The	_	
160-2	28893-28903	manuscript	_	
160-3	28904-28908	will	_	
160-4	28909-28916	undergo	_	
160-5	28917-28928	copyediting	_	
160-6	28928-28929	,	_	
160-7	28930-28941	typesetting	_	
160-8	28941-28942	,	_	
160-9	28943-28946	and	_	
160-10	28947-28953	review	_	
160-11	28954-28956	of	_	
160-12	28957-28960	the	_	
160-13	28961-28970	resulting	_	
160-14	28971-28976	proof	_	
160-15	28977-28983	before	_	
160-16	28984-28986	it	_	
160-17	28987-28989	is	_	
160-18	28990-28999	published	_	
160-19	29000-29002	in	_	
160-20	29003-29006	its	_	
160-21	29007-29012	final	_	
160-22	29013-29020	citable	_	
160-23	29021-29025	form	_	
160-24	29025-29026	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
161-1	29027-29033	Please	_	
161-2	29034-29038	note	_	
161-3	29039-29043	that	_	
161-4	29044-29050	during	_	
161-5	29051-29054	the	_	
161-6	29055-29065	production	_	
161-7	29066-29073	process	_	
161-8	29074-29080	errors	_	
161-9	29081-29084	may	_	
161-10	29085-29087	be	_	
161-11	29088-29098	discovered	_	
161-12	29099-29104	which	_	
161-13	29105-29110	could	_	
161-14	29111-29117	affect	_	
161-15	29118-29121	the	_	
161-16	29122-29129	content	_	
161-17	29129-29130	,	_	
161-18	29131-29134	and	_	
161-19	29135-29138	all	_	
161-20	29139-29144	legal	_	
161-21	29145-29156	disclaimers	_	
161-22	29157-29161	that	_	
161-23	29162-29167	apply	_	
161-24	29168-29170	to	_	
161-25	29171-29174	the	_	
161-26	29175-29182	journal	_	
161-27	29183-29190	pertain	_	
161-28	29190-29191	.	_	

#Text=Disclosure
#Text=The authors report no biomedical financial interests or potential conflicts of interest.
162-1	29192-29202	Disclosure	_	
162-2	29203-29206	The	_	
162-3	29207-29214	authors	_	
162-4	29215-29221	report	_	
162-5	29222-29224	no	_	
162-6	29225-29235	biomedical	_	
162-7	29236-29245	financial	_	
162-8	29246-29255	interests	_	
162-9	29256-29258	or	_	
162-10	29259-29268	potential	_	
162-11	29269-29278	conflicts	_	
162-12	29279-29281	of	_	
162-13	29282-29290	interest	_	
162-14	29290-29291	.	_	

#Text=Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males
#Text=Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity
#Text=Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study
#Text=Cannabis and Schizophrenia: A Longitudinal Study of Swedish Conscripts
#Text=Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis
#Text=Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users
#Text=Cannabis use and psychosis: A longitudinal population-based study
#Text=Human laboratory studies on cannabinoids and psychosis
#Text=Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis
#Text=Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function
#Text=Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users
#Text=Effort-based reinforcement processing and functional connectivity underlying amotivation in medicated patients with depression and schizophrenia
#Text=Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia
#Text=Long-term effects of marijuana use on the brain
#Text=Functional connectivity density mapping
#Text=Energetic cost of brain functional connectivity
#Text=Alcohol affects brain functional connectivity and its coupling with behavior: greater effects in male heavy drinkers
#Text=Dimensions underlying psychotic and manic symptomatology: Extending normal-range personality traits to schizophrenia and bipolar spectra
#Text=Brain structural and functional dissociated patterns in schizophrenia
#Text=The Human Connectome Project: A data acquisition perspective
#Text=Schizophrenia and personality: exploring the boundaries and connections between vulnerability and outcome
#Text=Structures of personality and their relevance to psychopathology
#Text=Linking “big” personality traits to anxiety, depressive, and substance use disorders: a meta-analysis
#Text=Personality and psychopathology: working toward the bigger picture
#Text=Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders
#Text=Affective traits in schizophrenia and schizotypy
#Text=Daily Marijuana Use Is Not Associated with Brain Morphometric Measures in Adolescents or Adults
#Text=Recreational marijuana use impacts white matter integrity and subcortical (but not cortical) morphometry
#Text=Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
#Text=Signal fluctuation sensitivity: An improved metric for optimizing detection of resting-state fMRI networks
#Text=The effects of age on resting state functional connectivity of the basal ganglia from young to middle adulthood
#Text=Resting-state functional connectivity of the striatum in early-stage Parkinson’s disease: Cognitive decline and motor symptomatology
#Text=Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults
#Text=Persistent cannabis users show neuropsychological decline from childhood to midlife
#Text=Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia
#Text=Dopamine-dependent architecture of cortico-subcortical network connectivity
#Text=Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity
#Text=Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users
#Text=Attenuated frontal and sensory inputs to the basal ganglia in cannabis users
#Text=Functional connectivity hubs in the human brain
#Text=Mapping small-world properties through development in the human brain: Disruption in schizophrenia
#Text=Aging and Functional Brain Networks
#Text=Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder
#Text=Effects of chronic and acute stimulants on brain functional connectivity hubs
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Evaluating dopamine reward pathway in ADHD: clinical implications
#Text=Addiction: beyond dopamine reward circuitry
#Text=The hubs of the human connectome are generally implicated in the anatomy of brain disorders
#Text=Association of Marijuana Use With Blunted Nucleus Accumbens Response to Reward Anticipation
#Text=Chronic effects of cannabis use on the human reward system: An fMRI study
#Text=Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism
#Text=Cannabis, psychosis and the thalamus: A theoretical review
#Text=Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis
#Text=Marijuana craving in the brain
#Text=Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study
#Text=Cannabinoid receptor localization in brain
#Text=Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana
#Text=Marijuana Use Patterns and Sleep among Community-Based Young Adults
#Text=Relations between anxious, depressive and borderline symptomatology and frequency of cannabis use and dependence
#Text=Evening-type military veterans report worse lifetime posttraumatic stress symptoms and greater brainstem activity across wakefulness and REM sleep
#Text=Brain development during childhood and adolescence: a longitudinal MRI study
#Text=Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia
#Text=Shared Predisposition in the Association Between Cannabis Use and Subcortical Brain Structure
#Text=Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms
#Text=Striatal dopamine release in schizophrenia comorbid with substance dependence
#Text=Subcortical lFCD results across the larger population of 441 HCP participants.
163-1	29293-29301	Cannabis	_	
163-2	29302-29309	Abusers	_	
163-3	29310-29314	Show	_	
163-4	29315-29329	Hypofrontality	_	
163-5	29330-29333	and	_	
163-6	29334-29341	Blunted	_	
163-7	29342-29347	Brain	_	
163-8	29348-29357	Responses	_	
163-9	29358-29360	to	_	
163-10	29361-29362	a	_	
163-11	29363-29372	Stimulant	_	
163-12	29373-29382	Challenge	_	
163-13	29383-29385	in	_	
163-14	29386-29393	Females	_	
163-15	29394-29397	but	_	
163-16	29398-29401	not	_	
163-17	29402-29404	in	_	
163-18	29405-29410	Males	_	
163-19	29411-29420	Decreased	_	
163-20	29421-29429	dopamine	_	
163-21	29430-29435	brain	_	
163-22	29436-29446	reactivity	_	
163-23	29447-29449	in	_	
163-24	29450-29459	marijuana	_	
163-25	29460-29467	abusers	_	
163-26	29468-29470	is	_	
163-27	29471-29481	associated	_	
163-28	29482-29486	with	_	
163-29	29487-29495	negative	_	
163-30	29496-29508	emotionality	_	
163-31	29509-29512	and	_	
163-32	29513-29522	addiction	_	
163-33	29523-29531	severity	_	
163-34	29532-29540	Cannabis	_	
163-35	29541-29544	use	_	
163-36	29545-29547	in	_	
163-37	29548-29559	adolescence	_	
163-38	29560-29563	and	_	
163-39	29564-29568	risk	_	
163-40	29569-29572	for	_	
163-41	29573-29578	adult	_	
163-42	29579-29588	psychosis	_	
163-43	29588-29589	:	_	
163-44	29590-29602	longitudinal	_	
163-45	29603-29614	prospective	_	
163-46	29615-29620	study	_	
163-47	29621-29629	Cannabis	_	
163-48	29630-29633	and	_	
163-49	29634-29647	Schizophrenia	_	
163-50	29647-29648	:	_	
163-51	29649-29650	A	_	
163-52	29651-29663	Longitudinal	_	
163-53	29664-29669	Study	_	
163-54	29670-29672	of	_	
163-55	29673-29680	Swedish	_	
163-56	29681-29691	Conscripts	_	
163-57	29692-29703	Association	_	
163-58	29704-29711	between	_	
163-59	29712-29715	age	_	
163-60	29716-29718	at	_	
163-61	29719-29724	onset	_	
163-62	29725-29727	of	_	
163-63	29728-29737	psychosis	_	
163-64	29738-29741	and	_	
163-65	29742-29745	age	_	
163-66	29746-29748	at	_	
163-67	29749-29754	onset	_	
163-68	29755-29757	of	_	
163-69	29758-29766	cannabis	_	
163-70	29767-29770	use	_	
163-71	29771-29773	in	_	
163-72	29774-29787	non-affective	_	
163-73	29788-29797	psychosis	_	
163-74	29798-29803	Daily	_	
163-75	29804-29807	use	_	
163-76	29807-29808	,	_	
163-77	29809-29819	especially	_	
163-78	29820-29822	of	_	
163-79	29823-29835	high-potency	_	
163-80	29836-29844	cannabis	_	
163-81	29844-29845	,	_	
163-82	29846-29852	drives	_	
163-83	29853-29856	the	_	
163-84	29857-29864	earlier	_	
163-85	29865-29870	onset	_	
163-86	29871-29873	of	_	
163-87	29874-29883	psychosis	_	
163-88	29884-29886	in	_	
163-89	29887-29895	cannabis	_	
163-90	29896-29901	users	_	
163-91	29902-29910	Cannabis	_	
163-92	29911-29914	use	_	
163-93	29915-29918	and	_	
163-94	29919-29928	psychosis	_	
163-95	29928-29929	:	_	
163-96	29930-29931	A	_	
163-97	29932-29944	longitudinal	_	
163-98	29945-29961	population-based	_	
163-99	29962-29967	study	_	
163-100	29968-29973	Human	_	
163-101	29974-29984	laboratory	_	
163-102	29985-29992	studies	_	
163-103	29993-29995	on	_	
163-104	29996-30008	cannabinoids	_	
163-105	30009-30012	and	_	
163-106	30013-30022	psychosis	_	
163-107	30023-30034	Interaction	_	
163-108	30035-30042	between	_	
163-109	30043-30053	functional	_	
163-110	30054-30061	genetic	_	
163-111	30062-30071	variation	_	
163-112	30072-30074	of	_	
163-113	30075-30079	DRD2	_	
163-114	30080-30083	and	_	
163-115	30084-30092	cannabis	_	
163-116	30093-30096	use	_	
163-117	30097-30099	on	_	
163-118	30100-30104	risk	_	
163-119	30105-30107	of	_	
163-120	30108-30117	psychosis	_	
163-121	30118-30129	Preliminary	_	
163-122	30130-30136	report	_	
163-123	30137-30139	of	_	
163-124	30140-30150	biological	_	
163-125	30151-30156	basis	_	
163-126	30157-30159	of	_	
163-127	30160-30171	sensitivity	_	
163-128	30172-30174	to	_	
163-129	30175-30178	the	_	
163-130	30179-30186	effects	_	
163-131	30187-30189	of	_	
163-132	30190-30198	cannabis	_	
163-133	30199-30201	on	_	
163-134	30202-30211	psychosis	_	
163-135	30211-30212	:	_	
163-136	30213-30217	AKT1	_	
163-137	30218-30221	and	_	
163-138	30222-30226	DAT1	_	
163-139	30227-30235	genotype	_	
163-140	30236-30245	modulates	_	
163-141	30246-30249	the	_	
163-142	30250-30257	effects	_	
163-143	30258-30260	of	_	
163-144	30261-30262	δ	_	
163-145	30262-30263	-	_	
163-146	30263-30264	9	_	
163-147	30264-30265	-	_	
163-148	30265-30285	tetrahydrocannabinol	_	
163-149	30286-30288	on	_	
163-150	30289-30297	midbrain	_	
163-151	30298-30301	and	_	
163-152	30302-30310	striatal	_	
163-153	30311-30319	function	_	
163-154	30320-30332	Confirmation	_	
163-155	30333-30337	that	_	
163-156	30338-30341	the	_	
163-157	30342-30346	AKT1	_	
163-158	30347-30348	(	_	
163-159	30348-30357	rs2494732	_	
163-160	30357-30358	)	_	
163-161	30359-30367	genotype	_	
163-162	30368-30378	influences	_	
163-163	30379-30382	the	_	
163-164	30383-30387	risk	_	
163-165	30388-30390	of	_	
163-166	30391-30400	psychosis	_	
163-167	30401-30403	in	_	
163-168	30404-30412	cannabis	_	
163-169	30413-30418	users	_	
163-170	30419-30431	Effort-based	_	
163-171	30432-30445	reinforcement	_	
163-172	30446-30456	processing	_	
163-173	30457-30460	and	_	
163-174	30461-30471	functional	_	
163-175	30472-30484	connectivity	_	
163-176	30485-30495	underlying	_	
163-177	30496-30507	amotivation	_	
163-178	30508-30510	in	_	
163-179	30511-30520	medicated	_	
163-180	30521-30529	patients	_	
163-181	30530-30534	with	_	
163-182	30535-30545	depression	_	
163-183	30546-30549	and	_	
163-184	30550-30563	schizophrenia	_	
163-185	30564-30576	Relationship	_	
163-186	30577-30584	between	_	
163-187	30585-30593	Duration	_	
163-188	30594-30596	of	_	
163-189	30597-30606	Untreated	_	
163-190	30607-30616	Psychosis	_	
163-191	30617-30620	and	_	
163-192	30621-30630	Intrinsic	_	
163-193	30631-30646	Corticostriatal	_	
163-194	30647-30659	Connectivity	_	
163-195	30660-30662	in	_	
163-196	30663-30671	Patients	_	
163-197	30672-30676	with	_	
163-198	30677-30682	Early	_	
163-199	30683-30688	Phase	_	
163-200	30689-30702	Schizophrenia	_	
163-201	30703-30712	Long-term	_	
163-202	30713-30720	effects	_	
163-203	30721-30723	of	_	
163-204	30724-30733	marijuana	_	
163-205	30734-30737	use	_	
163-206	30738-30740	on	_	
163-207	30741-30744	the	_	
163-208	30745-30750	brain	_	
163-209	30751-30761	Functional	_	
163-210	30762-30774	connectivity	_	
163-211	30775-30782	density	_	
163-212	30783-30790	mapping	_	
163-213	30791-30800	Energetic	_	
163-214	30801-30805	cost	_	
163-215	30806-30808	of	_	
163-216	30809-30814	brain	_	
163-217	30815-30825	functional	_	
163-218	30826-30838	connectivity	_	
163-219	30839-30846	Alcohol	_	
163-220	30847-30854	affects	_	
163-221	30855-30860	brain	_	
163-222	30861-30871	functional	_	
163-223	30872-30884	connectivity	_	
163-224	30885-30888	and	_	
163-225	30889-30892	its	_	
163-226	30893-30901	coupling	_	
163-227	30902-30906	with	_	
163-228	30907-30915	behavior	_	
163-229	30915-30916	:	_	
163-230	30917-30924	greater	_	
163-231	30925-30932	effects	_	
163-232	30933-30935	in	_	
163-233	30936-30940	male	_	
163-234	30941-30946	heavy	_	
163-235	30947-30955	drinkers	_	
163-236	30956-30966	Dimensions	_	
163-237	30967-30977	underlying	_	
163-238	30978-30987	psychotic	_	
163-239	30988-30991	and	_	
163-240	30992-30997	manic	_	
163-241	30998-31012	symptomatology	_	
163-242	31012-31013	:	_	
163-243	31014-31023	Extending	_	
163-244	31024-31036	normal-range	_	
163-245	31037-31048	personality	_	
163-246	31049-31055	traits	_	
163-247	31056-31058	to	_	
163-248	31059-31072	schizophrenia	_	
163-249	31073-31076	and	_	
163-250	31077-31084	bipolar	_	
163-251	31085-31092	spectra	_	
163-252	31093-31098	Brain	_	
163-253	31099-31109	structural	_	
163-254	31110-31113	and	_	
163-255	31114-31124	functional	_	
163-256	31125-31136	dissociated	_	
163-257	31137-31145	patterns	_	
163-258	31146-31148	in	_	
163-259	31149-31162	schizophrenia	_	
163-260	31163-31166	The	_	
163-261	31167-31172	Human	_	
163-262	31173-31183	Connectome	_	
163-263	31184-31191	Project	_	
163-264	31191-31192	:	_	
163-265	31193-31194	A	_	
163-266	31195-31199	data	_	
163-267	31200-31211	acquisition	_	
163-268	31212-31223	perspective	_	
163-269	31224-31237	Schizophrenia	_	
163-270	31238-31241	and	_	
163-271	31242-31253	personality	_	
163-272	31253-31254	:	_	
163-273	31255-31264	exploring	_	
163-274	31265-31268	the	_	
163-275	31269-31279	boundaries	_	
163-276	31280-31283	and	_	
163-277	31284-31295	connections	_	
163-278	31296-31303	between	_	
163-279	31304-31317	vulnerability	_	
163-280	31318-31321	and	_	
163-281	31322-31329	outcome	_	
163-282	31330-31340	Structures	_	
163-283	31341-31343	of	_	
163-284	31344-31355	personality	_	
163-285	31356-31359	and	_	
163-286	31360-31365	their	_	
163-287	31366-31375	relevance	_	
163-288	31376-31378	to	_	
163-289	31379-31394	psychopathology	_	
163-290	31395-31402	Linking	_	
163-291	31403-31404	“	_	
163-292	31404-31407	big	_	
163-293	31407-31408	”	_	
163-294	31409-31420	personality	_	
163-295	31421-31427	traits	_	
163-296	31428-31430	to	_	
163-297	31431-31438	anxiety	_	
163-298	31438-31439	,	_	
163-299	31440-31450	depressive	_	
163-300	31450-31451	,	_	
163-301	31452-31455	and	_	
163-302	31456-31465	substance	_	
163-303	31466-31469	use	_	
163-304	31470-31479	disorders	_	
163-305	31479-31480	:	_	
163-306	31481-31482	a	_	
163-307	31483-31496	meta-analysis	_	
163-308	31497-31508	Personality	_	
163-309	31509-31512	and	_	
163-310	31513-31528	psychopathology	_	
163-311	31528-31529	:	_	
163-312	31530-31537	working	_	
163-313	31538-31544	toward	_	
163-314	31545-31548	the	_	
163-315	31549-31555	bigger	_	
163-316	31556-31563	picture	_	
163-317	31564-31572	Research	_	
163-318	31573-31579	Domain	_	
163-319	31580-31588	Criteria	_	
163-320	31589-31590	(	_	
163-321	31590-31594	RDoC	_	
163-322	31594-31595	)	_	
163-323	31595-31596	:	_	
163-324	31597-31603	Toward	_	
163-325	31604-31605	a	_	
163-326	31606-31609	New	_	
163-327	31610-31624	Classification	_	
163-328	31625-31634	Framework	_	
163-329	31635-31638	for	_	
163-330	31639-31647	Research	_	
163-331	31648-31650	on	_	
163-332	31651-31657	Mental	_	
163-333	31658-31667	Disorders	_	
163-334	31668-31677	Affective	_	
163-335	31678-31684	traits	_	
163-336	31685-31687	in	_	
163-337	31688-31701	schizophrenia	_	
163-338	31702-31705	and	_	
163-339	31706-31716	schizotypy	_	
163-340	31717-31722	Daily	_	
163-341	31723-31732	Marijuana	_	
163-342	31733-31736	Use	_	
163-343	31737-31739	Is	_	
163-344	31740-31743	Not	_	
163-345	31744-31754	Associated	_	
163-346	31755-31759	with	_	
163-347	31760-31765	Brain	_	
163-348	31766-31778	Morphometric	_	
163-349	31779-31787	Measures	_	
163-350	31788-31790	in	_	
163-351	31791-31802	Adolescents	_	
163-352	31803-31805	or	_	
163-353	31806-31812	Adults	_	
163-354	31813-31825	Recreational	_	
163-355	31826-31835	marijuana	_	
163-356	31836-31839	use	_	
163-357	31840-31847	impacts	_	
163-358	31848-31853	white	_	
163-359	31854-31860	matter	_	
163-360	31861-31870	integrity	_	
163-361	31871-31874	and	_	
163-362	31875-31886	subcortical	_	
163-363	31887-31888	(	_	
163-364	31888-31891	but	_	
163-365	31892-31895	not	_	
163-366	31896-31904	cortical	_	
163-367	31904-31905	)	_	
163-368	31906-31917	morphometry	_	
163-369	31918-31925	Effects	_	
163-370	31926-31928	of	_	
163-371	31929-31937	Cannabis	_	
163-372	31938-31941	Use	_	
163-373	31942-31944	on	_	
163-374	31945-31950	Human	_	
163-375	31951-31959	Behavior	_	
163-376	31959-31960	,	_	
163-377	31961-31970	Including	_	
163-378	31971-31980	Cognition	_	
163-379	31980-31981	,	_	
163-380	31982-31992	Motivation	_	
163-381	31992-31993	,	_	
163-382	31994-31997	and	_	
163-383	31998-32007	Psychosis	_	
163-384	32007-32008	:	_	
163-385	32009-32010	A	_	
163-386	32011-32017	Review	_	
163-387	32018-32024	Signal	_	
163-388	32025-32036	fluctuation	_	
163-389	32037-32048	sensitivity	_	
163-390	32048-32049	:	_	
163-391	32050-32052	An	_	
163-392	32053-32061	improved	_	
163-393	32062-32068	metric	_	
163-394	32069-32072	for	_	
163-395	32073-32083	optimizing	_	
163-396	32084-32093	detection	_	
163-397	32094-32096	of	_	
163-398	32097-32110	resting-state	_	
163-399	32111-32115	fMRI	_	
163-400	32116-32124	networks	_	
163-401	32125-32128	The	_	
163-402	32129-32136	effects	_	
163-403	32137-32139	of	_	
163-404	32140-32143	age	_	
163-405	32144-32146	on	_	
163-406	32147-32154	resting	_	
163-407	32155-32160	state	_	
163-408	32161-32171	functional	_	
163-409	32172-32184	connectivity	_	
163-410	32185-32187	of	_	
163-411	32188-32191	the	_	
163-412	32192-32197	basal	_	
163-413	32198-32205	ganglia	_	
163-414	32206-32210	from	_	
163-415	32211-32216	young	_	
163-416	32217-32219	to	_	
163-417	32220-32226	middle	_	
163-418	32227-32236	adulthood	_	
163-419	32237-32250	Resting-state	_	
163-420	32251-32261	functional	_	
163-421	32262-32274	connectivity	_	
163-422	32275-32277	of	_	
163-423	32278-32281	the	_	
163-424	32282-32290	striatum	_	
163-425	32291-32293	in	_	
163-426	32294-32305	early-stage	_	
163-427	32306-32315	Parkinson	_	
163-428	32315-32316	’	_	
163-429	32316-32317	s	_	
163-430	32318-32325	disease	_	
163-431	32325-32326	:	_	
163-432	32327-32336	Cognitive	_	
163-433	32337-32344	decline	_	
163-434	32345-32348	and	_	
163-435	32349-32354	motor	_	
163-436	32355-32369	symptomatology	_	
163-437	32370-32377	Cluster	_	
163-438	32378-32385	failure	_	
163-439	32385-32386	:	_	
163-440	32387-32390	Why	_	
163-441	32391-32395	fMRI	_	
163-442	32396-32406	inferences	_	
163-443	32407-32410	for	_	
163-444	32411-32418	spatial	_	
163-445	32419-32425	extent	_	
163-446	32426-32430	have	_	
163-447	32431-32439	inflated	_	
163-448	32440-32454	false-positive	_	
163-449	32455-32460	rates	_	
163-450	32461-32468	Effects	_	
163-451	32469-32471	of	_	
163-452	32472-32479	regular	_	
163-453	32480-32488	cannabis	_	
163-454	32489-32492	use	_	
163-455	32493-32495	on	_	
163-456	32496-32510	neurocognition	_	
163-457	32510-32511	,	_	
163-458	32512-32517	brain	_	
163-459	32518-32527	structure	_	
163-460	32527-32528	,	_	
163-461	32529-32532	and	_	
163-462	32533-32541	function	_	
163-463	32541-32542	:	_	
163-464	32543-32544	a	_	
163-465	32545-32555	systematic	_	
163-466	32556-32562	review	_	
163-467	32563-32565	of	_	
163-468	32566-32574	findings	_	
163-469	32575-32577	in	_	
163-470	32578-32584	adults	_	
163-471	32585-32595	Persistent	_	
163-472	32596-32604	cannabis	_	
163-473	32605-32610	users	_	
163-474	32611-32615	show	_	
163-475	32616-32634	neuropsychological	_	
163-476	32635-32642	decline	_	
163-477	32643-32647	from	_	
163-478	32648-32657	childhood	_	
163-479	32658-32660	to	_	
163-480	32661-32668	midlife	_	
163-481	32669-32682	Resting-state	_	
163-482	32683-32693	functional	_	
163-483	32694-32706	connectivity	_	
163-484	32707-32709	of	_	
163-485	32710-32713	the	_	
163-486	32714-32721	nucleus	_	
163-487	32722-32731	accumbens	_	
163-488	32732-32734	in	_	
163-489	32735-32743	auditory	_	
163-490	32744-32747	and	_	
163-491	32748-32754	visual	_	
163-492	32755-32769	hallucinations	_	
163-493	32770-32772	in	_	
163-494	32773-32786	schizophrenia	_	
163-495	32787-32805	Dopamine-dependent	_	
163-496	32806-32818	architecture	_	
163-497	32819-32821	of	_	
163-498	32822-32841	cortico-subcortical	_	
163-499	32842-32849	network	_	
163-500	32850-32862	connectivity	_	
163-501	32863-32875	Differential	_	
163-502	32876-32879	and	_	
163-503	32880-32891	distributed	_	
163-504	32892-32899	effects	_	
163-505	32900-32902	of	_	
163-506	32903-32911	dopamine	_	
163-507	32912-32928	neuromodulations	_	
163-508	32929-32931	on	_	
163-509	32932-32945	resting-state	_	
163-510	32946-32953	network	_	
163-511	32954-32966	connectivity	_	
163-512	32967-32977	Functional	_	
163-513	32978-32990	connectivity	_	
163-514	32991-33002	alterations	_	
163-515	33003-33005	in	_	
163-516	33006-33011	brain	_	
163-517	33012-33020	networks	_	
163-518	33021-33029	relevant	_	
163-519	33030-33032	to	_	
163-520	33033-33047	self-awareness	_	
163-521	33048-33050	in	_	
163-522	33051-33058	chronic	_	
163-523	33059-33067	cannabis	_	
163-524	33068-33073	users	_	
163-525	33074-33084	Attenuated	_	
163-526	33085-33092	frontal	_	
163-527	33093-33096	and	_	
163-528	33097-33104	sensory	_	
163-529	33105-33111	inputs	_	
163-530	33112-33114	to	_	
163-531	33115-33118	the	_	
163-532	33119-33124	basal	_	
163-533	33125-33132	ganglia	_	
163-534	33133-33135	in	_	
163-535	33136-33144	cannabis	_	
163-536	33145-33150	users	_	
163-537	33151-33161	Functional	_	
163-538	33162-33174	connectivity	_	
163-539	33175-33179	hubs	_	
163-540	33180-33182	in	_	
163-541	33183-33186	the	_	
163-542	33187-33192	human	_	
163-543	33193-33198	brain	_	
163-544	33199-33206	Mapping	_	
163-545	33207-33218	small-world	_	
163-546	33219-33229	properties	_	
163-547	33230-33237	through	_	
163-548	33238-33249	development	_	
163-549	33250-33252	in	_	
163-550	33253-33256	the	_	
163-551	33257-33262	human	_	
163-552	33263-33268	brain	_	
163-553	33268-33269	:	_	
163-554	33270-33280	Disruption	_	
163-555	33281-33283	in	_	
163-556	33284-33297	schizophrenia	_	
163-557	33298-33303	Aging	_	
163-558	33304-33307	and	_	
163-559	33308-33318	Functional	_	
163-560	33319-33324	Brain	_	
163-561	33325-33333	Networks	_	
163-562	33334-33342	Abnormal	_	
163-563	33343-33353	functional	_	
163-564	33354-33366	connectivity	_	
163-565	33367-33369	in	_	
163-566	33370-33378	children	_	
163-567	33379-33383	with	_	
163-568	33384-33401	attention-deficit	_	
163-569	33401-33402	/	_	
163-570	33402-33415	hyperactivity	_	
163-571	33416-33424	disorder	_	
163-572	33425-33432	Effects	_	
163-573	33433-33435	of	_	
163-574	33436-33443	chronic	_	
163-575	33444-33447	and	_	
163-576	33448-33453	acute	_	
163-577	33454-33464	stimulants	_	
163-578	33465-33467	on	_	
163-579	33468-33473	brain	_	
163-580	33474-33484	functional	_	
163-581	33485-33497	connectivity	_	
163-582	33498-33502	hubs	_	
163-583	33503-33514	Dysfunction	_	
163-584	33515-33517	of	_	
163-585	33518-33521	the	_	
163-586	33522-33532	prefrontal	_	
163-587	33533-33539	cortex	_	
163-588	33540-33542	in	_	
163-589	33543-33552	addiction	_	
163-590	33552-33553	:	_	
163-591	33554-33566	neuroimaging	_	
163-592	33567-33575	findings	_	
163-593	33576-33579	and	_	
163-594	33580-33588	clinical	_	
163-595	33589-33601	implications	_	
163-596	33602-33612	Evaluating	_	
163-597	33613-33621	dopamine	_	
163-598	33622-33628	reward	_	
163-599	33629-33636	pathway	_	
163-600	33637-33639	in	_	
163-601	33640-33644	ADHD	_	
163-602	33644-33645	:	_	
163-603	33646-33654	clinical	_	
163-604	33655-33667	implications	_	
163-605	33668-33677	Addiction	_	
163-606	33677-33678	:	_	
163-607	33679-33685	beyond	_	
163-608	33686-33694	dopamine	_	
163-609	33695-33701	reward	_	
163-610	33702-33711	circuitry	_	
163-611	33712-33715	The	_	
163-612	33716-33720	hubs	_	
163-613	33721-33723	of	_	
163-614	33724-33727	the	_	
163-615	33728-33733	human	_	
163-616	33734-33744	connectome	_	
163-617	33745-33748	are	_	
163-618	33749-33758	generally	_	
163-619	33759-33769	implicated	_	
163-620	33770-33772	in	_	
163-621	33773-33776	the	_	
163-622	33777-33784	anatomy	_	
163-623	33785-33787	of	_	
163-624	33788-33793	brain	_	
163-625	33794-33803	disorders	_	
163-626	33804-33815	Association	_	
163-627	33816-33818	of	_	
163-628	33819-33828	Marijuana	_	
163-629	33829-33832	Use	_	
163-630	33833-33837	With	_	
163-631	33838-33845	Blunted	_	
163-632	33846-33853	Nucleus	_	
163-633	33854-33863	Accumbens	_	
163-634	33864-33872	Response	_	
163-635	33873-33875	to	_	
163-636	33876-33882	Reward	_	
163-637	33883-33895	Anticipation	_	
163-638	33896-33903	Chronic	_	
163-639	33904-33911	effects	_	
163-640	33912-33914	of	_	
163-641	33915-33923	cannabis	_	
163-642	33924-33927	use	_	
163-643	33928-33930	on	_	
163-644	33931-33934	the	_	
163-645	33935-33940	human	_	
163-646	33941-33947	reward	_	
163-647	33948-33954	system	_	
163-648	33954-33955	:	_	
163-649	33956-33958	An	_	
163-650	33959-33963	fMRI	_	
163-651	33964-33969	study	_	
163-652	33970-33977	Dynamic	_	
163-653	33978-33986	dopamine	_	
163-654	33987-33997	modulation	_	
163-655	33998-34000	in	_	
163-656	34001-34004	the	_	
163-657	34005-34010	basal	_	
163-658	34011-34018	ganglia	_	
163-659	34018-34019	:	_	
163-660	34020-34021	a	_	
163-661	34022-34040	neurocomputational	_	
163-662	34041-34048	account	_	
163-663	34049-34051	of	_	
163-664	34052-34061	cognitive	_	
163-665	34062-34070	deficits	_	
163-666	34071-34073	in	_	
163-667	34074-34083	medicated	_	
163-668	34084-34087	and	_	
163-669	34088-34100	nonmedicated	_	
163-670	34101-34113	Parkinsonism	_	
163-671	34114-34122	Cannabis	_	
163-672	34122-34123	,	_	
163-673	34124-34133	psychosis	_	
163-674	34134-34137	and	_	
163-675	34138-34141	the	_	
163-676	34142-34150	thalamus	_	
163-677	34150-34151	:	_	
163-678	34152-34153	A	_	
163-679	34154-34165	theoretical	_	
163-680	34166-34172	review	_	
163-681	34173-34183	Evaluating	_	
163-682	34184-34187	the	_	
163-683	34188-34194	impact	_	
163-684	34195-34197	of	_	
163-685	34198-34206	cannabis	_	
163-686	34207-34210	use	_	
163-687	34211-34213	on	_	
163-688	34214-34222	thalamic	_	
163-689	34223-34235	connectivity	_	
163-690	34236-34238	in	_	
163-691	34239-34244	youth	_	
163-692	34245-34247	at	_	
163-693	34248-34256	clinical	_	
163-694	34257-34261	high	_	
163-695	34262-34266	risk	_	
163-696	34267-34269	of	_	
163-697	34270-34279	psychosis	_	
163-698	34280-34289	Marijuana	_	
163-699	34290-34297	craving	_	
163-700	34298-34300	in	_	
163-701	34301-34304	the	_	
163-702	34305-34310	brain	_	
163-703	34311-34320	Comparing	_	
163-704	34321-34324	the	_	
163-705	34325-34331	effect	_	
163-706	34332-34334	of	_	
163-707	34335-34344	clozapine	_	
163-708	34345-34348	and	_	
163-709	34349-34360	risperidone	_	
163-710	34361-34363	on	_	
163-711	34364-34367	cue	_	
163-712	34368-34378	reactivity	_	
163-713	34379-34381	in	_	
163-714	34382-34386	male	_	
163-715	34387-34395	patients	_	
163-716	34396-34400	with	_	
163-717	34401-34414	schizophrenia	_	
163-718	34415-34418	and	_	
163-719	34419-34420	a	_	
163-720	34421-34429	cannabis	_	
163-721	34430-34433	use	_	
163-722	34434-34442	disorder	_	
163-723	34442-34443	:	_	
163-724	34444-34445	A	_	
163-725	34446-34456	randomized	_	
163-726	34457-34461	fMRI	_	
163-727	34462-34467	study	_	
163-728	34468-34479	Cannabinoid	_	
163-729	34480-34488	receptor	_	
163-730	34489-34501	localization	_	
163-731	34502-34504	in	_	
163-732	34505-34510	brain	_	
163-733	34511-34517	Effect	_	
163-734	34518-34520	of	_	
163-735	34521-34528	illicit	_	
163-736	34529-34541	recreational	_	
163-737	34542-34547	drugs	_	
163-738	34548-34552	upon	_	
163-739	34553-34558	sleep	_	
163-740	34558-34559	:	_	
163-741	34560-34567	Cocaine	_	
163-742	34567-34568	,	_	
163-743	34569-34576	ecstasy	_	
163-744	34577-34580	and	_	
163-745	34581-34590	marijuana	_	
163-746	34591-34600	Marijuana	_	
163-747	34601-34604	Use	_	
163-748	34605-34613	Patterns	_	
163-749	34614-34617	and	_	
163-750	34618-34623	Sleep	_	
163-751	34624-34629	among	_	
163-752	34630-34645	Community-Based	_	
163-753	34646-34651	Young	_	
163-754	34652-34658	Adults	_	
163-755	34659-34668	Relations	_	
163-756	34669-34676	between	_	
163-757	34677-34684	anxious	_	
163-758	34684-34685	,	_	
163-759	34686-34696	depressive	_	
163-760	34697-34700	and	_	
163-761	34701-34711	borderline	_	
163-762	34712-34726	symptomatology	_	
163-763	34727-34730	and	_	
163-764	34731-34740	frequency	_	
163-765	34741-34743	of	_	
163-766	34744-34752	cannabis	_	
163-767	34753-34756	use	_	
163-768	34757-34760	and	_	
163-769	34761-34771	dependence	_	
163-770	34772-34784	Evening-type	_	
163-771	34785-34793	military	_	
163-772	34794-34802	veterans	_	
163-773	34803-34809	report	_	
163-774	34810-34815	worse	_	
163-775	34816-34824	lifetime	_	
163-776	34825-34838	posttraumatic	_	
163-777	34839-34845	stress	_	
163-778	34846-34854	symptoms	_	
163-779	34855-34858	and	_	
163-780	34859-34866	greater	_	
163-781	34867-34876	brainstem	_	
163-782	34877-34885	activity	_	
163-783	34886-34892	across	_	
163-784	34893-34904	wakefulness	_	
163-785	34905-34908	and	_	
163-786	34909-34912	REM	_	
163-787	34913-34918	sleep	_	
163-788	34919-34924	Brain	_	
163-789	34925-34936	development	_	
163-790	34937-34943	during	_	
163-791	34944-34953	childhood	_	
163-792	34954-34957	and	_	
163-793	34958-34969	adolescence	_	
163-794	34969-34970	:	_	
163-795	34971-34972	a	_	
163-796	34973-34985	longitudinal	_	
163-797	34986-34989	MRI	_	
163-798	34990-34995	study	_	
163-799	34996-35006	Adolescent	_	
163-800	35007-35012	brain	_	
163-801	35013-35023	maturation	_	
163-802	35023-35024	,	_	
163-803	35025-35028	the	_	
163-804	35029-35039	endogenous	_	
163-805	35040-35051	cannabinoid	_	
163-806	35052-35058	system	_	
163-807	35059-35062	and	_	
163-808	35063-35066	the	_	
163-809	35067-35079	neurobiology	_	
163-810	35080-35082	of	_	
163-811	35083-35099	cannabis-induced	_	
163-812	35100-35113	schizophrenia	_	
163-813	35114-35120	Shared	_	
163-814	35121-35135	Predisposition	_	
163-815	35136-35138	in	_	
163-816	35139-35142	the	_	
163-817	35143-35154	Association	_	
163-818	35155-35162	Between	_	
163-819	35163-35171	Cannabis	_	
163-820	35172-35175	Use	_	
163-821	35176-35179	and	_	
163-822	35180-35191	Subcortical	_	
163-823	35192-35197	Brain	_	
163-824	35198-35207	Structure	_	
163-825	35208-35220	Dopaminergic	_	
163-826	35221-35229	function	_	
163-827	35230-35232	in	_	
163-828	35233-35241	cannabis	_	
163-829	35242-35247	users	_	
163-830	35248-35251	and	_	
163-831	35252-35255	its	_	
163-832	35256-35268	relationship	_	
163-833	35269-35271	to	_	
163-834	35272-35288	cannabis-induced	_	
163-835	35289-35298	psychotic	_	
163-836	35299-35307	symptoms	_	
163-837	35308-35316	Striatal	_	
163-838	35317-35325	dopamine	_	
163-839	35326-35333	release	_	
163-840	35334-35336	in	_	
163-841	35337-35350	schizophrenia	_	
163-842	35351-35359	comorbid	_	
163-843	35360-35364	with	_	
163-844	35365-35374	substance	_	
163-845	35375-35385	dependence	_	
163-846	35386-35397	Subcortical	_	
163-847	35398-35402	lFCD	_	
163-848	35403-35410	results	_	
163-849	35411-35417	across	_	
163-850	35418-35421	the	_	
163-851	35422-35428	larger	_	
163-852	35429-35439	population	_	
163-853	35440-35442	of	_	
163-854	35443-35446	441	_	
163-855	35447-35450	HCP	_	
163-856	35451-35463	participants	_	
163-857	35463-35464	.	_	

#Text=Maps are thresholded at T > 10, for visualization.
164-1	35465-35469	Maps	_	
164-2	35470-35473	are	_	
164-3	35474-35485	thresholded	_	
164-4	35486-35488	at	_	
164-5	35489-35490	T	_	
164-6	35491-35492	>	_	
164-7	35493-35495	10	_	
164-8	35495-35496	,	_	
164-9	35497-35500	for	_	
164-10	35501-35514	visualization	_	
164-11	35514-35515	.	_	

#Text=Hot colors indicate regions with high local connectivity density.
165-1	35516-35519	Hot	_	
165-2	35520-35526	colors	_	
165-3	35527-35535	indicate	_	
165-4	35536-35543	regions	_	
165-5	35544-35548	with	_	
165-6	35549-35553	high	_	
165-7	35554-35559	local	_	
165-8	35560-35572	connectivity	_	
165-9	35573-35580	density	_	
165-10	35580-35581	.	_	

#Text=Subcortical regions where lFCD was significantly higher in CA than controls (two-sample t-test, CA > CTRL).
166-1	35582-35593	Subcortical	_	
166-2	35594-35601	regions	_	
166-3	35602-35607	where	_	
166-4	35608-35612	lFCD	_	
166-5	35613-35616	was	_	
166-6	35617-35630	significantly	_	
166-7	35631-35637	higher	_	
166-8	35638-35640	in	_	
166-9	35641-35643	CA	_	
166-10	35644-35648	than	_	
166-11	35649-35657	controls	_	
166-12	35658-35659	(	_	
166-13	35659-35669	two-sample	_	
166-14	35670-35676	t-test	_	
166-15	35676-35677	,	_	
166-16	35678-35680	CA	_	
166-17	35681-35682	>	_	
166-18	35683-35687	CTRL	_	
166-19	35687-35688	)	_	
166-20	35688-35689	.	_	

#Text=Results are thresholded voxelwise at p < .001, with a nonparametric cluster-level threshold of p < .05 family-wise error (FWE) corrected, using SnPM13.
167-1	35690-35697	Results	_	
167-2	35698-35701	are	_	
167-3	35702-35713	thresholded	_	
167-4	35714-35723	voxelwise	_	
167-5	35724-35726	at	_	
167-6	35727-35728	p	_	
167-7	35729-35730	<	_	
167-8	35731-35735	.001	_	
167-9	35735-35736	,	_	
167-10	35737-35741	with	_	
167-11	35742-35743	a	_	
167-12	35744-35757	nonparametric	_	
167-13	35758-35771	cluster-level	_	
167-14	35772-35781	threshold	_	
167-15	35782-35784	of	_	
167-16	35785-35786	p	_	
167-17	35787-35788	<	_	
167-18	35789-35792	.05	_	
167-19	35793-35804	family-wise	_	
167-20	35805-35810	error	_	
167-21	35811-35812	(	_	
167-22	35812-35815	FWE	_	
167-23	35815-35816	)	_	
167-24	35817-35826	corrected	_	
167-25	35826-35827	,	_	
167-26	35828-35833	using	_	
167-27	35834-35840	SnPM13	_	
167-28	35840-35841	.	_	

#Text=See Table 3 for coordinates of each cluster in MNI space.
168-1	35842-35845	See	_	
168-2	35846-35851	Table	_	
168-3	35852-35853	3	_	
168-4	35854-35857	for	_	
168-5	35858-35869	coordinates	_	
168-6	35870-35872	of	_	
168-7	35873-35877	each	_	
168-8	35878-35885	cluster	_	
168-9	35886-35888	in	_	
168-10	35889-35892	MNI	_	
168-11	35893-35898	space	_	
168-12	35898-35899	.	_	

#Text=Error bars represent standard error of the mean (SEM).
169-1	35900-35905	Error	_	
169-2	35906-35910	bars	_	
169-3	35911-35920	represent	_	
169-4	35921-35929	standard	_	
169-5	35930-35935	error	_	
169-6	35936-35938	of	_	
169-7	35939-35942	the	_	
169-8	35943-35947	mean	_	
169-9	35948-35949	(	_	
169-10	35949-35952	SEM	_	
169-11	35952-35953	)	_	
169-12	35953-35954	.	_	

#Text=NOTE: SN/VTA = Substantia Nigra/Ventral Tegmental Area; VS = Ventral Striatum
#Text=Associations between subcortical lFCD and A) age at first use of cannabis and B) self-reported feelings of alienation.
170-1	35955-35959	NOTE	_	
170-2	35959-35960	:	_	
170-3	35961-35963	SN	_	
170-4	35963-35964	/	_	
170-5	35964-35967	VTA	_	
170-6	35968-35969	=	_	
170-7	35970-35980	Substantia	_	
170-8	35981-35986	Nigra	_	
170-9	35986-35987	/	_	
170-10	35987-35994	Ventral	_	
170-11	35995-36004	Tegmental	_	
170-12	36005-36009	Area	_	
170-13	36009-36010	;	_	
170-14	36011-36013	VS	_	
170-15	36014-36015	=	_	
170-16	36016-36023	Ventral	_	
170-17	36024-36032	Striatum	_	
170-18	36033-36045	Associations	_	
170-19	36046-36053	between	_	
170-20	36054-36065	subcortical	_	
170-21	36066-36070	lFCD	_	
170-22	36071-36074	and	_	
170-23	36075-36076	A	_	
170-24	36076-36077	)	_	
170-25	36078-36081	age	_	
170-26	36082-36084	at	_	
170-27	36085-36090	first	_	
170-28	36091-36094	use	_	
170-29	36095-36097	of	_	
170-30	36098-36106	cannabis	_	
170-31	36107-36110	and	_	
170-32	36111-36112	B	_	
170-33	36112-36113	)	_	
170-34	36114-36127	self-reported	_	
170-35	36128-36136	feelings	_	
170-36	36137-36139	of	_	
170-37	36140-36150	alienation	_	
170-38	36150-36151	.	_	

#Text=The difference in slopes between CA and CTRL groups was significant, p = .018.
171-1	36152-36155	The	_	
171-2	36156-36166	difference	_	
171-3	36167-36169	in	_	
171-4	36170-36176	slopes	_	
171-5	36177-36184	between	_	
171-6	36185-36187	CA	_	
171-7	36188-36191	and	_	
171-8	36192-36196	CTRL	_	
171-9	36197-36203	groups	_	
171-10	36204-36207	was	_	
171-11	36208-36219	significant	_	
171-12	36219-36220	,	_	
171-13	36221-36222	p	_	
171-14	36223-36224	=	_	
171-15	36225-36229	.018	_	
171-16	36229-36230	.	_	

#Text=Demographics of the CA and control samples.
172-1	36231-36243	Demographics	_	
172-2	36244-36246	of	_	
172-3	36247-36250	the	_	
172-4	36251-36253	CA	_	
172-5	36254-36257	and	_	
172-6	36258-36265	control	_	
172-7	36266-36273	samples	_	
172-8	36273-36274	.	_	

#Text=Values are reported as mean ± standard deviation.
173-1	36275-36281	Values	_	
173-2	36282-36285	are	_	
173-3	36286-36294	reported	_	
173-4	36295-36297	as	_	
173-5	36298-36302	mean	_	
173-6	36303-36304	±	_	
173-7	36305-36313	standard	_	
173-8	36314-36323	deviation	_	
173-9	36323-36324	.	_	

#Text=Depression, anxiety, tobacco, and alcohol use values were converted to Z-scores based on the larger population of 441 participants.
174-1	36325-36335	Depression	_	
174-2	36335-36336	,	_	
174-3	36337-36344	anxiety	_	
174-4	36344-36345	,	_	
174-5	36346-36353	tobacco	_	
174-6	36353-36354	,	_	
174-7	36355-36358	and	_	
174-8	36359-36366	alcohol	_	
174-9	36367-36370	use	_	
174-10	36371-36377	values	_	
174-11	36378-36382	were	_	
174-12	36383-36392	converted	_	
174-13	36393-36395	to	_	
174-14	36396-36404	Z-scores	_	
174-15	36405-36410	based	_	
174-16	36411-36413	on	_	
174-17	36414-36417	the	_	
174-18	36418-36424	larger	_	
174-19	36425-36435	population	_	
174-20	36436-36438	of	_	
174-21	36439-36442	441	_	
174-22	36443-36455	participants	_	
174-23	36455-36456	.	_	

#Text=See Tobacco and Alcohol Use section in Supplementary Material for a description of how the combined past- and present use measures were derived.
175-1	36457-36460	See	_	
175-2	36461-36468	Tobacco	_	
175-3	36469-36472	and	_	
175-4	36473-36480	Alcohol	_	
175-5	36481-36484	Use	_	
175-6	36485-36492	section	_	
175-7	36493-36495	in	_	
175-8	36496-36509	Supplementary	_	
175-9	36510-36518	Material	_	
175-10	36519-36522	for	_	
175-11	36523-36524	a	_	
175-12	36525-36536	description	_	
175-13	36537-36539	of	_	
175-14	36540-36543	how	_	
175-15	36544-36547	the	_	
175-16	36548-36556	combined	_	
175-17	36557-36561	past	_	
175-18	36561-36562	-	_	
175-19	36563-36566	and	_	
175-20	36567-36574	present	_	
175-21	36575-36578	use	_	
175-22	36579-36587	measures	_	
175-23	36588-36592	were	_	
175-24	36593-36600	derived	_	
175-25	36600-36601	.	_	

#Text=CA\tCTRL\tt-test p-value\t \tAge\t29.17 ± 3.07\t30.23 ± 2.74\t0.161\t \tSex\t22 Male\t20 Male\tχ2 = 0.573\t \tEdu\t14.6 ± 1.89\t14.6 ± 1.92\t1.000\t \tBMI\t27.17 ± 3.6\t26.83 ± 4.89\t0.757\t \tDSM Depression\t0.03 ± 0.86\t−0.13 ± 0.83\t0.452\t \tDSM Anxiety\t0.07 ± 1.04\t−0.16 ± 0.95\t0.383\t \tAlcohol Use (Composite Z)\t0.27 ± 0.4\t0.15 ± 0.38\t0.250\t \tTobacco Use (Composite Z)\t0.57 ± 0.83\t0.32 ± 0.85\t0.260\t \t
#Text=Scores on measures of cognition and negative emotionality in CA and controls.
176-1	36603-36605	CA	_	
176-2	36606-36610	CTRL	_	
176-3	36611-36617	t-test	_	
176-4	36618-36625	p-value	_	
176-5	36628-36631	Age	_	
176-6	36632-36637	29.17	_	
176-7	36638-36639	±	_	
176-8	36640-36644	3.07	_	
176-9	36645-36650	30.23	_	
176-10	36651-36652	±	_	
176-11	36653-36657	2.74	_	
176-12	36658-36663	0.161	_	
176-13	36666-36669	Sex	_	
176-14	36670-36672	22	_	
176-15	36673-36677	Male	_	
176-16	36678-36680	20	_	
176-17	36681-36685	Male	_	
176-18	36686-36688	χ2	_	
176-19	36689-36690	=	_	
176-20	36691-36696	0.573	_	
176-21	36699-36702	Edu	_	
176-22	36703-36707	14.6	_	
176-23	36708-36709	±	_	
176-24	36710-36714	1.89	_	
176-25	36715-36719	14.6	_	
176-26	36720-36721	±	_	
176-27	36722-36726	1.92	_	
176-28	36727-36732	1.000	_	
176-29	36735-36738	BMI	_	
176-30	36739-36744	27.17	_	
176-31	36745-36746	±	_	
176-32	36747-36750	3.6	_	
176-33	36751-36756	26.83	_	
176-34	36757-36758	±	_	
176-35	36759-36763	4.89	_	
176-36	36764-36769	0.757	_	
176-37	36772-36775	DSM	_	
176-38	36776-36786	Depression	_	
176-39	36787-36791	0.03	_	
176-40	36792-36793	±	_	
176-41	36794-36798	0.86	_	
176-42	36799-36800	−	_	
176-43	36800-36804	0.13	_	
176-44	36805-36806	±	_	
176-45	36807-36811	0.83	_	
176-46	36812-36817	0.452	_	
176-47	36820-36823	DSM	_	
176-48	36824-36831	Anxiety	_	
176-49	36832-36836	0.07	_	
176-50	36837-36838	±	_	
176-51	36839-36843	1.04	_	
176-52	36844-36845	−	_	
176-53	36845-36849	0.16	_	
176-54	36850-36851	±	_	
176-55	36852-36856	0.95	_	
176-56	36857-36862	0.383	_	
176-57	36865-36872	Alcohol	_	
176-58	36873-36876	Use	_	
176-59	36877-36878	(	_	
176-60	36878-36887	Composite	_	
176-61	36888-36889	Z	_	
176-62	36889-36890	)	_	
176-63	36891-36895	0.27	_	
176-64	36896-36897	±	_	
176-65	36898-36901	0.4	_	
176-66	36902-36906	0.15	_	
176-67	36907-36908	±	_	
176-68	36909-36913	0.38	_	
176-69	36914-36919	0.250	_	
176-70	36922-36929	Tobacco	_	
176-71	36930-36933	Use	_	
176-72	36934-36935	(	_	
176-73	36935-36944	Composite	_	
176-74	36945-36946	Z	_	
176-75	36946-36947	)	_	
176-76	36948-36952	0.57	_	
176-77	36953-36954	±	_	
176-78	36955-36959	0.83	_	
176-79	36960-36964	0.32	_	
176-80	36965-36966	±	_	
176-81	36967-36971	0.85	_	
176-82	36972-36977	0.260	_	
176-83	36981-36987	Scores	_	
176-84	36988-36990	on	_	
176-85	36991-36999	measures	_	
176-86	37000-37002	of	_	
176-87	37003-37012	cognition	_	
176-88	37013-37016	and	_	
176-89	37017-37025	negative	_	
176-90	37026-37038	emotionality	_	
176-91	37039-37041	in	_	
176-92	37042-37044	CA	_	
176-93	37045-37048	and	_	
176-94	37049-37057	controls	_	
176-95	37057-37058	.	_	

#Text=Values are reported as mean ± standard deviation.
177-1	37059-37065	Values	_	
177-2	37066-37069	are	_	
177-3	37070-37078	reported	_	
177-4	37079-37081	as	_	
177-5	37082-37086	mean	_	
177-6	37087-37088	±	_	
177-7	37089-37097	standard	_	
177-8	37098-37107	deviation	_	
177-9	37107-37108	.	_	

#Text=Raw values for each measure were converted to Z-scores based on the larger population of 441 participants.
178-1	37109-37112	Raw	_	
178-2	37113-37119	values	_	
178-3	37120-37123	for	_	
178-4	37124-37128	each	_	
178-5	37129-37136	measure	_	
178-6	37137-37141	were	_	
178-7	37142-37151	converted	_	
178-8	37152-37154	to	_	
178-9	37155-37163	Z-scores	_	
178-10	37164-37169	based	_	
178-11	37170-37172	on	_	
178-12	37173-37176	the	_	
178-13	37177-37183	larger	_	
178-14	37184-37194	population	_	
178-15	37195-37197	of	_	
178-16	37198-37201	441	_	
178-17	37202-37214	participants	_	
178-18	37214-37215	.	_	

#Text=CA\tCTRL\tt-test p-value\t \tCognition (Composite Z)\t0.02 ± 0.49\t−0.05 ± 0.49\t0.572\t \tEpisodic Memory\t−0.33 ± 1.16\t−0.11 ± 0.99\t0.440\t \tWorking Memory\t−0.07 ± 0.9\t0.17 ± 1.08\t0.344\t \tFlexibility\t0.17 ± 0.96\t−0.05 ± 0.82\t0.343\t \tInhibitory Control\t0.03 ± 0.97\t0.09 ± 0.93\t0.799\t \tProcessing Speed\t0.1 ± 0.85\t−0.09 ± 1.25\t0.494\t \tDelay Discounting\t0.02 ± 0.85\t−0.28 ± 1.06\t0.229\t \tFluid Intelligence\t0.28 ± 0.79\t−0.03 ± 0.96\t0.183\t \tSpatial Orientation\t0.22 ± 0.98\t0.01 ± 0.96\t0.393\t \tVerbal Episodic Memory\t−0.24 ± 1.04\t−0.18 ± 0.93\t0.799\t \tNegative Emotionality (Composite Z)\t0.35 ± 0.74\t−0.05 ± 0.71\t0.036\t \tAggression\t0.42 ± 0.96\t0.14 ± 0.82\t0.240\t \tAlienation\t0.43 ± 0.85\t−0.1 ± 0.92\t0.022\t \tStress\t0.2 ± 1.05\t−0.2 ± 1.02\t0.138\t \t
#Text=Subcortical regions where lFCD was significantly higher in CA than controls (two-sample t-test, CA > CTRL).
179-1	37217-37219	CA	_	
179-2	37220-37224	CTRL	_	
179-3	37225-37231	t-test	_	
179-4	37232-37239	p-value	_	
179-5	37242-37251	Cognition	_	
179-6	37252-37253	(	_	
179-7	37253-37262	Composite	_	
179-8	37263-37264	Z	_	
179-9	37264-37265	)	_	
179-10	37266-37270	0.02	_	
179-11	37271-37272	±	_	
179-12	37273-37277	0.49	_	
179-13	37278-37279	−	_	
179-14	37279-37283	0.05	_	
179-15	37284-37285	±	_	
179-16	37286-37290	0.49	_	
179-17	37291-37296	0.572	_	
179-18	37299-37307	Episodic	_	
179-19	37308-37314	Memory	_	
179-20	37315-37316	−	_	
179-21	37316-37320	0.33	_	
179-22	37321-37322	±	_	
179-23	37323-37327	1.16	_	
179-24	37328-37329	−	_	
179-25	37329-37333	0.11	_	
179-26	37334-37335	±	_	
179-27	37336-37340	0.99	_	
179-28	37341-37346	0.440	_	
179-29	37349-37356	Working	_	
179-30	37357-37363	Memory	_	
179-31	37364-37365	−	_	
179-32	37365-37369	0.07	_	
179-33	37370-37371	±	_	
179-34	37372-37375	0.9	_	
179-35	37376-37380	0.17	_	
179-36	37381-37382	±	_	
179-37	37383-37387	1.08	_	
179-38	37388-37393	0.344	_	
179-39	37396-37407	Flexibility	_	
179-40	37408-37412	0.17	_	
179-41	37413-37414	±	_	
179-42	37415-37419	0.96	_	
179-43	37420-37421	−	_	
179-44	37421-37425	0.05	_	
179-45	37426-37427	±	_	
179-46	37428-37432	0.82	_	
179-47	37433-37438	0.343	_	
179-48	37441-37451	Inhibitory	_	
179-49	37452-37459	Control	_	
179-50	37460-37464	0.03	_	
179-51	37465-37466	±	_	
179-52	37467-37471	0.97	_	
179-53	37472-37476	0.09	_	
179-54	37477-37478	±	_	
179-55	37479-37483	0.93	_	
179-56	37484-37489	0.799	_	
179-57	37492-37502	Processing	_	
179-58	37503-37508	Speed	_	
179-59	37509-37512	0.1	_	
179-60	37513-37514	±	_	
179-61	37515-37519	0.85	_	
179-62	37520-37521	−	_	
179-63	37521-37525	0.09	_	
179-64	37526-37527	±	_	
179-65	37528-37532	1.25	_	
179-66	37533-37538	0.494	_	
179-67	37541-37546	Delay	_	
179-68	37547-37558	Discounting	_	
179-69	37559-37563	0.02	_	
179-70	37564-37565	±	_	
179-71	37566-37570	0.85	_	
179-72	37571-37572	−	_	
179-73	37572-37576	0.28	_	
179-74	37577-37578	±	_	
179-75	37579-37583	1.06	_	
179-76	37584-37589	0.229	_	
179-77	37592-37597	Fluid	_	
179-78	37598-37610	Intelligence	_	
179-79	37611-37615	0.28	_	
179-80	37616-37617	±	_	
179-81	37618-37622	0.79	_	
179-82	37623-37624	−	_	
179-83	37624-37628	0.03	_	
179-84	37629-37630	±	_	
179-85	37631-37635	0.96	_	
179-86	37636-37641	0.183	_	
179-87	37644-37651	Spatial	_	
179-88	37652-37663	Orientation	_	
179-89	37664-37668	0.22	_	
179-90	37669-37670	±	_	
179-91	37671-37675	0.98	_	
179-92	37676-37680	0.01	_	
179-93	37681-37682	±	_	
179-94	37683-37687	0.96	_	
179-95	37688-37693	0.393	_	
179-96	37696-37702	Verbal	_	
179-97	37703-37711	Episodic	_	
179-98	37712-37718	Memory	_	
179-99	37719-37720	−	_	
179-100	37720-37724	0.24	_	
179-101	37725-37726	±	_	
179-102	37727-37731	1.04	_	
179-103	37732-37733	−	_	
179-104	37733-37737	0.18	_	
179-105	37738-37739	±	_	
179-106	37740-37744	0.93	_	
179-107	37745-37750	0.799	_	
179-108	37753-37761	Negative	_	
179-109	37762-37774	Emotionality	_	
179-110	37775-37776	(	_	
179-111	37776-37785	Composite	_	
179-112	37786-37787	Z	_	
179-113	37787-37788	)	_	
179-114	37789-37793	0.35	_	
179-115	37794-37795	±	_	
179-116	37796-37800	0.74	_	
179-117	37801-37802	−	_	
179-118	37802-37806	0.05	_	
179-119	37807-37808	±	_	
179-120	37809-37813	0.71	_	
179-121	37814-37819	0.036	_	
179-122	37822-37832	Aggression	_	
179-123	37833-37837	0.42	_	
179-124	37838-37839	±	_	
179-125	37840-37844	0.96	_	
179-126	37845-37849	0.14	_	
179-127	37850-37851	±	_	
179-128	37852-37856	0.82	_	
179-129	37857-37862	0.240	_	
179-130	37865-37875	Alienation	_	
179-131	37876-37880	0.43	_	
179-132	37881-37882	±	_	
179-133	37883-37887	0.85	_	
179-134	37888-37889	−	_	
179-135	37889-37892	0.1	_	
179-136	37893-37894	±	_	
179-137	37895-37899	0.92	_	
179-138	37900-37905	0.022	_	
179-139	37908-37914	Stress	_	
179-140	37915-37918	0.2	_	
179-141	37919-37920	±	_	
179-142	37921-37925	1.05	_	
179-143	37926-37927	−	_	
179-144	37927-37930	0.2	_	
179-145	37931-37932	±	_	
179-146	37933-37937	1.02	_	
179-147	37938-37943	0.138	_	
179-148	37947-37958	Subcortical	_	
179-149	37959-37966	regions	_	
179-150	37967-37972	where	_	
179-151	37973-37977	lFCD	_	
179-152	37978-37981	was	_	
179-153	37982-37995	significantly	_	
179-154	37996-38002	higher	_	
179-155	38003-38005	in	_	
179-156	38006-38008	CA	_	
179-157	38009-38013	than	_	
179-158	38014-38022	controls	_	
179-159	38023-38024	(	_	
179-160	38024-38034	two-sample	_	
179-161	38035-38041	t-test	_	
179-162	38041-38042	,	_	
179-163	38043-38045	CA	_	
179-164	38046-38047	>	_	
179-165	38048-38052	CTRL	_	
179-166	38052-38053	)	_	
179-167	38053-38054	.	_	

#Text=Results are thresholded voxelwise at p < .001, with a nonparametric cluster-level threshold of p < .05 family-wise error (FWE) corrected, using SnPM13.
180-1	38055-38062	Results	_	
180-2	38063-38066	are	_	
180-3	38067-38078	thresholded	_	
180-4	38079-38088	voxelwise	_	
180-5	38089-38091	at	_	
180-6	38092-38093	p	_	
180-7	38094-38095	<	_	
180-8	38096-38100	.001	_	
180-9	38100-38101	,	_	
180-10	38102-38106	with	_	
180-11	38107-38108	a	_	
180-12	38109-38122	nonparametric	_	
180-13	38123-38136	cluster-level	_	
180-14	38137-38146	threshold	_	
180-15	38147-38149	of	_	
180-16	38150-38151	p	_	
180-17	38152-38153	<	_	
180-18	38154-38157	.05	_	
180-19	38158-38169	family-wise	_	
180-20	38170-38175	error	_	
180-21	38176-38177	(	_	
180-22	38177-38180	FWE	_	
180-23	38180-38181	)	_	
180-24	38182-38191	corrected	_	
180-25	38191-38192	,	_	
180-26	38193-38198	using	_	
180-27	38199-38205	SnPM13	_	
180-28	38205-38206	.	_	

#Text=Note that there were no significant results for the reverse contrast (i.e., CTRL > CA).
181-1	38207-38211	Note	_	
181-2	38212-38216	that	_	
181-3	38217-38222	there	_	
181-4	38223-38227	were	_	
181-5	38228-38230	no	_	
181-6	38231-38242	significant	_	
181-7	38243-38250	results	_	
181-8	38251-38254	for	_	
181-9	38255-38258	the	_	
181-10	38259-38266	reverse	_	
181-11	38267-38275	contrast	_	
181-12	38276-38277	(	_	
181-13	38277-38280	i.e	_	
181-14	38280-38281	.	_	
181-15	38281-38282	,	_	
181-16	38283-38287	CTRL	_	
181-17	38288-38289	>	_	
181-18	38290-38292	CA	_	
181-19	38292-38293	)	_	
181-20	38293-38294	.	_	

#Text=NOTE: SN/VTA = Substantia Nigra/Ventral Tegmental Area; VS = Ventral Striatum
#Text=\t\t\tMNICoordinates(mm)\t\t \t\t \tCluster Size (mm3)\tFWE-corrected p-value\tPeak t-value\tX\tY\tZ\tIdentified Region\t \t2544\t.008\t5.20\t20\t−20\t6\tRight Thalamus\t \t\t\t4.15\t18\t−22\t−6\t\t \t\t\t4.11\t6\t−26\t−12\t\t \t3880\t.002\t4.77\t2\t−36\t−30\tBrainstem\t \t\t\t4.70\t2\t−34\t−40\t\t \t\t\t4.69\t−8\t−34\t−30\t\t \t1968\t.002\t4.58\t−16\t−20\t−10\tMidbrain (including SN/VTA)\t \t\t\t4.18\t−22\t−12\t−6\t\t \t\t\t4.06\t−28\t−12\t0\t\t \t976\t.017\t4.36\t−10\t20\t−6\tVS\t \t\t\t3.94\t−8\t12\t−8\t\t \t\t\t3.84\t−12\t12\t2
182-1	38295-38299	NOTE	_	
182-2	38299-38300	:	_	
182-3	38301-38303	SN	_	
182-4	38303-38304	/	_	
182-5	38304-38307	VTA	_	
182-6	38308-38309	=	_	
182-7	38310-38320	Substantia	_	
182-8	38321-38326	Nigra	_	
182-9	38326-38327	/	_	
182-10	38327-38334	Ventral	_	
182-11	38335-38344	Tegmental	_	
182-12	38345-38349	Area	_	
182-13	38349-38350	;	_	
182-14	38351-38353	VS	_	
182-15	38354-38355	=	_	
182-16	38356-38363	Ventral	_	
182-17	38364-38372	Striatum	_	
182-18	38376-38390	MNICoordinates	_	
182-19	38390-38391	(	_	
182-20	38391-38393	mm	_	
182-21	38393-38394	)	_	
182-22	38401-38408	Cluster	_	
182-23	38409-38413	Size	_	
182-24	38414-38415	(	_	
182-25	38415-38418	mm3	_	
182-26	38418-38419	)	_	
182-27	38420-38433	FWE-corrected	_	
182-28	38434-38441	p-value	_	
182-29	38442-38446	Peak	_	
182-30	38447-38454	t-value	_	
182-31	38455-38456	X	_	
182-32	38457-38458	Y	_	
182-33	38459-38460	Z	_	
182-34	38461-38471	Identified	_	
182-35	38472-38478	Region	_	
182-36	38481-38485	2544	_	
182-37	38486-38490	.008	_	
182-38	38491-38495	5.20	_	
182-39	38496-38498	20	_	
182-40	38499-38500	−	_	
182-41	38500-38502	20	_	
182-42	38503-38504	6	_	
182-43	38505-38510	Right	_	
182-44	38511-38519	Thalamus	_	
182-45	38524-38528	4.15	_	
182-46	38529-38531	18	_	
182-47	38532-38533	−	_	
182-48	38533-38535	22	_	
182-49	38536-38537	−	_	
182-50	38537-38538	6	_	
182-51	38544-38548	4.11	_	
182-52	38549-38550	6	_	
182-53	38551-38552	−	_	
182-54	38552-38554	26	_	
182-55	38555-38556	−	_	
182-56	38556-38558	12	_	
182-57	38562-38566	3880	_	
182-58	38567-38571	.002	_	
182-59	38572-38576	4.77	_	
182-60	38577-38578	2	_	
182-61	38579-38580	−	_	
182-62	38580-38582	36	_	
182-63	38583-38584	−	_	
182-64	38584-38586	30	_	
182-65	38587-38596	Brainstem	_	
182-66	38601-38605	4.70	_	
182-67	38606-38607	2	_	
182-68	38608-38609	−	_	
182-69	38609-38611	34	_	
182-70	38612-38613	−	_	
182-71	38613-38615	40	_	
182-72	38621-38625	4.69	_	
182-73	38626-38627	−	_	
182-74	38627-38628	8	_	
182-75	38629-38630	−	_	
182-76	38630-38632	34	_	
182-77	38633-38634	−	_	
182-78	38634-38636	30	_	
182-79	38640-38644	1968	_	
182-80	38645-38649	.002	_	
182-81	38650-38654	4.58	_	
182-82	38655-38656	−	_	
182-83	38656-38658	16	_	
182-84	38659-38660	−	_	
182-85	38660-38662	20	_	
182-86	38663-38664	−	_	
182-87	38664-38666	10	_	
182-88	38667-38675	Midbrain	_	
182-89	38676-38677	(	_	
182-90	38677-38686	including	_	
182-91	38687-38689	SN	_	
182-92	38689-38690	/	_	
182-93	38690-38693	VTA	_	
182-94	38693-38694	)	_	
182-95	38699-38703	4.18	_	
182-96	38704-38705	−	_	
182-97	38705-38707	22	_	
182-98	38708-38709	−	_	
182-99	38709-38711	12	_	
182-100	38712-38713	−	_	
182-101	38713-38714	6	_	
182-102	38720-38724	4.06	_	
182-103	38725-38726	−	_	
182-104	38726-38728	28	_	
182-105	38729-38730	−	_	
182-106	38730-38732	12	_	
182-107	38733-38734	0	_	
182-108	38738-38741	976	_	
182-109	38742-38746	.017	_	
182-110	38747-38751	4.36	_	
182-111	38752-38753	−	_	
182-112	38753-38755	10	_	
182-113	38756-38758	20	_	
182-114	38759-38760	−	_	
182-115	38760-38761	6	_	
182-116	38762-38764	VS	_	
182-117	38769-38773	3.94	_	
182-118	38774-38775	−	_	
182-119	38775-38776	8	_	
182-120	38777-38779	12	_	
182-121	38780-38781	−	_	
182-122	38781-38782	8	_	
182-123	38788-38792	3.84	_	
182-124	38793-38794	−	_	
182-125	38794-38796	12	_	
182-126	38797-38799	12	_	
182-127	38800-38801	2	_	
